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Abstract 
Diabetes is a metabolic syndrome characterized by failure of multiple organ systems to 
maintain normoglycemia. At the crux of this malfunction lies the pancreatic Islet of 
Langerhans, which secretes hormones responsible for regulation of circulating blood 
glucose levels. Not only in the autoimmune Type 1 Diabetes (T1D), but also in Type 2 
Diabetes (T2D), the survival and function of the insulin secreting β-cells is diminished. In 
T1D, β-cell destruction occurs through immune mediated processes involving 
mononuclear cell infiltration in the pancreatic islets and interaction between antigen 
presenting cells and T-cells leading to high local concentrations of inflammatory 
cytokines, chemokines, reactive oxygen species (ROS) and other inflammatory 
products and subsequently to β-cell apoptosis. Pro-inflammatory cytokines and 
chemokines are produced and secreted not only by activated infiltrating macrophages, 
but also by adipocytes and pancreatic β-cells themselves. On the other hand, T2D is 
diagnosed in individuals with relative insulin insufficiency; ?-cells have lost the ability to 
compensate and produce sufficient insulin to maintain normoglycemia in the face of 
higher insulin demands. For many years, the mechanisms of β-cell apoptosis only in 
T1D were thought to be immune system mediated and were supposed to be distinct 
from the stressed β-cell death in T2D. In contrast, recent studies show local 
inflammation in the islets also in T2D (IL-1β, IL-6, IL-8, CXCL-10), linking T1D and T2D 
as inflammatory diseases. 
Current therapies in diabetes lack focus on maintenance of endogenous β-cell mass. In 
order to come up with novel targets for improving β-cell mass, this thesis aimed to 
investigate the varied aspects of β-cell survival and function, with special focus on 
inflammation in islets.  
In the first study, I revealed a novel target TOSO, which inhibited the death receptor Fas 
activation by restoring endogenous levels of FLIP. TOSO could not only protect the β-
cells from elevated glucose mediated apoptosis, but also induced limited round of 
proliferation in these cells. To assess the proliferation of β-cells induced by TOSO, I 
adapted a novel technique called Sequential thymidine analogue labeling, to detect 
multiple rounds of cell division in vitro. Using this assay, I could confirm the low 
proliferative capacity of adult β-cells. Nevertheless, TOSO induced an early round of 
proliferation in the β-cells. Thus, TOSO could be a potential target for protecting the β- 
cells and restoring their mass in the face of diabetes.  
An additional aim of the thesis was to understand the effect of an existing class of drugs 
improving insulin secretion, the DPP4-inhibitors, on the survival and function of β-cells 
in islets. DPP4 is an enzyme, which cleaves the incretin GLP1, thus abolishing the 
potentiation of insulin secretion by the β-cells. My investigations show that the DPP4 
inhibitor Linagliptin improves β-cell function and survival under diabetogenic conditions 
by stabilizing GLP1 and activating an anti-inflammatory/antioxidative stress pathway. 
The major investigation of this thesis has been the systemic inflammation observed in 
diabetes and its role in β-cell apoptosis. The signaling and activation of immune cells is 
brought by secreted stimulators or via cell-cell interactions. Different cell surface 
receptors and adhesion molecules play a role in the immune system activation. One 
such family of adhesion and signaling molecules are Sialic acid-binding 
immunoglobulin-like lectins (Siglecs). Siglecs are I-type lectins. which recognize and 
interact with sialylated glycan residues on cell surfaces via immunoglobulin (Ig)-like 
domains. Siglec expression has been found mainly in the hematopoietic and immune 
systems. Most siglecs have one or more cytosolic immunoreceptor tyrosine-based 
inhibitory motif (ITIM) in the intracellular domain, suggesting a role for siglecs in 
signaling events through the recruitment of tyrosine and inositol phosphatases.  
These cell-cell signaling interactions play an important role in immune system activation 
and triggering of inflammation. As a consequence, they might be initiators of the 
inflammatory cascade in diabetes and the deleterious interaction of the immune cells 
with the β-cells. Hence, exploring the role of siglecs in diabetes is necessary to 
understand the possible pro-inflammatory triggers of β-cell destruction. In this thesis, I 
investigated expression and function of siglecs in the pancreas, as well as in the 
immune cells, under diabetogenic conditions. Cell type specific expression of siglecs 
could be detected in islets in the human pancreas: Siglec-3, -5 and -8 are expressed in 
the glucagon producing α-cells; Siglec-1, -2, -7 and -10 are expressed in the insulin 
producing β-cells. Also, the β-cell specific Siglec-7 and -10 were down-regulated in 
diabetes, with opposite regulation of the ligands. Restoration of Siglec-7 in the β-cells 
could improve their function and protect them from elevated glucose, free fatty acid and 
cytokine induced apoptosis by inhibiting the activation of the classical NFκB pathway 
and the subsequent cytokine secretion. Similar loss of Siglec-7 was observed in 
activated monocytes. Ultimately, the migration of immune cells towards inflamed islets 
could also be prevented by restoration of Siglec-7 in these islets.  In summary, from our 
data we can predict that Siglec-7 expression is necessary for maintenance of an anti-
apoptotic pro-survival state in islets, and its loss aggravates the activation of immune 
system and islet inflammation occurring in diabetes. 
In conclusion, these investigations have brought to surface the presence of siglecs in 
non-inflammatory cells in pancreatic tissue, opening a whole new perspective for the 
role of siglecs in general. This thesis widens the understanding of islet inflammation and 
puts forth novel targets to protect the β-cells under these circumstances.   
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Zusammenfassung 
 
Diabetes ist eine Stoffwechselerkrankung, bei der eine komplexe Fehlregulation 
mehrerer Organsysteme zur Erhöhung der Blutzuckerwerte führt. Ein 
Funktionsverlust der Langerhansschen Inselzellen des Pankreas, deren sezernierte 
Hormone im gesunden Organismus den Blutzucker regulieren, stellen dabei die 
Hauptursache der Manifestation des Diabetes dar. Sowohl im autoimmunen Typ 1 
Diabetes (T1D), als auch im Übergewicht-assoziierten Typ 2 Diabetes (T2D) sind 
Überleben und Funktion der insulinproduzierenden β-Zellen beeinträchtigt. In T1D 
werden die Inselzellen von Immunzellen infiltriert; das Zusammenspiel 
antigenpräsentierender- und T-Zellen führt zur lokalen Entzündung mit erhöhten 
Konzentrationen von inflammatorischen Zytokinen, Chemokinen, reaktiven 
Sauerstoffspezies (ROS) und anderen Produkten und spezifischer Zerstörung der 
insulinproduzierenden β-Zelle in den Inseln durch programmierten Zelltod 
(Apoptose). Proinflammatorische Zytokine und Chemokine werden dabei nicht nur 
von aktivierten infiltrierenden Makrophagen sekretiert, sondern auch von β-Zellen 
selbst. T2D tritt in Patienten auf, die die Fähigkeit verloren haben, ausreichende 
Mengen an Insulin zur Aufrechterhaltung physiologischer Blutzuckerwerte in 
Situationen erhöhtem Insulinbedarfs (z.B. Übergewicht, Insulinresistenz) zu 
produzieren. Lange Zeit nahm man an, dass der Mechanismus der β-Zell-Apoptose 
im T1D immunsystemabhängig und damit unterschiedlich zum stressinduzierten β-
Zell-Tod im T2D sei. Im Gegensatz dazu zeigen neuere Studien auch im T2D eine 
lokale Entzündung in den Inseln (IL-1β, IL-6, IL-8, CXCL-10), somit stellt eine 
Aktivierung von Entzündungsfaktoren und der daraus resultierende Tod der ?-Zelle 
eine Gemeinsamkeit beider Hauptformen des Diabetes, T1D und T2D dar. Kausale 
Therapien zur Erhaltung der β-Zell-Masse stehen derzeit noch nicht zur Verfügung. 
Um neue Ansatzpunkte für einen Schutz der β-Zell-Masse zu erhalten, sollen in 
dieser Arbeit verschiedene Aspekte des β-Zell-Überlebens und –Funktion untersucht 
werden, mit dem speziellen Fokus auf die Hemmung der Inflammation in den 
Inselzellen. 
In der ersten Studie untersuchte ich das Protein TOSO, ein Regulationsprotein 
innerhalb des pro-apoptotischen Fas Signalweges. Durch die Wiederherstellung 
endogener Konzentrationen von FLIP, ein Potein, das den Fas-Signalweg inhibiert,   
schützte TOSO die β-Zellen nicht nur vor Glukose-induzierter Apoptose, sondern 
erzielte außerdem eine erhöhte Proliferationrate in ?-Zellen. Mittels sequentieller 
Thymidin-analogafärbung gelang es mir, mehrere Zyklen der Zellteilung in vitro zu 
untersuchen. Mit Hilfe dieses Assays konnte ich die niedrige Proliferationskapazität 
von adulten β-Zellen bestätigen. TOSO induzierte eindeutige Erhöhung der β-Zell-
Proliferation, jedoch die von mir erhoffte mehrmalige Induktion der Zellteilung in 
spezialisierten ?-Zellen konnte nicht bestätigt werden.  
Ein weiteres Ziel dieser Arbeit war, den direkten Einfluss einer bereits existierenden 
Klasse von Medikamenten, die Inhibitoren der Dipeptidylpeptidase 4 (DPP4), auf 
Überleben und Funktion der β-Zelle zu untersuchen. 
DPP4 ist ein Enzym, das das Inkretin GLP1 spaltet und damit die Potenzierung der 
Insulinsekretion in β-Zellen verhindert. DPP4 Inhibitoren erhöhen die Glukose-
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induzierte Insulinsekretion. Meine Untersuchungen zeigen, dass der DPP4-Inhibitor 
Linagliptin das β-Zell-Überleben und deren Funktion unter diabetogenen 
Bedingungen verbessert, in dem er GLP1 stabilisiert und einen anti-
inflammatorischen/antioxidativen Signalweg induziert. 
Der Großteil der Untersuchungen dieser Arbeit konzentrierte sich auf die 
Entzündungsreaktionen, die bei Diabetes beobachtet werden können und dessen 
Rolle bei der β-Zell-Apoptose. Die Kommunikation und Aktivierung von Immunzellen 
wird durch sekretierte Stimulatoren oder durch Zell-Zell-Interaktionen vermittelt. In 
der Aktivierung des Immunsystems spielen verschiedene Oberflächenrezeptoren und 
Zelladhäsionsmoleküle eine Rolle. Eine Familie dieser Adhäsions- und 
Signalmoleküle sind die Sialic acid-binding immunoglobulin-like lectins (Siglecs). 
Siglecs sind I-Typ Lectine, die sialinsäurehaltige  Polysaccharide auf Zelloberflächen 
durch immunglobolin-(Ig) ähnliche Domänen erkennen und mit ihnen interagieren.  
Siglecs werden hauptsächlich im hämatopoetischen und in Immunzellen exprimiert. 
Die meisten Siglecs haben ein oder mehrere zytosolische Immunorezeptor-tyrosin-
basierende inhibierende Motive (ITIM) in der intrazellulären Domäne, was auf eine 
Rolle der Siglecs bei Signalkaskaden durch Tyrosin- und Inositolphosphatasen 
schließen lässt. Diese Zell-Zell-Interaktionen spielen eine wichtige Rolle bei der 
Aktivierung des Immunsystems und bei der Steuerung von Entzündungsreaktionen. 
Sie könnten Initiatoren der inflammatorischen Kaskade im Diabetes und des 
schädlichen Zusammenspiels mit der β-Zelle sein. Daher ist es notwendig, die Rolle 
der Siglecs im Diabetes zu untersuchen und die möglichen proinflammatorischen 
Einflüsse, die zur β-Zell-Zerstörung führen, zu verstehen. In dieser Arbeit habe ich 
die Expression und Funktion der Siglecs im Pankreas und in Immunzellen unter 
diabetogenen Bedingungen untersucht. In humanen Inselzellen konnte eine 
zelltypspezifische Expression der Siglecs gezeigt werden: Siglecs-3, -5 und -8 
werden von glukagon-produzierenden α-Zellen exprimiert, während Siglecs-1, -2, -7 
und -10 in insulin-produzierenden β-Zellen nachgewiesen werden konnten. Die β-
zellspezifischen Siglecs-7 und -10 waren im Diabetes niedriger exprimiert, mit 
gegenteiliger Regulation ihrer Liganden. Die Überexpression von Siglec-7 in β-Zellen 
konnte deren Funktion verbessern und sie vor Diabetes-induziertem Zelltod 
schützen, in dem sie den klassischen NF-κB Signalweg und die nachfolgende 
Zytokinsekretion inhibierte. 
Ein ähnlicher Verlust von Siglec-7 wurde auch in aktivierten Monozyten beobachtet. 
Die Migration von Immunzellen hin zu den entzündeten Inseln konnte ebenfalls durch 
die Überexpression von Siglec-7 verhindert werden. Zusammengefasst kann man 
von meinen Beobachtungen darauf schließen, dass Siglec-7 Expression wichtig zur 
Erhaltung eines antiapoptotischen und überlebensfähigen Status in Inseln ist, und 
dass dessen Verlust die Aktivierung des Immunsystems und die Inselentzündung 
verstärkt, was anschließend zu Diabetes führt. 
Meine Untersuchungen zeigen erstmalig das Vorkommen von Siglecs in 
nichtentzündlichen Zellen im pankreatischem Gewebe, was eine komplett neue 
Perspektive auf die Rolle der Siglecs eröffnet. Diese Arbeit erweitert das Verständnis 
von entzündlichen Mechanismen in Inseln und zeigt neue Wege auf, um die β-Zellen 
unter diesen Umständen zu schützen. 
P a g e  | 6 
 
 
          
 
 
1. Abbreviations 
ADP 
AML 
AMP 
ATP 
APC 
CD 
CKK-8 
CLSM 
CTL 
DISC 
DNA 
DPP-4 
ER 
FACS 
FADH 
FADD 
FCS 
FFA 
FLIP 
Faim/TOSO 
GABA 
GAD 
GIP 
GLP-1/2 
GlcNAc 
GLUT2  
Gm-CSF 
GSIS 
HFD 
IFG 
IFN –γ 
IL-1β 
ITAM 
ITIM 
LPS 
ManNAc 
MCP1 
MHC 
mRNA 
Adenosine diphosphate 
Acute myeloid leukaemia 
Adenosine monophosphate 
Adenosine triphosphate 
Antigen presenting cell 
Cluster of differentiation 
Cholecystokinin 8 
Confocal laser scanning microscope 
Cytotoxic T lymphocytes 
Death inducing signaling complex 
Deoxyribonucleic acid 
Dipeptidyl peptidase 4 
Endoplasmic reticullum 
Fluorescence assorted cell sorting 
Flavin adenine dinucleotide 
Fas associated death domain 
Fetal calf serum 
Free fatty acids 
FLICE inhibitory protein  
Fas apoptotic inhibitory molecule 
γ-Aminobutyric acid 
Glutamic acid decarboxylase 
Gastric inhibitory polypeptide 
Glucagon-like peptide 1/ 2 
N-acetylated D-glucosamine 
Glucose transporter 2  
Granulocyte macrophages colony stimulating factor 
Glucose stimulated insulin secretion 
High fat diet 
Impaired fasting glucose 
Interferon-γ 
Interleukin 1β 
Immunoreceptor tyrosine-based activation motifs 
Immunoreceptor tyrosine-based activation motifs 
Lipopolysaccharide 
N-acetylated D- mannosamine 
Monocyte chemotactic protein 1 
Major histocompatibility complex 
Messenger RNA 
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NADH 
Neu3 
Neu5Ac 
NK-cells 
NOD 
PACAP 
PAL 
Pax6 
PBS 
Pdx1 
PC 1/3 
PC 2 
PCR 
PolyI:C 
RNA 
RT-PCR 
ROS 
SHP1/2 
Sia 
Siglecs 
STZ 
ST8Sia1 
TBS 
TCA cycle 
TCR 
TNF-α 
T1D 
T2D 
WHO 
Nicotinamide adenine dinucleotide 
Neuraminidase 3 
N-acetylneuraminic acid  
Natural killer cells 
Non-obese diabetic  
Pituitary adenylate cyclase activating polypeptide 
Palmitate 
Paired box gene 6 
Phosphate buffered saline 
Pancreatic and duodenal homeobox 1 
Prohormone convertase 1/3 
Prohormone convertase 2 
Polymerase chain reaction 
Polyinosinic polycytidilic acid 
Ribonucleic acid 
Real-Time Polymerase chain reaction 
Reactive oxygen species 
SH2 domain-bearing protein tyrosine phosphatase (PTP) 1/2 
Sialic acids 
Sialic acid binding immunoglobulin-like lectins 
Streptozotocin 
 α- 2,8 Sialyltransferase 1 
Tris buffered saline 
Tricarboxylic acid cycle 
T cell receptor 
Tumor necrosis factor-α 
Type 1 Diabetes mellitus 
Type 2 Diabetes mellitus 
World Health organisation 
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2. Introduction  
2.1 Pancreas: structure and function  
The digestive system of vertebrates comprises of gland organs secreting endocrine 
and exocrine hormones, which facilitate the process of digestion. The pancreas is 
one of the components of this system and is located between the stomach and the 
kidneys in higher mammals. In adults, its size ranges from 12.5-15 cm, weighing from 
60-100 g [1]. It empties its exocrine digestive juices into the duodenum, while the 
endocrine secretions are released directly into the blood (Figure 1). The pancreas, in 
concert with the other digestive organs, is not only responsible for digestion, but also 
has a prime physiological role in maintaining glucose homeostasis.   
Primarily, the exocrine pancreas consists of a network of ducts arising from acinar 
cells. The acini are arranged at the apices of the branching ductal network, and thus 
resemble grape clusters. The intralobular ducts create a hierarchical network, forming 
the pancreatic duct which empties into the duodenum [2]. The digestive juices 
secreted by the acinar cells comprises of zymogens, precursors of the digestive 
enzymes, which get cleaved into their active form by enteropeptidases in the 
intestine. The catabolic enzymes primarily consist of pro-lipases and pro-proteases, 
aiding the breakdown of ingested lipids and proteins.  
Maintenance of normoglycemia in an organism is very crucial for its metabolic 
balance. In vertebrates, this function is carried out by the endocrine pancreas which 
consists of the Islets of Langerhans. Named after its discoverer, the German biologist 
Paul Langerhans, these islets are made up of five different types of cells secreting 
varied hormones essential for regulation of glucose metabolism: α-cells secreting 
glucagon, β-cells secreting insulin, δ-cells secreting somatostatin, ε-cells secreting 
hunger stimulating hormone ghrelin and PP-cells secreting pancreatic polypeptide 
[3]. In concert with each other, these hormones have several anabolic and catabolic 
effects in order to keep blood glucose concentration in a narrow range.  
 
2.2 The endocrine pancreas: hormones and their effects 
In order to understand the complexity of glucose homeostasis, this chapter 
introduces the endocrine secretions of the pancreas and their paracrine functions. 
Somatostatin is an inhibitory peptide, which suppresses the release of several 
neuronal, gastrointestinal and pancreatic hormones, especially insulin and glucagon 
[4]. Another hormone secreted post-prandially is the pancreatic polypeptide, whose 
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action is directed mainly towards suppression of food intake and gastric emptying as 
well as increase in energy expenditure [5, 6]. The hormone insulin is released by the 
β-cells in response to several stimuli, the main one being increase in blood glucose 
concentrations. It ensures clearance of glucose from blood by inducing uptake of 
glucose by muscle, adipose tissue and liver. It also down-regulates breakdown of 
stored glycogen (glycogenolysis) so as to prevent rise in blood sugar levels. [7]. On 
the other hand, when blood glucose levels drop below normal, e.g. after exercise or 
in-between meals, α-cells produce glucagon which acts mainly on the liver [8]. 
Glucagon signals drive the hepatic cells to carry out glycogenolysis, thus causing rise 
in circulating glucose concentrations, ultimately preventing hypoglycemia. Thus, the 
interplay between insulin and glucagon keeps the plasma glucose concentrations 
balanced. The secretion of both these hormones is tightly regulated by blood glucose 
levels and other paracrine signals. To understand the regulation of glucose 
homeostasis, knowledge of the mechanisms underlying secretion of these hormones 
need to be addressed.    
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Figure 1: Pancreas: anatomy and physiology. A. Structure of pancreas B. The 
exocrine pancreas C. The endocrine pancreas D. Structure of Islet of Langerhans. 
Different cell types and respective hormone production by Islets. (Adapted from [2, 
9]) 
 
2.3 Insulin: structure and function  
Insulin is a peptide hormone, which is synthesized in the β-cells as proinsulin 
containing a B-, C- and A-chain. Maturation of proinsulin involves proteolytic removal 
of the C-peptide, thus resulting in a peptide of 51 amino acids consisting of the B- 
and A-chain bound together by disulphide bonds [10]. 
 2.3.1 Glucose stimulated insulin secretion (GSIS) 
In the β-cells, circulating glucose is taken up via the glucose transporter 2 (GLUT2). 
Subsequent glucose metabolism leads to pyruvate formation and entry into the 
mitochondrial tricarboxylic acid (TCA) cycle. There is concomitant increase in the 
cellular ATP:ADP ratio because of electron transfer from the TCA cycle (in the form 
of NADH and FADH2) to the respiratory chain (oxidative phosphorylation). This 
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change in the ratio is sensed by the ATP-sensitive potassium (K+) channels, which 
shut down in response to this elevation. Thus, membrane depolarization takes place, 
which results in Ca2+ influx through voltage-sensitive Ca2+ channels. The Ca2+ pulses 
trigger insulin granule exocytosis, and the insulin granules are released directly into 
the blood (Figure 2). Insulin circulates through the body and acts on different organs, 
including muscles, adipose tissues and liver. To ensure glucose clearance, insulin 
not only promotes glucose uptake, glycogen and lipid synthesis, but also inhibits 
glycogenolysis, synthesis of glucose from precursors (gluconeogenesis), breakdown 
of lipids and proteins (lipolysis and proteinolysis).  
 
Figure 2: Mechanism of insulin secretion by the β-cells [11]. Uptake and 
metabolism of glucose leads to elevation in the ATP: ADP ratio, which causes the 
potassium channels to shut, leading to membrane depolarization and influx of 
calcium which aids in the exocytotic release of insulin from its storage granules. 
(Adapted from[11]) 
 
2.3.2 Incretins: stimuli for insulin secretion 
As compared to intravenous administration of glucose, higher levels of insulin are 
secreted by β-cells upon oral intake of glucose. This potentiating effect of glucose 
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stimulated insulin secretion has been attributed to existence of gut-derived factors, 
called incretins, and therefore referred to as the ‘incretin effect’. Glucose-dependent 
insulinotropic peptide (GIP) was the first incretin to be characterized which can 
potentiate GSIS [12]. Nevertheless, complete removal of GIP does not terminate this 
gut-mediated potentiation. This observation hinted towards the presence of additional 
factors contributing in this process. A second peptide with incretin activity was 
identified more than a decade after the discovery of GIP, by characterization and 
cloning of the proglucagon gene. In both preclinical and human studies, the ability of  
Glucagon-like peptide-1 (GLP-1), a peptide co-encoded carboxyterminally to 
glucagon in the proglucagon gene, to potentiate GSIS was demonstrated [13, 14]. 
Intestinal L-cells secrete GLP1 following nutrient intake [14]. Similar to glucose, GLP-
1 contributes to closure of ATP-sensitive K (KATP) channels, aiding in membrane 
depolarization and the induction of electrical activity (Figure 3). Upon exposure to 
elevated levels of glucose and GLP-1, Ca2+ influx is induced, accompanied by 
mobilization of intracellular Ca2+ stores through protein kinase A (PKA) and exchange 
protein activated by cAMP (EPAC2)-dependent mechanisms. As a consequence, 
insulin exocytosis is triggered and further potentiated by increased cAMP levels. 
Owing to the binding of cAMP to PKA and EPAC2, there is accelerated insulin 
granule mobilization, which amplifies the insulin pool that is available for immediate 
release [15]. Hence, GLP1 has an effect on “first phase” of insulin secretion wherein 
stored insulin granules are rapidly released as a response to elevated glucose levels. 
In spite of the expanding knowledge on mechanisms and regulation of insulin 
secretion from the β-cells, the phenomenon of glucagon secretion by the α-cells in 
response to glucose is not as well understood. Both, paracrine signals [16] and 
intrinsic regulation [17], are under debate, and it remains unclear whether glucagon 
secretion is primarily modulated by any or both of these mechanisms.    
 
2.4 Glucagon: structure, secretion and function  
Glucagon is a hormone secreted by α-cells in the Islets of Langerhans. Being a 
member of the pituitary adenylate cyclase activating polypeptide (PACAP) 
superfamily of peptide hormones, proglucagon gene is expressed as a 2-kb transcript 
encoding glucagon and glucagon-like peptides (GLP-1 and GLP-2). Prohormone 
convertase 1/3 (PC3) processes proglucagon to form GLP-1 and GLP-2 in the L-cells 
of the duodenum. 
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Figure 3. GLP-1 potentiates the stimulation of insulin secretion [18]. GLP-1 
binds to its receptor on the β-cell, which results in activation of adenylate cyclase. As 
a consequence, intracellular cAMP levels are increased, followed by activation of 
protein kinase A (PKA) and cAMP-regulated guanine nucleotide exchange factor II 
(cAMP-GEFII, also known as EPAC2).  The potentiating effect comes from the  ability 
of cAMP to accelerate insulin granule mobilization, and thus causes an increased 
amount of readily available pools of granules which can be instantly released. 
[Modified from Holst and Gromada [19]]. 
 
Prohormone convertase  2 (PC2)  expressed in the pancreatic α-cells,  processes the 
proglucagon into  glucagon, which is a single 29 amino acids long polypeptide chain 
with a molecular weight of 3483 dalton [20],[21],[22]. In response to elevated glucose 
concentrations, glucagon secretion is down-regulated. Investigations for underlying 
mechanisms of this regulation have shown various regulatory molecules like Zn2+ or 
γ-Aminobutyric acid (GABA) secreted by the β-cells [23] and somatostatin released 
by neighboring δ-cells [24] to be able to inhibit glucagon secretion. In spite of the 
neuronal regulation of glucagon secretion, an additional paracrine effect of products 
secreted by β-cells in face of hyperglycemia play a primary role [25, 26].  
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Glucagon carries out its primary function of glucose homeostasis through its actions 
on the liver. The main impact of glucagon in liver is an increase in hepatic glucose 
output, which comes from increase in glycogenolysis, gluconeogenesis, and 
reduction in glycolysis. In T2D, with subsequent insulin insufficiency, the regulation of 
glucagon secretion is lost; and hyperglycemia induces glucagon secretion, instead of 
inhibiting it, thus causing further disruption of the insulin-glucagon axis [26, 27]. 
The balanced and regulated secretion of these endocrine hormones is thus essential 
for maintaining blood glucose levels. To summarize the previous chapters, the 
apparent dysregulation in insulin and glucagon production and secretion in the 
endocrine pancreas, as well as signaling in the insulin-responsive tissues, leads to 
the metabolic syndrome: diabetes.     
 
2.5 Diabetes: Incidence and Etiology  
Diabetes mellitus, or diabetes, is a metabolic syndrome in which regulation of 
glucose metabolism is lost, leading to abnormally high plasma glucose 
concentrations. Its incidence is attributed to complex events arising from a 
combination of hereditary and environmental causes. The current generation has 
seen an enormous increase in the number of individuals suffering from diabetes, with 
more than 366 million people being diabetic, as per the WHO factsheet. WHO also 
projects that diabetes will be the 7th leading cause of death in 2030 [28]. To curb this 
epidemic and introduce new preventative and curative therapies, clear understanding 
of the molecular mechanisms leading to occurrence of diabetes needs to be 
prioritized. Some of the medical conditions associated with diabetes are: high blood 
pressure, elevated cholesterol levels, coronary artery disease, post gestational 
diabetes, polycystic ovary syndrome, chronic pancreatitis, fatty liver, 
hemochromatosis, cystic fibrosis, several mitochondrial neuropathies and 
myopathies, myotonic dystrophy, Friedreich's ataxia, some of the inherited forms of 
neonatal hyperinsulinism [29]. Diabetes-related complications are varied and are 
even fatal. When medications are not able to bring diabetes under control, acute 
complications (hypoglycemia, ketoacidosis, or nonketotic hyperosmolar coma) may 
occur [30]. Prolonged imbalances in glucose homeostasis may result in secondary 
complications like cardiovascular disease (doubled risk), chronic renal failure, retinal 
damage (which can lead to blindness), nerve damage (of several kinds), and 
microvascular damage, which may cause erectile dysfunction and poor wound 
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healing [30]. Lifestyle interventions such as proper diet, regular exercise, blood 
pressure control and non-smoking may improve susceptibility to various 
complications. Diabetes manifests itself in the form of three classical symptoms: 
frequent urination or polyuria, increased fluid intake or polydipsia and increased 
appetite or polyphagia [31]. Depending on the primary cause of incidence, diabetes is 
divided into two major types, viz. type 1 diabetes (T1D) (formerly known as 
childhood-onset or insulin-dependent diabetes) and type 2 diabetes (T2D) (formerly 
known as adult-onset or non-insulin dependent diabetes) [31]. 
 
2.5.1 Type 1 Diabetes mellitus (T1D)  
T1D incidence is majorly attributed to the autoimmune destruction of the insulin 
producing β-cells, resulting in an absolute insulin deficiency [32]. As is true in most of 
the autoimmune disorders, interactions between environmental factors and genetic 
predispositions contribute to the triggering of T1D [33, 34]. The manifestation and 
progression of T1D can be divided into two phases: a moderate to long-term 
symptomless phase of insulitis wherein islets are infiltrated by a mixed population of 
leukocytes [35] and overt diabetes with evident hyperglycemia and hypoinsulinemia  
where most β-cells are destroyed. Study of various T1D mouse models, typically 
non-obese diabetic (NOD) mice, have given insights into mechanisms of onset and 
development of T1D [36]. Regardless of the interplay of various immune cells like B-
cells, macrophages and dendritic cells being responsible for T1D development, it is 
considered to primarily be a T-cell mediated disease. Activation of the cytotoxic T-cell 
response has been observed against several autoantigens including peptides derived 
from insulin [37] and glutamic acid decarboxylase (GAD) [38]. The initial step in the 
development of T1D is thought to be autoantigen presentation by macrophages and/ 
or dendritic cells to CD4+ T-helper cells. Subsequent secretion of various cytokines 
including interleukin (IL) -1β, tumor necrosis factor (TNF) -α and interferon (IFN) -γ by 
the activated macrophages and CD4+ T-cells induce CD8+ T-cell activation and 
infiltration in the islets. These cells then destroy β-cells by different mechanisms such 
as release of granzymes and perforin as well as by Fas - Fas-Ligand interactions [39] 
(Figure 4). Triggers for β-cell specific destruction vary leading to variable clinical 
parameters in patients. Therefore, diverse phenomenon could initiate the incidence 
of T1D, involving different initiating antigens, primary effector cell types and 
mechanisms of β-cell death [35]. A major therapeutic intervention for T1D is islet 
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transplantation, but graph rejections and post transplantation complications are a 
crucial risk factor. Inflamed state of the transplanted islets as observed by increased 
secretion of monocyte-chemoattractant protein-1 (CCL2/MCP-1) and tissue factor 
(TF) tends to negatively contribute to graft function and outcome [40].  
 
 
Figure 4. Cellular and molecular mechanisms in the development or prevention 
of type 1 diabetes [41]. In the initiation phase of T1D following β-cell damage, 
conventional dendritic cells (cDCs) capture and process β-cell antigens. Phase 2 is 
marked by the migration of activated cDCs to the lymph nodes where they prime 
pathogenic islet antigen-specific T cells. In Phase 3, β-cells can be killed by 
diabetogenic T cells and NK cells through the release of interferon-γ (IFNγ), 
granzymes and perforin, as well as by macrophages through the production of 
tumour necrosis factor (TNF), IL-1β and nitric oxide. This complex crosstalk between 
innate and adaptive immune cells results in the development of T1D. APC, antigen-
presenting cell; TCR, T cell receptor.(Adapted from [38] ) 
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2.5.2 Type 2 Diabetes mellitus (T2D)  
T2D manifests itself as a progressive decline in β-cell function along with chronic 
insulin resistance. The development of T2D is strongly affected  by environmental 
factors, such as sedentary lifestyle, nutrition and obesity.  
Nevertheless, only a small percentage of obese people suffer from diabetes, and 
non-obese diabetic individuals also exist, hinting that other factors are also involved 
in the etiology of T2D. Genetic predisposition is also one of the parameters affecting 
the incidence as evidenced by association of  polymorphisms within many genes with 
decreased/increased risk of T2D [42]. Disease progression in T2D has been 
proposed to have five stages [43]: Stage 1 is compensatory increase in insulin 
secretion in the face of insulin resistance. This compensation has been attributed to 
both expansion of β-cell mass [44, 45] and increased  β-cell function [46, 47]. Stage 2 
is a static state of β-cell adaptation that can last for years but is already accompanied 
by loss of β-cell mass and acute glucose-stimulated insulin secretion [48]. Stage 3 is 
an unstable, transient stage wherein the compensation starts falling short of the 
demand for insulin and glucose levels start rising, leading to stage 4 of fulminate 
diabetes. In most cases, this stage lasts for the entire lifespan of a patient as they 
typically have enough insulin secretion left rather than progressing to ketoacidosis. 
Only in T1D does the disease progress to Stage 5 where severe destruction of β-
cells leads to ketoacidosis and the patient becomes dependant on insulin 
administration for survival. 
 
2.6 Insulin resistance  
In contrast to T1D, where severe destruction of the islets drastically reduces the 
supply of the hormone insulin, in T2D there is insulin production at diagnosis, and 
often even hyperinsulinemia. However, the insulin is insufficient in stimulating 
glucose clearance by target tissues. Insulin resistance is the condition in which the 
biological effects of insulin are less pronounced for both glucose disposal in skeletal 
muscle and inhibition  of gluconeogenesis  in the liver [49]. Healthy individuals 
compensate for  this insulin resistance by increasing insulin secretion by increase in 
β-cell mass and function. However, in about 10% of individuals, this compensation 
fails to meet the metabolic demand, hence resulting in chronic hyperglycemia and 
diabetes [50].  Inflammation of multiple organ systems like liver, muscle, adipose 
tissue and hypothalamus have been associated with insulin resistance. The loss of 
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energy homeostasis due to hepatic inflammation occurs  through decreased hepatic 
glycogen storage, increased gluconeogenesis, and lipogenesis, associated with 
hepatic lipid accumulation [51]. Hypothalamic inflammation disrupts leptin and insulin 
signaling [51, 52].  Also, inflammation inhibits muscle glucose uptake and glycogen 
synthesis [51, 52]. Adipose tissue inflammation has been implicated during the 
course of development of insulin resistance, with amplification of the pro-
inflammatory environment by secretion of adipokines and cytokines [53].  
The phenomenon of insulin resistance results in increased demand for insulin to 
maintain normoglycemia, which stresses the pancreatic β-cells to increase insulin 
secretion or its mass [54]. When these compensatory mechanisms fail to meet the 
increased demand of insulin, glucose homeostasis is disturbed and T2D develops 
[54].  
2.7 Defects in incretin mediated insulin secretion 
T2D is essentially a plethora of regulatory malfunctions. One of the aspects of T2D 
has been the abnormalities in incretin-mediated insulin secretion [55], in the form of  
defective GIP action and reduced GLP-1 secretion and action [56]. Loss of glucose 
homeostasis observed in T2D, thus, is partially resulting from the decreased incretin 
effect [57]. When the secretion of GIP and GLP1 in response to elevated glucose 
was compared in both normal subjects and patients with T2D, only healthy subjects 
were able to respond to orally administered glucose, by increasing its insulinotropic 
effect [58].  Also, in patients with T2D, postprandial GIP responses were less affected 
than the GLP-1 response [59]. In addition to this, the defective incretin action can 
also impair the suppression of glucagon secretion in response to nutrient intake, thus 
further contributing to the endocrine hormonal imbalance observed in T2D [60, 61]. 
A crucial factor contributing to the short-term stimulatory effect of the incretins is their 
degradation and inactivation by enzymes which maintain their low half-life in serum.  
Dipeptidyl peptidase 4 (DPP-4) is a ubiquitous cell membrane associated enzyme 
responsible for cleaving and inactivating both incretins: GLP-1 and GIP [62] (Figure 
5). Thus, some strategies to restore the incretin effect in T2D are: use of injectable 
GLP-1 receptor agonists, or use of DPP-4 inhibitors to increase half-life of 
endogenous GLP-1. These treatments have been shown to be effective in stimulating 
insulin secretion as well as in inhibition of glucagon secretion, without any risk for 
hypoglycaemia [63], although an increased risk for pancreatitis has been recently 
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discussed [64]. Even though long-term clinical effects of incretin-based drugs on the 
β-cell are still speculative [65], numerous in vivo and in vitro studies in rodents show 
that GLP-1 increases β-cell mass, proliferation [66-68] and β-cell neogenesis [69]. 
GLP-1 has been shown to not only inhibit β-cell apoptosis in human islets [70-72], but 
also has a protective role in islets isolated from patients with T2D [73]. On these lines 
stabilizing GLP-1 by DPP-4 inhibition restores glycemic control in diabetic animal 
models [74], improves β-cell survival, replication and neogenesis in the diabetic 
mouse and rat streptozotocin model [75, 76] and in the VDF diabetic rat [77].  
 
Figure 5: The incretin effect on glycemic control (adapted from [78]) The oral 
ingestion of glucose leads to secretion of incretins GLP1 and GIP, which potentiate 
insulin secretion by the β-cells and inhibit glucagon secretion by the α-cells. 
Periodically, DPP-4 cleaves off the incretins, so as to control this potentiation. DPP-4 
inhibitors help to maintain the incretins in circulation for longer durations, thus helping 
glucose clearance in diabetic individuals.  
 
Nevertheless, the direct effect of DPP-4 inhibitors on human β-cells has not been 
investigated yet, which has been addressed in this thesis. 
 
 
2.8 Decreased β-cell function and mass 
As discussed earlier, T2D is characterized by progressive β-cell dysfunction which 
begins as a loss in first-phase insulin secretion and followed by reduction of glucose 
sensitivity of second-phase insulin secretion, that leads to subsequent β-cell 
exhaustion, culminating in reduction of β-cell mass [79, 80]. The symphony of events 
contributing to defective insulin secretion in T2D can be summarized as impaired  
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glucose stimulus-secretion coupling, altered insulin granule exocytosis and reduction 
in insulin biosynthesis [80]. In addition to these secretory defects, the continual stress 
on the β-cells in T2D leads to loss of β-cell mass, when compared to age- and 
weight-matched non-diabetic controls [80].  β-cell mass is plastic and fluctuates to 
maintain a balance between insulin supply and demand. β-cell compensation is the 
term coined to define the adapted increase in β-cell mass upon  increased metabolic 
load caused by obesity and the inherent insulin resistance. In only 10% of pre-
diabetic individuals this compensation is inadequate leading to manifestation of T2D 
[50]. As seen by a study investigating human pancreata from autopsy, patients with  
impaired fasting glucose (IFG) revealed a 40% loss of β-cell mass, whereas in T2D, 
63% of β-cell mass was lost as compared to weight matched controls [54]. In addition 
to this, lean diabetic patients had loss of 41% of β-cell volume compared with lean 
controls. This decreased β-cell mass was found correlated with increased β-cell 
apoptosis. The observed loss in β-cell mass in pre-diabetic individuals with impaired 
fasting glucose levels provides evidence for β-cell destruction even at early stages of 
T2D [54]. Diverse phenomena like endoplasmic reticulum (ER) stress, oxidative 
stress, chronic hyperglycemia, dyslipidemia, and systemically and locally increased 
levels of cytokines, have been implicated to trigger β-cell apoptosis occurring during 
the pathogenesis of T2D.  
 
2.9 Mechanisms of β-cell death 
In T1D, destruction of β-cells occurs through activation of immune mediated 
processes such as mononuclear cell infiltration in the pancreatic islets; interaction 
between antigen presenting cells and T-cells which leads to high local concentrations 
of inflammatory cytokines, chemokines, reactive oxygen species (ROS) and other 
inflammatory products [81, 82]. Such cytokines and chemokines secreted by various 
cell-types like activated macrophages, adipocytes and also by pancreatic β-cells 
have been suggested to trigger β-cell apoptosis [83]. Two major pathways have been 
thought to occur at the onset of T1D; the perforin/granzyme and the Fas/FasL system 
[35]. Focusing on the Fas/FasL system, the expression of Fas and Fas ligand has 
been observed in inflamed islets in pancreas sections of patients with recent-onset 
T1D [84] as well as in patients with poorly controlled T2D [85]. 
The Fas receptor (CD95), a 45-kDa type I trans-membrane protein, is activated by 
interactions between β-cells and T-cells. It can also be activated through expression 
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of inflammatory mediators, i.e., cytokines, chemokines and other inflammatory 
compounds [35, 86], in addition to its binding to the endogenous ligand (FasL). The 
engagement of Fas-FasL triggers a death signaling cascade in the  β-cells [86].  
FasL is  a type II transmembrane protein of 40 kDa which is secreted in a soluble 
form (26 kDa), and is primarily expressed  on activated T-lymphocytes [87] and also 
on β-cells [85, 88]. Upon activation, Fas-associated death domain protein (FADD) 
and caspase-8 (also known as FLICE) is recruited to the receptor. Following 
caspase-8 recruitment, there occurs an autoproteolytic cleavage which activates it, 
and there is subsequent release of the active subunits. A new cycle of activation 
starts when the remaining caspase-8 prodomain is replaced by uncleaved 
procaspase-8. Previously our lab has shown that exposure of the islets to elevated 
glucose concentrations induced Fas expression, caspase-8 and -3 activation, and β-
cell apoptosis [85]. Additional investigations revealed that, Fas signals do not always 
result in apoptosis but can also trigger a pathway that leads to proliferation [89]. An 
inhibitor of Fas-induced apoptosis, termed cellular FLICE (caspase-8)-inhibitory 
protein (FLIP) [90] structurally resembles caspase-8 and thus interferes with its 
recruitment to the death-inducing signaling complex (DISC) (Figure 6). Thereby, FLIP 
can act as a switch capable of turning apoptotic signals into pro-survival  ones  [91].  
We have previously investigated this regulatory ability of FLIP with regards to its 
potential to expand β-cell mass [92]. We observed a drastic decrease in endogenous 
FLIP levels upon exposure of human islets to elevated glucose concentrations. 
Restoring the FLIP levels in these islets by over-expression induced an increase in β-
cell proliferation and reversal of apoptosis. In support of our work, a study by Cottet 
et al. has shown that FLIP is also protective against cytokine-induced activation of 
caspase-8-dependent apoptosis in an insulin-secreting cell line [93].  
An upstream regulator in the Fas signaling  is the cell surface protein TOSO or Fas 
apoptotic inhibitory protein (Faim). It has been described to be expressed in activated 
T-cells [94, 95]. In Jurkat cells, TOSO has been shown to protect from Fas induced 
apoptosis through expression of FLIP [94]. Also, in TOSO deficient mice, FLIP 
expression is down-regulated, rendering these mice to be susceptible to Fas 
triggered apoptosis [96]. In spite of the accumulating evidences of the anti-apoptotic 
role of TOSO, its presence and function in the pancreas remains to be elucidated. 
Such an investigation would provide a promising tool to block Fas induced apoptosis 
observed in β-cells during the manifestation of diabetes. Taking this into 
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consideration, this thesis addresses the presence and function of TOSO in the 
pancreatic islets, and brings forth novel observations on its role in blocking the Fas-
receptor mediated death signaling in these cells. 
 
Figure 6. Model for c-FLIP-mediated resistance to CD95 (Fas)-induced 
apoptosis [97]. A. Anti-CD95 mAb triggers CD95 leads to the recruitment of FADD 
and caspase-8 to the receptor, followed by autoproteolytic cleavage and activation of 
caspase-8. The released pro-domain is replaced by uncleaved procaspase-8, thus 
initiating another round of activation. B. This progression can be blocked by 
recruitment of c-FLIP along with caspase-8. Following initial cleavage of both 
molecules, the cleavage intermediates remain bound to the receptor and can no 
longer be replaced by procaspase-8. (Adapted from [97]) 
 
On a broader note, β-cell toxicity has been linked to various stimuli including elevated 
glucose, free fatty acids and, pro-inflammatory cytokines, leading to ER stress, and 
oxidative stress (Figure 8) [98-101]. Elevated glucose concentrations can induce β-
cell death and this may be a crucial mechanism causing β-cell failure in diabetes. 
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High glucose concentrations are detrimental to β-cell function and survival in multiple 
ways such as induction of oxidative and ER stress, β-cell overstimulation and 
elevated levels of Ca2+, inflammation, hexoamine pathway and β-cell de-
differentiation [100, 102, 103]. Reports of glucose-induced β-cell apoptosis have 
been observed in several animal models of T2D including the Psammomys obesus or 
the ZDF rat [104, 105]. Not only glucotoxicity, but also lipotoxicity plays an important 
role in underlying mechanism of type 2 diabetes. Chronically elevated levels of FFAs 
like palmitic acid induces β-cell apoptosis via varied mechanisms like generation of 
ceramide and ROS and ER stress [106-108]. FFAs, in combination with elevated 
glucose levels, further induce β-cell apoptosis, termed as glucolipotoxicity [109]. 
Another way in which this diabetogenic milieu can bring about initiation and/or 
progression of T2D is the triggering of chronic inflammation.  
 
2.10 Systemic and pancreatic inflammation  
Chronic low-grade inflammation has been shown to precede and predict the 
development of T2D [110]. Sustained activation of the immune system exists in 
obesity as witnessed by adipose tissue macrophage infiltration and pro-inflammatory 
activity of macrophages [111]. Both these cell-types have been proposed to be the 
origin of elevated circulating levels of various cytokines and chemokines, such as IL-
6, IL-8, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein 
(MIP)-1α, and TNF-α observed in patients with T2D [111]. Elevated levels of 
circulating pro-inflammatory cytokines have been implicated in development of insulin 
resistance [112], loss of β-cell function [113]. Application of anti-inflammatory 
mediators may reverse both these deleterious effects [114, 115], re-iterating the role 
of  inflammation in development of  T2D (Figure 7).  
Inflammation is local response of the immune system which involves immune cell 
migration, release of cytokines and chemokines leading to functional or structural 
damage of the invaded tissues. Inflammation is the red flag that locates and 
eliminates any infections, and also promotes regeneration of the damaged tissue. in 
spite of this, a by-stander effect might amplify the tissue damage due to inflammatory 
mediators, reactive oxygen species, and complement components [116]. When 
looked at islets from T2D individuals, the occurrence of inflammation is evidenced by 
the presence of cytokines, apoptotic cells, immune cell infiltration, amyloid deposits, 
and eventually fibrosis in these islets.  
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As the presence of inflammatory cells in islets in T2D has only recently been shown, 
inflammation of pancreatic islet in T2D is a recent concept in the context of T2D. This 
immune cell infiltration has been demonstrated in several animal models of T2D and 
in human pancreatic sections of patients with T2D [117, 118]. High fat diet increased 
the  number of islet-associated Cd11b+ cells in C57BL/6 mice as early as after 8 
weeks on this diet. Similar induction is also seen in the spontaneous model of T2D, 
the leptin receptor deficient db/db mouse. As compared to non-diabetic controls, an 
increased number of CD68+ cells/islet are seen in patients with T2D. The activated 
status of macrophages was indicated by expression of HLA-2 and CD163 by these 
cells [117]. This hints towards the possibility of inflammation being one of the 
triggering events  in T2D pathophysiology and which probably also contributes to the 
progression of the disease. Thus, in addition to systemic tissue inflammation, local 
islet inflammation might precede incidence of T2D. 
 
 
Figure 7. Type 2 diabetes as an inflammatory disease[99]. Elevated glucose 
levels induce  production of interleukin-1β (IL-1β) by the β-cells, through the 
dissociation of thioredoxin-interacting protein (TXNIP) from its inhibitor thioredoxin 
(TXR), which results in  activation of the NOD-, LRR- and pyrin domain-containing 3 
(NLRP3) inflammasome, activation of caspase 1 and processing of pro-IL-1β into its 
mature form. By activating nuclear factor-κB (NF-κB), IL-1β induces the production of 
a wide range of cytokines and chemokines such as CC-chemokine ligand 2 (CCL2), 
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CCL3 and CXC-chemokine ligand 8 (CXCL8). This is enhanced by free fatty acid 
(FFA)-induced activation of Toll-like receptor 2 (TLR2) or TLR4 and leads to the 
recruitment of macrophages. FFAs may also directly activate the NLRP3 
inflammasome. Islet-derived amyloid can activate the recruited macrophages through 
the NLRP3 inflammasome, increasing IL-1β production and the vicious cycle of IL-1β 
autostimulation through IL-1 receptor type 1 (IL-1R1). ASC, apoptosis-associated 
speck-like protein containing a CARD; MYD88, myeloid differentiation primary-
response protein 88. (Adapted from [99]) 
 
2.8.1 Cell-Cell interactions in Inflammation 
In the event of activation of an inflammatory response, elaborate series of events 
take place, which culminate in the accumulation of leukocytes and other mediators in 
the inflamed tissue. Various cell types of the immune system interact with each other 
and these interactions lead to the manifestation of the symptoms observed in 
inflammation.  Of these leukocytes, the cell types that are circulating in the blood are 
neutrophils, monocytes, eosinophils, lymphocytes, basophils. Only the lymphocytes 
have the ability to show diversity, specificity, memory, and self/non-self recognition, 
the hallmarks of an adaptive immune response. The other cell types assist in this 
adaptive immune response by either activating these lymphocytes, regulating antigen 
clearance or secreting various immune mediators. Differential expression of 
membrane proteins is used to identify different lineages or maturational stages of 
lymphocytes. These cell surface proteins are termed as a cluster of differentiation 
(CD) which are used in defining the sub-populations of these cells [119]. These cell 
surface molecules play an important role in the functional interactions between cells 
of the immune system. Along with cell surface receptors, cell adhesion molecules 
also contribute to the activation and function of the cell. Various adhesion molecules 
have been shown to contribute to the interactions between helper T(TH) cells and 
APCs, TH and B cells, and cytotoxic T lymphocytes (CTLs) and target cells. One such 
adhesion and signaling molecules are Sialic acid binding immunoglobulin-like lectins 
(Siglecs). 
 
2.11 Sialic acids 
Glycocalyx of a cell is decorated with glyco-conjugates which are contributing to the 
ability of a cell to sense the external conditions. Sialic acids (Sia) are the most 
abundant terminal carbohydrate motifs on cell surface glyco-conjugates in eukaryotic 
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cells. Sialic acids (N-acetylneuraminic acid (Neu5Ac)) are a family of acidic 9-carbon 
amino sugars (Figure 8). Neu5Ac, is synthesized in the cytoplasm from N-acetylated 
D-glucosamine (GlcNAc) or D-Mannosamine (ManNAc) by several sequential 
enzymatic reactions [120]. Neu5Ac gets converted to monophosphate (CMP)-
activated Neu5Ac in the nucleus [121], which is then transferred onto 
oligosaccharides of glycoconjugates by specific sialyl transferases in the Golgi 
apparatus [122]. In nature more than 40 forms of sialic acids exist due to additional 
modifications like O-glycosylation [123]. In addition, sialic acids can be attached in a 
variety of linkages to the underlying glycans on N-glycans, O-glycans or glycolipids, 
which are responsible for their diversity and specificity [124]. 
Sialic acids are known to play crucial roles in many cell-cell interactions, which can 
be attributed to their prominent position, negative charge and widespread distribution 
[123, 125] (Figure 8). As a consequence, altered sialylation patterns have also been 
shown to affect cellular responses such as tumorigenicity and metastatic behavior of 
malignant cells [126, 127]. Taking into account their role in cellular communication, 
the discovery of a group of lectins that specifically recognize sialic acids, i.e siglecs, 
expressed on mammalian cells of the hematopoietic system has given rise to a new 
perspectives of their role in regulation of immune response.  
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Figure 8: Examples of roles of sialic acids [128].  (A) Neu5Ac, the most common 
sialic acid in mammals (B) attribution of negative charge makes the cell hydrophilic 
(C) inhibition of complement fixation pathway (D) initiation of leukocyte extravasation. 
(E) engagement with siglecs causing inhibition or induction of cellular activation (F) 
pathogen binding (G) microbial interactions (H) modulation of immune cell function (I) 
alteration of host immune response by microbial mimicry of host Sias (J) fimbriae 
stabilization of microbes (K) Siglec-1 (sialoadhesin) expressed on macrophages 
recognizes pathogens expressing Sias and facilitates phagocytosis. (L) receptors for 
invasion of bacteriophages (M) regulate dendritic cell -T-cell interactions (N) decoys 
for Sia-binding microbes. (O) on erythrocytes and in plasma, can trap viruses (P) 
biological masks which inhibit constitutive activation of intrinsic receptors (Q) alter 
antigenicity of surface glycoconjugates  (R) formation of “xeno-autoantigens,” (S) 
reproductive incompatibility during conception (T) blood-group determination in cats 
(U) O-acetylation of Sias modulate microbial lectin interactions (V) modulate effects 
of IgG antibodies (Adapted from [128]) 
 
2.12 Siglecs: Sialic acid binding immunoglobulin-like lectins  
Siglecs are I-type lectins which recognize and interact with sialylated glycan residues 
on cell surfaces via immunoglobulin (Ig)-like domains. Structurally, siglecs are single-
pass type I integral membrane proteins showing three different domains: extracellular 
N-terminal V-set Ig domain, followed by variable numbers of C2-set Ig domains, 
ranging from 16 in Sn to 1 in CD33, and a cytosolic domain having conserved 
tyrosine residues [129]. For sialic acid recognition by the siglecs, a conserved 
arginine residue is located in their V-set domains [130]. The intracellular domains 
have  immuno-receptor tyrosine-based motifs in majority of the siglecs, which take 
part in signaling cascades. Taking into consideration the abundance of sialic acid 
residues, siglecs specifically bind either to sialylated glycans on the same cell 
surface, termed as cis-interaction, or binding to other cells, extracellular matrix 
protein or secreted glycoproteins, termed as trans-interactions. Due to their cis-
interactions, the siglecs may be masked from making any trans-interactions. 
Sialidases are enzymes that cleave sialic acid residues, hence making them 
available for any trans-interactions, this phenomenon is called 'unmasking'. Siglecs 
can be divided into two gropus on the basis of evolutionary conservation and 
sequence similarity: an evolutionarily conserved subgroup (Siglecs-1, -2, -4 and -15) 
and a rapidly evolving CD33/Siglec- 3-related subgroup (Siglecs-3; -5–11 and -14, -
16 in primates. Majority of the siglecs are expressed on the cells of the hematopoietic 
system, the exceptions being glial cell specific Siglec-4 (also known as myelin-
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associated glycoprotein or MAG) and placental Siglec-6.  The expression pattern of 
siglecs is very cell-type specific. The different cells of the immune system of both 
human and mouse express unique siglecs at different stages of development and 
activation, which is illustrated in Figure 9. 
 
 
Figure 9. Siglec expression in hematopoietic and immune cells. Illustration 
shows the cell-type specific distribution of Siglecs in human hematopoietic and 
immune cells. [131] 
 
Taking into consideration the fact that each siglec binds with highest affinity to a 
unique set of sialylated ligands, it has been assumed to carry out specific functions in 
the cell type that expresses it [132]. The intracellular domains of CD22 and most 
CD33-related siglecs have one or more immunoreceptor tyrosine-based inhibitory 
motifs (ITIMs).  Normally, these ITIMs recruit tyrosine and inositol phosphatases and 
are known to act against signaling cascades involving other activatory receptors 
having immunoreceptor tyrosine-based activation motifs (ITAMs) These cellular 
signaling interactions play a role in the immune system [132]. The constitutive cis-
interactions of the siglecs play a role in the suppression of immune responses by 
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modulating the activation states of these cells. On the other hand, the trans-
interactions facilitate cell-cell cross talk and signaling. Thus both these cis- and trans-
interactions may play an important role in immune system activation and triggering of 
inflammation. 
The structures of the different siglecs expressed in human and mouse are illustrated 
in Figure 10. 
 
 
 
Figure 10: Nomenclature and structure of siglecs in humans and mice. [131]. 
Left: CD33-related siglec subfamily in human (top) and mice (bottom).,Right: 
evolutionary conserved siglec subfamily [131] 
 
We hypothesized, that specific siglecs may be present in the pancreas due to the fact 
that inflammation contributes to the manifestation and progression of diabetes. After 
screening the human pancreatic tissue for siglecs expression, we found the 
expression of Siglec-3, -5 and -8 in the α-cells, Siglec-1, -2, -7 and -10 in the β-cell of 
the islets. Out of these siglecs, because of its observed regulation in diabetes, we 
focused our analysis on Siglec-7. Therefore, the characteristics of Siglec-7 are 
introduced in detail below.  
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2.12.1 Siglec-7: expression, structure and function 
Siglec-7 is a CD-33 related siglec expressed at low levels on granulocytes, moderate 
levels on monocytes and dendritic cells, and relatively high levels on a major subset 
of NK-cells (CD56+) and a small subset of CD8+ T cells [133]. Its molecular structure 
consists of one NH 2-terminal V-type immunoglobulin-like domain which recognizes 
mainly α-2,8 sialic acid linkages, two C2-type, a trans-membrane region and a 
cytoplasmic tail containing two tyrosine residues located in immunoreceptor tyrosine-
based inhibitory motifs [133, 134]. Functionally, Siglec-7 is an inhibitory receptor with 
regards to cell activation and differentiation. As seen in cord blood derived CD34+ 
myeloid precursor cells, cross linking of Siglec-7 on these cells inhibited their 
proliferation and differentiation [135]. However, in contrast to the use of anti-Siglec-3 
antibodies, cross linking of Siglec-7 on cells from several patients with acute myeloid 
leukemia exerted a strong inhibitory effect in distinct cases characterized by a high in 
vitro proliferation rate [136], suggesting that Siglec-7 impairs cell cycle progression 
and hence cells with a high proliferation rate are susceptible to a Siglec-7 mediated 
inhibition. In spite of the fact that Siglec-3 and Siglec-7 are expressed on the same 
cell and both recruit protein tyrosine phosphatase SHP-1, it remains to be elucidated 
by which mechanisms can they mediate different signaling events. Siglec-7 is an 
inhibitory receptor on human natural killer cells (NK cells) and monocytes [137]. 
Siglec-7 has been demonstrated to negatively regulate NK cell activation after 
engagement by antibodies [138] or binding with sialic acid-containing ligands [139]. 
Upon phosphorylation, it can majorly recruit the SH2 domain-bearing protein tyrosine 
phosphatase (PTP) SHP-1 [138]. Based on the presence of these siglecs on T cells, 
it was also shown that both Siglec-7 and Siglec-9 are capable of negative regulation 
of T cell receptor (TCR) signaling and that ligand binding is required for this activity 
[140], and ITIMs are critical for this inhibition mediated by Siglecs-7 and -9 [141]. 
Siglec-7 inhibits the FcRI-mediated serotonin release from RBL cells following cross-
linking, in an ITIM dependant manner, recruiting SHP-1 and SHP-2 [141].  
In summary, Siglec-7 can be considered as an inhibitory receptor, participating in the 
regulation of cellular activation, function and survival. We hypothesized that Siglec-7 
expression in β-cells maintains cell survival and protects the cell from an overload of 
inflammatory signals as well as the migration of activated immune cells. Therefore, I 
investigated the role of Siglec-7 on β-cell survival and function in the context of 
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diabetes. In addition to this, Siglec-7 expression was also assessed on activated 
immune cells. Taken together, the present study focuses on the role of cell adhesion 
molecules, siglecs, in the pathophysiology of diabetes.   
 
2.12.2 Involvement of siglecs in immune system responses 
Since their discovery, siglecs have been shown to play varied roles in the immune 
system [142]. One of the main points that need to be considered in inferring the 
functions of these cell adhesion molecules is the fact that their ligands i.e. sialic acids 
are very ubiquitously expressed on every cell, as a result of which the adhesion 
molecules are interacting with 'self-ligands' as well. The constitutive masked state of 
the siglecs via endogenous cis-interactions plays a prominent role in the active state 
of the immune system [143]. Sialic acid recognition of the siglecs and the subsequent 
signaling is still poorly understood. To clarify the exact mechanisms behind the 
interaction dynamics, understanding of the mechanisms of masking and unmasking 
of the siglecs may shed light on the immunoregulatory events taking place in innate 
immunity [144, 145].  
Focusing on Siglec-7, sialic acid recognition by Siglec-7 inhibited the cytoxicity of 
cells over-expressing GD3, a Siglec-7 ligand [139]. On similar lines, Siglec-7 and -9 
over-expression in a human Jurkat T cell line inhibited T cell receptor signaling, which 
was lost after mutating the residues taking part in sialic acid binding [140]. Even 
though both Siglec-7 and -9 show high homology of structure and function, the extent 
to which they individually recruit the tyrosine phosphatases is different, the latter 
being stronger than the former [137]. Also the sialic acid residues that the recognize 
are different, endogenous ligand for Siglec-7 being GD3 and that of Siglec-9 being 
GD1a [146]. 
Taken together, these findings emphasize on the differential effects of sialic acid 
recognition of the siglecs, which play decisive roles in the activation of immune 
responses.  
Alterations in the state of the immune system have been shown to be accompanied 
by alterations in siglec expression and function. Known triggers of immune system 
activation like LPS have been shown to induce Siglec-E (mouse orthologue) 
expression on bone marrow–derived macrophages in a TLR-dependant fashion 
[147]. This up-regulation is accompanied with suppression of the pro-inflammatory 
cytokine response that is a hallmark of such TLR engagement. Translating the results 
P a g e  | 34 
 
to human Siglec-9, its inhibitory effect against TLRs was evidenced as a decrease in 
TNF-α and IL-6 production, which required its intact ITIM signaling [148]. In support 
of these findings, there is reduced expression of IL-12 after LPS stimulation of 
monocyte-derived dendritic cells observed after induction of Siglec-9 signaling in 
these cells [149]. Another important observation from these studies is that functional 
or structural orthologues of the human siglecs in mice do not always show identical 
regulation in these animals, as seen by the contradictory down-regulation of Siglec-9 
in DCs exposed to LPS [149].  
In terms of regulation of the inhibitory signaling of siglecs, not only is the extent of 
interaction between receptor and ligand crucial, but also modulation of cell-surface 
expression can be a mechanism of control. As is shown in a recent study, SH2-
domain containing suppressor of cytokine signaling-3 (SOCS-3) competes with 
SHP1/2 for binding to human and Siglec-7 ITIMs [150] Ligation of SOCS-3 leads to 
recruitment of ECS E3 ligase which marks the Siglec-7 for proteosomal degradation. 
This in turn leads to loss of inhibition of cytokine-induced cell proliferation by Siglec-7, 
leading to regulation of inflammatory responses in these cells.  
In summary, recent studies in this field support the hypothesis that siglecs are a 
family of receptors, which regulate the immune responses by affecting the 
proliferation, differentiation and activation of the cell-type expressing them. Thus, 
signaling cascades involving sialic acid recognition in a trans [144] or cis [140, 151] 
manner might take part in regulation of leukocyte responses in the event of 
inflammation.  
 
2.11 Aims of the thesis  
This thesis investigates different aspects of β-cell function and survival in the face of 
diabetes to explore 3 different angles to rescue the β-cell in diabetes, and answer 3 
questions: (1) Are there any tools to induce proliferation in mature β-cell? (2) What 
are the effects DPP4 inhibitors on β-cell turnover and function? and (3) What are the 
players involved in the complex interplay of immune cells and β-cells within 
pancreatic islets? As introduced in the previous chapters, the phenomenon of β-cell 
loss is multi-factorial. Also, diabetes is a metabolic syndrome in which multiple organ 
systems are affected. Alongside with insulin resistance and chronic inflammation, 
T2D progresses after loss of β-cell function and mass. In this dissertation, I worked 
on diverse molecules which play a role in diabetes progression.  
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(1) In order to come up with strategies to rescue the β-cells from apoptosis, I 
investigated Fas/FasL mediated β-cell death, and introduced a novel regulator, 
TOSO, of this pathway in the β-cell.  Whether TOSO is present and functioning in the 
pancreas has not been investigated, but would provide a promising tool to block Fas 
induced apoptosis also in β-cells. The advantage of TOSO would be to regulate 
endogenous FLIP levels to enhance the cell's proliferative capacity. Here, I provide 
evidence for constitutive expression of TOSO in the human β-cell and suggest a 
novel approach to prevent and treat diabetes by switching Fas signaling from 
apoptosis to proliferation. 
(2) One of the aims of this thesis was to test whether a DPP-4 inhibitor would restore 
β-cell function and survival under diabetogenic conditions in human islets and 
whether cytokine production from islets under such conditions is affected. For our 
studies, Linagliptin, a xanthine-based, highly potent and long-acting DPP-4 inhibitor 
was used, which has recently been approved for the treatment of T2D (18, 19). This 
thesis provides evidence that Linagliptin improves β-cell survival and function in 
human islets through stabilization of GLP-1, which is secreted during islet culture. 
(3) Taking into consideration the role of siglecs in an immune response and the 
implication of inflammation in the development of diabetes, I hypothesized that 
siglecs are expressed within pancreatic islets and are affected by a diabetic milieu 
and such changes in siglec expression could cause β-cell death and dysfunction. 
After screening human pancreas, analyses revealed differential expression of siglecs 
in the Islet of Langerhans. Specifically, Siglec-7 was expressed solely in the β-cell 
and was down-regulated in inflamed islets in diabetes. Restoring Siglec-7 expression 
in these islets could improve β-cell survival and function by inhibiting the pro-
inflammatory responses. As Siglec-7 is known to be endogenously expressed in 
monocytes, I assessed it’s regulation during the activation of these cells observed in 
diabetes. As shown here, Siglec-7 expression is decreased in activated immune 
system. Finally, this thesis aimed to elucidate the significance of siglecs in the 
activation of immune cells, and brought forth the protective role of Siglec-7 in 
prevention of immune cell migration towards stressed and inflamed islets. 
Thus, this thesis aimed to explore the β-cell destruction caused by chronic 
inflammation during the progression of diabetes. The ultimate goal is to bring forth 
novel players in the triggering of islet inflammation, which could be potential targets in 
prevention and/or cure of diabetes.  
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TOSO promotes b-cell proliferation and protects
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ABSTRACT
Decreased b-cell mass reflects a shift from quiescence/proliferation into apoptosis, it plays a crucial role in the pathophysiology of diabetes.
A major attempt to restore b-cell mass and normoglycemia is to improve b-cell survival. Here we show that switching off the Fas pathway
using Fas apoptotic inhibitory protein (Faim/TOSO), which regulates apoptosis upstream of caspase 8, blocked b-cell apoptosis and
increased proliferation in human islets. TOSO was clearly expressed in pancreatic b-cells and down-regulated in T2DM. TOSO expression
correlated with b-cell turnover; at conditions of improved survival, TOSO was induced. In contrast, TOSO downregulation induced b-cell
apoptosis. Although TOSO overexpression resulted in a 3-fold induction of proliferation, proliferating b-cells showed a very limited capacity
to undergo multiple rounds of replication. Our data suggest that TOSO is an important regulator of b-cell turnover and switches b-cell
apoptosis into proliferation.
& 2012 Elsevier GmbH. All rights reserved.
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INTRODUCTION
In both T1DM and T2DM, the major mechanism leading to decreased
b-cell mass is increased b-cell apoptosis [1–3]. In T1DM, b-cell
destruction occurs through immune mediated processes; mononuclear
cell infiltration in the pancreatic islets and interaction between antigen
presenting cells and T-cells lead to high local concentrations of
inflammatory cytokines, chemokines, reactive oxygen species (ROS)
and other inflammatory products [4,5]. Cytokines and chemokines
produced and secreted by activated macrophages, adipocytes and also
by pancreatic b-cells have been suggested to initiate b-cell apopto-
sis [6]. Two major pathways trigger the onset of T1DM; the perforin/
granzyme and the Fas/FasL system [7]. The Fas receptor (CD95), a 45-
kDa type I transmembrane protein, is activated through interactions
between antigen presenting b-cell and T-cells as well as through local
expression of inflammatory mediators, i.e. cytokines, chemokines and
other inflammatory compounds [5,7]. Fas binds to its ligand (FasL) and
thus, initiates b-cell apoptosis [5].
FasL, a type II transmembrane protein of 40 kDa that can be secreted
in a soluble form (26 kDa), is expressed primarily on activated T-
lymphocytes [8] and also on b-cells [9,10]. Fas and Fas ligand are
expressed in inflamed islets in pancreas sections of patients with
recent-onset T1DM [11] as well as in patients with poorly controlled
T2DM [9]. Triggering of Fas leads to the recruitment of Fas-associated
death domain protein (FADD) and caspase-8 to the receptor (see Fig. 4).
Binding of caspase-8 results in its activation by autoproteolytic
cleavage and the release of the active subunits. The remaining
caspase-8 prodomain is replaced by uncleaved procaspase-8, which
then starts a new activation cycle.
A NOD mouse strain with a mutation in the Fas receptor, NOD lpr/lpr,
did not develop diabetes [12]. b-cells from NOD mice that express a
dominant-negative form of the Fas-associated death domain protein
(FADD) were resistant to Fas induced cell death in vitro and in vivo.
Furthermore, deletion of Fas protects islets from the toxic effects of
cytokines [13] and of islet amyloid polypeptide (hIAPP) [14], which is
suggested to be a major contributor to b-cell failure in T2DM [15].
In line with this observation, there are numerous studies on isolated
rodent and human islets showing cytokine-induced Fas upregulation in
the b-cell [10,16–18]. On the other hand, islets from NOD lpr/lpr were
not protected against the autoimmune attack when transplanted into
diabetic wild type recipients [19]; and only very few Fas-expressing b-
cells were detected in islets of NOD mice at the onset of hyperglycemia
[20]. Also, Fas signaling is needed for insulin secretion as shown in
mice, pointing to a physiological role of the Fas receptor in b-cells. In
human islets, an inhibitor of Fas-induced apoptosis, termed cellular
FLICE (caspase-8)-inhibitory protein (FLIP) [21], was able to protect b-
cells from cell death and restored b-cell function even under
hyperglycemic conditions and in the presence of Fas. FLIP structurally
resembles caspase-8 and thus interferes with its recruitment to the
death-inducing signaling complex (DISC) and hence plays a critical role
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as an endogenous modulator of apoptosis [22]. Moreover, Fas signals
do not always result in apoptosis but can also trigger a pathway that
leads to proliferation [23]. Thereby, FLIP is pivotal in turning signals
from cell death into those for cell survival/proliferation [24]. In b-cells,
FLIP switched Fas activation from a death signal into a proliferation
signal, and this may potentially expand b-cell mass [25]. The
antagonistic anti-Fas antibody ZB4 inhibited the beneficial effect of
FLIP at elevated glucose, demonstrating that Fas receptor activation is
required for FLIP mediated proliferation. FLIP is also protective against
cytokine-induced activation of caspase-8-dependent apoptosis [26].
A further upstream regulator of Fas is the cell surface protein TOSO,
also named Fas apoptotic inhibitory protein (Faim3). It is expressed in
activated T-cells [27,28]. TOSO negatively regulates FasL- and TNFa-
induced apoptosis in lymphoma cell lines [29]. Also, a TOSO antibody
potentiates TNFa induced apoptosis [29]. TOSO overexpressing Jurkat
cells are resistant to Fas induced apoptosis through expression of FLIP
[27]. FLIP expression levels are down-regulated in TOSO-deficient
mice, causing these mice to be highly sensitive to Fas triggered
apoptosis [30].
Thus, TOSO would provide a promising tool to block Fas induced
apoptosis in b-cells, and its presence and function in human islets was
investigated in the present study. The advantage of TOSO would be to
regulate endogenous FLIP levels. These physiological FLIP levels are
often not achieved by FLIP overexpression, and higher FLIP levels could
even reverse its effect by induction of cell death. In the present study
we provide evidence for constitutive expression of TOSO in the human
b-cell and suggest a novel approach to prevent and treat diabetes by
switching Fas signaling from apoptosis to proliferation. However,
multiple rounds of self-duplication could not be achieved in human
b-cells, confirming previous observations, which show that human b-
cells have only a very limited capacity to self-duplicate [31].
MATERIAL AND METHODS
Islet culture
Human islets were isolated from pancreata of 8 healthy organ donors at
the University of Lille or University of Chicago and cultured in CMRL-
1066 medium as described previously [32]. Islets were cultured on
extracellular matrix coated dishes derived from bovine corneal
endothelial cells (Novamed Ltd., Jerusalem, Israel) for 4 days, allowing
the cells to attach to the dishes and spread [33] and exposed to 5.5,
11.1, or 33.3 mM glucose or 5.5 mM plus recombinant human IL-1b
(0.02–2 ng/ml, R&D Systems, Minneapolis, MN) or IFNg (1000 U/ml,
PeproTec, Rocky Hill, NJ, USA).
Transfection
At 2 days post-isolation and culture on extracellular matrix coated
dishes, isolated islets were exposed to transfection using Ca2þ–KRH
medium (KCl 4.74 mM, KH2PO4 1.19 mM, MgCl26H2O 1.19 mM, NaCl
119 mM, CaCl2 2.54 mM, NaHCO3 25 mM, HEPES 10 mM). After 1 h
incubation lipoplexes (Lipofectamine2000, Invitrogen, Carlsbad, CA,
USA)/DNA ratio 2.5:1, 3 mg CMV-TOSO, RIP-TOSO, or CMV-GFP control
plasmid DNA/100 islets or 50 nM siRNA to TOSO (RNAs of 21
nucleotides, designed to target human TOSO; ON-TARGETplus SMART-
pool human FAIM3), (Dharmacon, Lafayette CO, USA) and scramble
siRNA (Dharmacon) were added to transfect the cells as described
previously [34,35]. After additional 6 h incubation, CMRL 1066 medium
containing 20% FCS and L-Glutamine were added to the transfected
islets. Transfection efficiency was determined using RT PCR,
immunocytochemistry and western blotting. TOSO plasmid was
obtained from the Full-Length Mammalian Gene Collection (invitrogen)
and cloned into the pIRES2-AcGFP1 vector (invitrogen) named CMV-
TOSO or into the pIT-HindIII-A-myc vector (kindly provided by T. Tru¨b,
University Hospital Zurich), named RIP-TOSO.
Cell culture and thymidine analog administration
Post-transfection, the culture medium was supplemented with
10 mmol/L of CldU (Sigma, St. Louis, MO, USA, cat#C6891) for 1 or
2 days followed by 10 mmol/L of IdU (MP Biomedicals, Illkirch, France,
cat#100357) for same time duration.
Glucose stimulated insulin secretion
Islets used to perform glucose-stimulated insulin secretion experiments
were kept in culture medium on matrix-coated plates. For acute insulin
release in response to glucose, islets were washed and pre-incubated
(30 min) in Krebs-Ringer bicarbonate buffer (KRB) containing 2.8 mM
glucose and 0.5% BSA. KRB was then replaced by KRB 2.8 mM
glucose for 1 h (basal), followed by an additional 1 h in KRB 16.7 mM
glucose (stimulated). Islets were extracted with 0.18 N HCl in 70%
ethanol for determination of insulin content. Islet insulin was deter-
mined using mouse insulin ELISA (ALPCO, Salem, NH, USA).
RNA extraction and RT-PCR analysis
Total RNA was isolated from cultured human islets as described
previously [32]. For quantitative analysis, we used the Applied
Biosystems StepOne Real-Time PCR system (Applied Biosystems,
Carlsbad, CA, USA) with a commercial kit (Power SYBR Green PCR
Master Mix; Applied Biosystems). Primers used: 50CATGAACACAGA
CCGGG30/50GAACTGGAGGGACCTTG-30 (human TOSO), 50GTTGGCCAGG
CTGGTGTCCAG30/50CTGTGATGAGCTGCTCAGGGTGG30 (human tubulin),
and 50TCACCCACACTGTGCCCATCTACGA30/50CAGCGGAACCGCTCATTGC
CAATGG30 (b-actin).
Western blot analysis
At the end of the incubation periods, islets were washed in ice-cold
PBS and lysed for 40 min on ice in 40 ml lysis buffer containing 20 mM
Tris acetate, 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 1%
Triton X-100, 5 mM sodium pyrophosphate and 10 mM b-glyceropho-
sphate. Prior to use, the lysis buffer was supplemented with Protease-
and Phosphatase-inhibitors (Pierce, Rockford, IL, USA). Equivalent
amounts of protein from each treatment group were run on a NuPAGE
4–12% Bis-Tris gel (Invitrogen) and electrically transferred onto PVDF
membranes. Membranes were incubated with rabbit anti-TOSO and
rabbit anti-FLIPL (C-19), (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA), and rabbit anti-b-actin (Cell Signaling Technology, Danvers, MA,
USA) antibodies, followed by horseradish-peroxidase-linked anti-
rabbit IgG.
Immunocytochemistry
Pancreatic sections from 8 healthy controls (4 lean and 4 obese) and
from 7 patients (3 lean and 4 obese) with T2DM were obtained from the
National Disease Research Interchange (NDRI), approval for the studies
were granted by the Ethical Commission of Bremen University. For
detection of b-cell TOSO expression insulin and TOSO staining were
performed, 3 sections/pancreas were incubated in blocking buffer
containing 0.2% Tween 20, 3% IgG-free Bovine serum albumin (BSA),
0.5% Triton X-100 for 1 h RT and overnight at 4 1C with rabbit anti-
TOSO (Santa Cruz). Subsequently, all sections were double-stained for
insulin and detected by donkey anti-guinea pig FITC-conjugated
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antibody (Dako, Hamburg, Germany). To evaluate TOSO antibody
specificity, the antibody was pre-incubated for 1 h at 37 1C with TOSO
blocking peptide (Santa Cruz). Intensity and saturation of the staining
was measured using Adobe Photoshop& Extended analysis software
after an adapted model used by Pham et al. [36], expressed per islet
area and normalized to the background signal.
For lineage tracing experiments, cultured islets were fixed in 4%
paraformaldehyde for 30 min RT; permeabilized by 0.5% Triton-X-100
for 4 min RT and incubated in freshly diluted 1.5 N HCl for 40 min RT.
After blocking for 1 h RT, staining for IdU and insulin was carried with
by incubating with mouse anti-BrdU antisera (1:100) (Dako) and guinea
pig anti-insulin (1:100) (Cat#18-0067; Zymed Laboratories Inc., San
Francisco, CA, USA) overnight at 4 1C. The dishes were washed in a
low salt TBST Buffer (36 mM Tris, 50 mM NaCl, 0.5% Tween-20; pH
8.0) and then in PBS. For CldU staining, dishes were incubated with Rat
anti BrdU (Dako) (1:100; diluted in antibody dilution buffer) overnight at
4 1C. Incubation with secondary antibodies was carried out using AMCA
donkey anti-Guinea Pig (1:100), Cy3 donkey anti-rat (1:100 and FITC
donkey anti-mouse (1:100) at RT for 1 h).
For detection of b-cell apoptosis and proliferation, insulin and TUNEL or
Ki67 staining (In Situ Cell Death Detection Kit, TMR red; Roche
Diagnostics, Mannheim, Germany) were performed as described
previously [37]. Fluorescent dishes were analyzed using Nikon
MEA53200 (Nikon GmbH, Dusseldorf, Germany) microscope and
images were acquired using NIS-Elements software (Nikon).
Statistical analysis
Samples were evaluated in a randomized manner by 2 investigators
(G.D, S.L.) who were blinded to the treatment conditions. Data are
presented as means7SE and were analyzed by Student’s t-tests. To
account for multiplicity in the treated cells in vitro, a Bonferroni
correction was used.
RESULTS
TOSO is down-regulated in diabetes and correlates positively with b-
cell proliferation and negatively with b-cell apoptosis
To identify cell type specific TOSO localization in the human pancreas,
we assessed TOSO expression in pancreatic sections from autopsy
from lean and obese non-diabetic patients and from patients with
T2DM. The specificity of the antibody was confirmed by pre-incubation
with TOSO blocking peptide as a negative control (Fig. 1A, right panel).
Constitutive expression of TOSO was detected in insulin producing b-
cells in human pancreatic sections. TOSO was expressed in both lean
and obese non-diabetic patients but depleted in lean and obese
patients with T2DM (Fig. 1A). Quantification of the staining showed a
2.1-fold and 8.6-fold decrease in intensity and saturation in lean
patients with T2DM vs. lean controls and a 3.5- and 9.9-fold decrease
in intensity and saturation in obese patients with T2DM vs. obese
controls, respectively (Fig. 1B).
To investigate whether such changes in TOSO expression occur during
the process of the switch from proliferation into apoptosis, we analyzed
TOSO expression in isolated human islets in response to short-term
(12 h, Fig. 1C) and long-term (72 h, Fig. 1D) incubation with elevated
glucose concentrations, 2 distinct conditions when glucose induced
proliferation (Fig. 1F) or apoptosis (Fig. 1G).
TOSO was up-regulated dependent on glucose concentrations during
12 h of exposure; in contrast, TOSO was down regulated to almost
undetectable levels after long-term incubation of the islets for 72 h
(Fig. 1D), a condition where glucose induced b-cell apoptosis (Fig. 1G).
Previously we have found that the cytokine IL-1b has also a dual
physiological role on the regulation of b-cell function and survival
[38,39], it induces proliferation at low and apoptosis at high
concentrations (Fig. 1H). In line with these findings, low-dose IL-1b
induced TOSO expression while high-dose almost depleted TOSO mRNA
expression (Fig. 1E).
TOSO improves b-cell survival and function under diabetogenic
conditions
To understand the physiological role of TOSO depletion in diabetes on
the b-cell, the expression of TOSO was silenced in isolated human
islets by using specific siRNAs. TOSO levels resulting from its
overexpression and depletion were analyzed by immunocytochemistry
(Fig. 2A), RT-PCR (Fig. 2D) and Western blotting (Fig. 2E). Protein was
almost undetectable in islets upon siRNA treatment and RNA was 4.3-
fold down-regulated (Fig. 2D), while overexpression was achieved in
almost all islet cells even under elevated glucose or IL-1b/IFNg
exposure (Fig. 2A).
TOSO depletion resulted in a 3.3-fold induction of b-cell apoptosis,
similar to cytokine exposure for 4 days (3.5-fold induction, Fig. 2A
and B).
Also, b-cell apoptosis was 4-fold increased by the cytokine mix IL-1b/
IFNg and 3.5-fold by 33.3 mM glucose, which was prevented by CMV-
TOSO overexpression.
On the other hand, TOSO overexpression induced a 2.6-fold increase in
b-cell proliferation, as assessed by the mitotic marker Ki67 (Fig. 2C).
b-cell proliferation decreased upon cytokine and elevated glucose
treatment, which was back to basal levels upon TOSO overexpression.
The pro-survival effect of TOSO expression was hypothesized to be due
to the regulation of cFLIP, which leads to inhibition of apoptotic Fas
signaling and acts as a switch to proliferation. Hence, we analyzed the
levels of FLIP upon depletion and overexpression of TOSO. To address
the effect of paracrine signaling, overexpression was carried out either
specifically in the b-cells by using a rat insulin promoter driven
expression plasmid (RIP-TOSO), or in all islet cell types using a
cytomegalovirus driven plasmid (CMV-TOSO). Western blot analysis
confirmed the efficient silencing and overexpression of TOSO at the
protein level (Fig. 2E). Depletion of TOSO caused reduced FLIP
expression; and, similarly, the increased amount of TOSO induced FLIP
expression (Fig. 2E). b-cell proliferation was analyzed using the Ki67
antibody as shown in Fig. 2C, and was confirmed to be increased upon
both b-cell specific and universal induction of TOSO expression, thus
emphasizing its signaling in b-cells themselves (Fig. 2F).
The effect of the varying levels of TOSO expression on b-cell function
was analyzed by carrying out glucose stimulated insulin secretion
(GSIS) after depletion or overexpression of TOSO in presence and
absence of diabetic stimuli. Elevated glucose and cytokines completely
abolished GSIS, and also TOSO depletion resulted in a 2.2-fold
(po0.05) reduction in the stimulatory index at basal conditions, but
had no additive effect in islets exposed to diabetic milieu (Fig. 2G and
H) at elevated glucose (33.3 mM) or the cytokine mixture. In contrast,
TOSO overexpression improved GSIS 3.1-fold at elevated glucose levels
and 1.4-fold (po0.05) at cytokine treatment (Fig. 2I and J), while at
basal condition at 5.5 mM glucose, it had no effect.
TOSO overexpression induces early proliferation in b-cells
Sequential thymidine analog labeling is a recent and effective method
for lineage tracing of proliferating cells, previously used in vivo to show
the lack of any specialized b-cell progenitors in mice [40]. We
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Fig. 1: TOSO is downregulated in T2DM and correlates positively with b-cell proliferation and negatively with b-cell apoptosis. (A,B) Representative co-staining for TOSO in red and insulin in green in human pancreatic sections from poorly controlled lean (n¼4) and
obese (n¼3) patients with T2DM and lean (n¼4) and obese (n¼4) non-diabetic controls. From each pancreas, 3 sections were stained and analyzed and measurements for intensity and saturation are given as signal divided by islet area and normalized to
background. Small symbols show means of all analyzed islets/pancreas, large symbols show means7SE of all pancreases/group. (C–H) Human pancreatic islets were cultured on extracellular matrix-coated dishes and exposed to increasing concentrations of glucose
(5.5–33.3 mM) for 12 (C,F) and 72 (D,G) h or to IL-1b (0.01–2 ng/ml) for 72 h (E,H). TOSO mRNA expression was analyzed by RT-PCR and expressed as relative changes of control and compared to Tubulin levels (C–E). In parallel, proliferation was measured by
the Ki67 antibody stained in red and apoptosis analyzed by the TUNEL assay (F–H). Islets were triple-stained for insulin and counterstained for DAPI (not shown). Results are means7SE of the percentage of Ki67- and TUNEL-positive b-cells. The average number of
b-cells counted was 8150 for each treatment group in 3 separate experiments from 3 different organ donors.
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optimized the protocol to be used to detect multiple rounds of
proliferation in vitro using immunocytochemistry.
To assess the nature of increased proliferation of b-cells upon TOSO
overexpression, sequential thymidine analog labeling was carried out
after overexpression of TOSO driven by the rat insulin promoter (RIP-
TOSO) or cytomegalovirus promoter (CMV-TOSO). On day 1 and 2 after
the RIP/CMV-TOSO transfection, we incorporated 10 mmol/L of the
thymidine analogs 5-chloro-2-deoxyuridine (CldU) and 5-iodo-2-
deoxyuridine (IdU), respectively for 1 day (Fig. 3A) into the islet culture
medium. To exclude an effect of the expression changes of TOSO after
overexpression and to take into account the number of days after
transfection, analogs were also incorporated on day 2 and day 4 after
transfection in a parallel experiment (Fig. 3B). The incorporation
of the analogs, and thus the proliferation, was visualized using
immunocytochemistry.
After quantification, it was observed that under control conditions, the
extent of proliferation during administration of both the analogs was
similar (Fig. 3A and B). In the TOSO transfected islets, there was an
about 2-fold induction in b-cell proliferation (2.4-fold and 3.0-fold by
RIP- and CMV-TOSO, respectively when CldU was administered over
1 day, Fig. 3A, and 3.1-fold and 4.3-fold by RIP- and CMV-TOSO,
respectively when CldU was administered over 2 days, Fig. 3B). The
percentage of b-cells undergoing proliferation during the administration
of the second analog IdU was significantly less than that during the first
CldU administration (1.5-fold and 1.7-fold decrease during IdU
compared to CldU by RIP- and CMV-TOSO, respectively when analogs
were administered over 1 day, Fig. 3A, and 2.0-fold and 2.8-fold
increase during IdU administration by RIP- and CMV-TOSO, respectively
when analogs were administered over 2 days, Fig. 3B). A very small
percentage (0.04–0.08%) of co-labeled cells were observed in the
TOSO transfected samples as compared to 0.01% in the control
(Fig. 3A and B), suggesting a very limited capacity of b-cells to undergo
multiple rounds of proliferation. To eliminate the possibility of
preferential analog uptake, the sequence of analogs was reversed
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medium. Thereafter, islets were fixed and labeled for thymidine incorporation by using specific antibodies against CldU and IdU (see material and methods). Results are means7SE of the percentage of CldU/IdU-positive b-cells. The average number of b-
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and the data obtained was found to be consistent (data not shown).
Also, for taking into account the number of days after transfection,
2 different administration time durations were implemented, 2 days or
1 day per analog, which consistently showed that TOSO overexpression
led to an induction of an early round of proliferation in the b-cells
(Fig. 3A and B).
As a proof of principle, lineage tracing was carried out in HeLa cells
and proliferating differentially labeled cells could be observed (Fig. 3C).
Fig. 3D–F shows fluorescent microscopic images of a very limited
number of cells inside the islets carrying the thymidine analog labels.
Co-staining for insulin confirms the analysis in b-cells (Fig. 3E and F).
DISCUSSION
More than a decade ago, Hitoshi et al. cloned and characterized a novel
immunoglobulin domain-containing type I transmembrane protein,
TOSO, exhibiting potent pathway-specific anti-apoptotic effects in
hematopoietic cells [27]. TOSO inhibited apoptosis induced by Fas-,
TNFa-, FADD-, and PMA/ionomycin; but not staurosporine- or
ceramide-induced apoptosis. The mechanism of inhibition and its
specificity were hypothesized to be due to inhibition of caspase-8
processing through induction of cFLIP expression. The name TOSO was
given after a Japanese liquor that is drunk on New Year’s Day to
celebrate long life and eternal youth [27], reflecting its pro-survival
effect.
The role of TOSO in maintaining cFLIP expression during Fas mediated
apoptosis of lymphocytes and hepatocytes has been elucidated using
TOSO / mice [30]. B-cells and thymocytes from these mice show
increased sensitivity to Fas-triggered apoptosis, and these mice suffer
greater mortality and exhibit exacerbated liver damage in response to
Fas engagement in vivo. TOSO modulates Fas-mediated apoptosis by
influencing the expression of c-FLIP and regulating the physical binding
of caspase-8 to Fas receptor.
The anti-apoptotic function of TOSO depends on ubiquitination of an
adapter kinase, RIP1, and involves the recruitment of the death adapter
FADD to a TOSO/RIP1 protein complex. Upon activation by FasL and
TNFa, TOSO promotes the activation of pro-survival signaling pathways
and protects from liver damage [29]. TLR activation leads to decreased
TOSO expression shown in leukemic B-cells [41].
The activation of inflammatory pathways has been discovered as a
causal event for b-cell destruction in diabetes [42,43], which is also
mediated by TLR activation [32,44].
Thereby, not only pro-inflammatory compounds are activated (e.g. IL-
1b, Fas), but also the anti-inflammatory cytokine interleukin-1 receptor
antagonist and the anti-apoptotic cFLIP are down-regulated in b-cells
in diabetes [9,42,45], and also TOSO downregulation was reported in
response to TLR activation [41].
Thus, attempts to block Fas-induced apoptosis and the activation of
pro-inflammatory cytokines could be a strategy to prevent diabetes.
Here we show down-regulation of another protective factor in T2DM,
and its loss promotes b-cell destruction.
TOSO expression correlated positively with b-cell proliferation; both the
proliferation-inducing treatments i.e. acute high glucose and low dose
IL-1b positively regulated TOSO expression. On the other hand, pro-
apoptotic stimuli i.e. chronic elevated glucose and high dose IL-1b
almost depleted TOSO mRNA expression. Thus, depletion of TOSO
coincides with activation of b-cell apoptosis under conditions of stress.
TOSO, when overexpressed, not only rescued b-cells from apoptosis
but also triggered proliferation. This pro-survival signaling has also
been observed in TOSO overexpressing Jurkat cells in which CD95L-
and TNFa stimulation readily induced the activation of Erk1/2 [29].
While TNFa potentiates cell death, it is insufficient to cause apoptosis
in b-cells [46]. Since TOSO promotes the TNFa induced signaling
cascade, it is possible, that TNFa would induce b-cell apoptosis in the
absence of TOSO, but there is no experimental proof for this hypothesis
so far.
Intact Fas receptor signaling is also necessary for b-cell secretory
function [47]. Hence, we investigated whether TOSO expression can
also contribute to glucose stimulated insulin secretion. While TOSO
overexpression was not effective at basal glucose levels, our results
show that TOSO protected the inhibition of insulin secretion by elevated
glucose and cytokines and restored b-cell function.
Mature human b-cells have only a very limited capacity to undergo
proliferation [31]. To control and to foster b-cell proliferation has
become a long-term goal in b-cell research. With the goal to find a
subpopulation of b-cells with a higher proliferative capacity, we
overexpressed TOSO and investigated the nature of the induced
proliferation by using the technique of sequential thymidine analog
labeling, previously developed in mice by Teta et al. [40].
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We optimized the method so that it could be used in a similar fashion
in vitro in human islets, to detect multiple rounds of proliferation. TOSO
overexpression induced an early round of proliferation in the isolated
human islets, irrespective of any effect of sequence of analog
administration or time after transfection, however, only in a very
limited number of islets (maximum 0.08%), more than one round of
proliferation was observed during the 6-d culture period. Such limited
proliferation capacity is in confirmation with the results from mouse b-
cells in vivo [40,48].
CONCLUSIONS
In summary, TOSO is a novel anti-apoptotic protein, which interferes
with the Fas triggered apoptosis by regulating FLIP and thereby
initiating a pro-survival signaling cascade (see Fig. 4 for our model).
Thus, TOSO hints to be a promising therapeutic target to rescue b-cells
from apoptosis induced by elevated glucose and cytokines and, hence,
intervening in the progression of diabetes. However, with the means of
TOSO, we were unable to develop a b-cell, which would undergo
multiple rounds of replication during culture.
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Context. Inhibition of Dipeptidyl peptidase-4 (DPP-4) is a potent strategy to increase GIP and
GLP-1 induced insulin secretion in diabetes. It is important to know if new drugs approved for
the treatment of type 2 diabetes have direct effects on the -cell.
Objective. Herein, we investigated the effect of linagliptin, a novel DPP-4 inhibitor, on -cell
function and survival.
Design. Human islets were exposed to a diabetic milieu (11.1–33.3 mM glucose, 0.5 mM palmitic
acid, the mixture of 2 ng/ml IL-11,000 U/ml IFN- or 50 M H2O2) with or without 500 ng/ml
Interleukin-1Receptor Antagonist (IL-1Ra) or 30–50 nM linagliptin.
Results. Linagliptin restored -cell function and turnover, which was impaired when islets were
exposed to elevated glucose, palmitate, cytokines or H2O2. Pre-treatment with IL-1Ra was sim-
ilarly effective, except against H2O2 treatment. Nitrotyrosine concentrations in islet lysates, an
indicator of oxidative stress, were highly elevated under diabetic conditions, but not in islets
treatedwith linagliptin or IL-1Ra. Linagliptin also reduced cytokine secretion and stabilizedGLP-1
in islet supernatants.
Conclusions. We show that the novel DPP-4 inhibitor linagliptin protected from gluco-, lipo- and
cytokine-toxicity and stabilized active GLP-1 secreted from human islets. This provides a direct
GLP-1 mediated protective effect of linagliptin on -cell function and survival.
Dipeptidyl peptidase 4 (DPP-4) is a ubiquitous cell-membrane protein enzyme responsible for cleaving
and inactivating both incretins - glucagon like peptide 1
(GLP-1) and glucose-dependent insulinotropic polypep-
tide (GIP) (1), which are released by cells in the small
intestine after the ingestion of food and which potentiate
glucose stimulated insulin secretion (2). Patients with type
2 diabetes mellitus (T2D) have impaired insulin secretion,
chronic hyperglycaemia and the effect of the incretins is
significantly reduced (3).
Incretin-based therapies such as injectable GLP-1 re-
ceptor agonists or DPP-4 inhibitors are established treat-
ments for T2D because of their glucose-dependent stim-
ulation of insulin secretion, their inhibition of glucagon
secretion and their intrinsic lack of risk for hypoglycemia
(4), although an increased risk for pancreatitis has been
discussed recently (5).
Long-termclinical effects of incretin-baseddrugson the
-cell are still speculative (6). However, numerous in vivo
and in vitro studies in rodents show that GLP-1 increases
-cell mass, proliferation (7, 8, 9) and -cell neogenesis
(10). GLP-1 inhibits -cell apoptosis in human islets (11,
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12, 13), and a protective effect was also observed in islets
isolated from patients with T2D (14).
Accordingly, stabilizing GLP-1 byDPP-4 inhibition re-
stores glycemic control in diabetic animal models (2), im-
proves -cell survival, replication and neogenesis in the
diabetic mouse and rat streptozotocin model (15, 16) and
in the VDF diabetic rat (17).
The direct effect of DPP-4 inhibitors on human -cells
has not been investigated yet. Thus, the aim of this study
was to test whether aDPP-4 inhibitor would restore-cell
function and survival under diabetogenic conditions in
human islets and whether cytokine production from islets
under such conditions is affected. For our studies, lina-
gliptin, a xanthine-based, highly potent and long-acting-
DPP-4 inhibitor was used, which has recently been ap-
proved for the treatment of T2D (18, 19). Interleukin-1
Receptor antagonist (IL-1Ra), which improves -cell sur-
vival and functionbyneutralizing IL-1 (20, 21),wasused
as a positive control for a -cell protective effect. In the
present study we provide evidence that linagliptin im-
proves -cell survival and function in human islets
through stabilization of GLP-1, which is secreted during
islet culture.
Materials and Methods
Cell culture. Human islets were isolated from eight pancreata of
healthy organ donors at Lille University and cultured in CMRL-
1066 medium as described previously (22, 23). Islet purity was
greater than 95% as judged by dithizone staining (if this degree
of purity was not achieved by routine isolation, islets were hand-
picked). For long-term in vitro studies (96h), islets were cultured
on extracellular matrix–coated plates derived from bovine cor-
neal endothelial cells (Novamed Ltd., Jerusalem, Israel), allow-
ing the cells to attach to the dishes and spread, preserving their
functional integrity (24). In parallel, islets were cultured in sus-
pension dishes, treated for 72h, and fixed with Bouin´s solution.
Islet sections were prepared as described previously (21).
Human islets were exposed to a diabetic milieu (11.1–33.3
mM glucose, or 5.5 mM glucose0.5 mM palmitic acid, the
mixture of 2 ng/ml recombinant human (rh) IL-1 (R&D Sys-
tems,Minneapolis,MN)1,000U/ml rh IFN- (PeProTech) for
72h or 50 M H2O2 for 8h with or without 500 ng/ml Inter-
leukin-1Receptor Antagonist (IL-1Ra), 10 nM-1 uM linagliptin,
200 nM sitagliptin, 100 nM Exendin- (9–39) (Bachem) or 0.5
nM GLP-1 (Sigma). Compounds were added 1h before the ex-
posure to the diabetogenic conditions and throughout the cul-
ture. Palmitic acid was dissolved as described previously (25).
Ethical approval for the use of islets had been granted by the
Ethical Committee of University of Bremen. We received the
islets from the European Consortium For Islet Transplantation
(ECIT). Whenever an islet isolation fails to be suitable for trans-
plantation, centers provide them for islet research. Thus, these
research projects comply with NIH regulations PHS 398, ex-
emption 4. Human pancreata were harvested from brain dead
donors, according to the European and National regulations for
organ procurement. Donors or their family members gave writ-
ten consent todonateorgans for transplantationand research, all
documented by the transplantation centers. Human islet isola-
tionswere performedwith the approved protocols of the centers.
Cell turnover.Fordetectionof-cell apoptosis, 100human islets
were cultured in suspension dishes, treated for 72h, and fixed
with Bouin´s solution. Islet sections were prepared as described
previously, deparaffinized, rehydrated and incubated with 20
mg/ml proteinase K (Roche) for 15 min at 37°C before staining.
In parallel, islets on ECM coated dishes were fixed using 4%
paraformaldehyde and insulin costained with apoptosis ana-
lyzed by the terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL) technique according to the
manufacturer’s instructions (In Situ Cell Death Detection Kit,
TMR red; Roche Applied Science) (26).
For analysis of -cell proliferation, fixed islets on ECM
coated dishes were incubated overnight at 4°C with mouse an-
tihuman Ki67 (Invitrogen), followed by detection with donkey-
rat Cy3-conjugated antibody (Jackson). Insulin was analyzed by
anti guinea pig insulin antibody (Dako) followed by detection
with donkey anti guinea pig FITC-conjugated antibody (Jack-
son). Islets and islet sections were embedded in Vectashield
mounting medium. Fluorescence was analyzed using a Nikon
Eclipse Ti-U inverted research microscope (Nikon GmbH,
Dusseldorf, Germany) and images were acquired using NIS-El-
ements software (Nikon).
Glucose stimulated insulin secretion (GSIS). Islets used to per-
formglucose-stimulated insulin secretion experimentswere kept
in culture medium on matrix-coated dishes. For each indepen-
dent experiment, 20 islets were plated and exposed to the treat-
ment conditions as indicated above. For acute insulin release,
islets were washed and preincubated (30 min) in Krebs-Ringer
bicarbonate buffer (KRB) containing 2.8 mM glucose. The KRB
was then replaced by KRB containing 2.8 mM glucose for 1 h
(basal), followed by an additional 1 h incubation in KRB con-
taining 16.7 mM glucose (stimulated). Islets were lysed in lysis
buffer and whole islet protein measured by bicinchoninic acid
(BCA) protein assay (Pierce, Rockford, IL/Thermo Scientific).
Insulin was determined using a human insulin ELISA kit (Alpco,
Windham, NH) and normalized to whole islet cell lysate protein
content.
Determination of nitrotyrosine. Nitrotyrosine concentration in
human islets after the 4-d culture period was determined in islet
cell lysates by an adapted ELISAmethod as previously described
(27, 28). At the end of the incubation, islets (a total of 30 islets/
condition) were washed in PBS, suspended, and lysed for 40min
on ice in lysis buffer (20 mM Tris acetate, pH 7.0, 0.27 M su-
crose, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 1% Triton X-
100, 5mM sodium pyrophosphate, 10mM -glycerophosphate
(all Sigma Aldrich) containing 1x protease and a phosphate in-
hibitor cocktail (Thermo Scientific, Rockford, IL USA). Protein
concentrations of islet cell lysates were determined by BCA pro-
tein assay, and whole-cell lysates were stored at –80°C until
assayed. The standard curve samples were prepared by dissolv-
ing 1 mg/ml BSA (Sigma) in 50 mmol/L KH2PO4. After addition
of 1 mmol/L tetranitromethan (TNM), the dilution was incu-
bated for 30 min at 37°C and adjusted to pH10 and the amount
of nitrotyrosine present was measured at 430 nm and moles
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nitrotyrosine for eachmole protein was calculated directly using
theBeer–Lambert law, 4300M1cm-1 (29). Standards of 0.05–
0.6 pmol/L were prepared. Maxisorp ELISA plate (BD Fal-
con#353279) was coated with standards and samples in coating
buffer (50mmol/l Na2CO-NaHCO3 buffer at pH9.6) overnight
at 4°C, washed 6 times with 0.05% Tween20 in PBS and incu-
bated with IgG monoclonal antinitrotyrosin (Upstate Biotech-
nology, Lake Placid, NY/ Millipore) for 2h RT, washed and
incubated for 45 min at 37°C with HPR conjugated goat anti-
mouse (Zymed) and washed again. For the peroxidase reaction,
100l tetramethyl-benzidine microwell peroxidase substrate
(TBM; Sigma) was added for 10 min at RT and the reaction was
stopped by adding 50 l stop solution (BD Opty Kit B/ 0.5 M
H2SO4) and read at 492 nm on a microplate reader. Concentra-
tion of nitrotyrosinewas normalized towhole protein content of
islet lysates.
Determination of cytokines, GLP-1 and DPP-4. After the 4-d
culture period, human islet supernatants were measured for cy-
tokine release using theHumanProInflammatoryTissueCulture
Kit (Meso Scale Discovery, MSD, Rockville, MD). Total and
active human GLP-1 was detected by the same assay platform
(Meso Scale).
DPP-4 activity was detected using H-Ala-Pro-7-amido-4-tri-
fluoromethylcoumarin (Ala-Pro-AFC; purchased from Bachem)
in a 200 mM stock solution in dimethylformamide which was
diluted 1000-fold with water before the assay. The assay itself
was performed in black flat-bottom 96-well plates by mixing 50
l of the diluted substrate (final concentration in the assay 100
M), 25 l of supernatant and 25 l of assay buffer (100 mM
Tris-HCl, 100mMNaCl, pH7.8). The platewas then incubated
at room temperature for 1 h and fluorescence was measured at
excitation/emission wavelengths of 405/535 nm. For standards,
20l of appropriate compound dilutionswere prepared in assay
buffer (compound stock solutions in dimethylsulfoxide (DMSO)
final concentration in the assay 1%).
RNA extraction and RT-PCR analysis.Total RNAwas isolated
from cultured human islets by the Trizol method (peqGOLD
TriFast, PeQLab, Erlangen, Germany). For quantitative analy-
sis, we used the Applied Biosystems StepOne Real-Time PCR
system (Applied Biosystems, CA, USA) with a commercial kit
(Power SYBR Green PCR Master Mix or TaqMan(R) Fast Uni-
versal PCR Master Mix for TaqMan assays; Applied Biosys-
tems). Primers used were 5-ggctggtcatatggagggta-3/5-
cagggctttggagatctgag-3 (DPP-4), 5-agagccaacgtcaagcatct-3/
5-ctttagcttcgggtcaatgc-3 (SDF1a), 5-tccccaactcctgagttcac-3/
5-acatcctcgacggcatctcag-3 (IL-6), 5tcctcctcggcttcagacac-3/
5-gtaattggccgccacacagt (GLP-1R) 5-gttggccaggctggtgtccag-3/
5-ctgtgatgagctgctcagggtgg-3 (tubulin), 5-ccaaccgcgagaagatga-
3/5-ccagaggcgtacagggatag-3 (actin) 5tacgggtcctggcatcttgt3/
5ccatttgtgttgggtccagc3 (cyclophilin),
5aaacggctaccacatccaag3/ 5cctccaatggatcctcgtta3 (18S). Taq-
Man(R) Gene Expression Assays (Applied Biosystems) were
used for IL-1, IL-8, cyclophylin and tubulin.
Statistical analysis. Immunostainings were evaluated in a ran-
domized manner by two investigators (P.S., S.L.) who were
blinded to the treatment conditions Data are presented as means
/-SEM and were analyzed by paired Student’s t test or by anal-
ysis of variance (ANOVA)with a Bonferroni correction formul-
tiple group comparisons.
Results
Linagliptin, Sitagliptin and IL-1Ra improve -cell
survival
Loss of -cells by apoptosis and decreased -cell mass
have been recognized asmajor pathological factors for the
progression of diabetes.We tested the hypothesis whether
linagliptin can protect -cells from damage induced by
diabetogenic conditions. Isolated human pancreatic islets
were exposed for 4 d to increasing glucose concentrations
(5.5, 11.1, 33.3 mM), 0.5 mM palmitate, the mixture of
cytokines (2 ng/ml IL-11,000U/ml IFN-) or to 50M
H2O2, for 8h, conditions which caused -cell apoptosis
and almost complete loss of proliferation. Islets were
coculturedwith 500 ng/ml IL-1Ra, which has been shown
to improve -cell survival (21) or with 50 nM linagliptin,
which was added 1h before the diabetogenic conditions
and maintained throughout the 4-d culture. At basal cul-
ture conditions of 5.5 mM glucose for 4 d, 10–1000 nM
linagliptin had no influence on -cell turnover (data not
shown). Elevated glucose concentrations, free fatty acids,
cytokines and oxidative stress induced -cell apoptosis in
isolated human islets, compared to control (2.5-, 3.6-,
3–1-, 3.7- and 4.5-fold induction by 11.1 and 33.3 mM
glucose and by 0.5 mM palmitate, IL-1IFN and
H2O2, respectively, P  .001, Figure 1A) in isolated hu-
man islets, compared to control incubations. This was re-
versedby coculturewith IL-1Raaswell aswith linagliptin.
IL-1Ra reduced apoptosis 2.5, 2.0-, 2.1- and 3.0-fold in
11.1 mM and 33.3 mM glucose, palmitate and IL-
1IFN, respectively (P  .01), but in H2O2, only a
tendency but no significant protective effect was observed
(Figure 1A). 50 nM linagliptin reduced apoptosis 2.3-,
3.8-, 2.0-, 2.5- and 2.1-fold in all diabetogenic conditions
(P  .01, Figure 1A).
Human islets on the ECM-coated dishes had a very
limited capacity to proliferate in culture (0.4  0.1%
Ki67/insulin double positive cells at 5.5mMglucose basal
condition). A diabetic milieu even further reduced this
proliferative capacity (2.2-, 2.8-, 2.3-, 1.7- and 1.9-fold
reduction by 11.1 and 33.3 mM glucose and by 0.5 mM
palmitate, IL-1IFN when incubated for 4 d, and
H2O2 when incubated for 8 h, respectively, compared to
control, P .01, Figure 1B). In contrast, IL-1Ra and lina-
gliptin restored proliferation (4.3-, 5.8-, 4.0- and 3.1-fold
induction by IL-1Ra and 4.8-, 6.8-, 4.4-, 2.1- and 4.1-fold
by linagliptin in 11.1 and 33.3 mM glucose, in 0.5 mM
palmitate, IL-1IFN and H2O2, respectively, com-
pared to vehicle, P .01, Figure 1B). IL-1Ra had no pro-
doi: 10.1210/jc.2013-1029 jcem.endojournals.org 3
tective effect on-cell proliferationunderH2O2 exposure.
This was also confirmed in mouse islets which were ex-
posed for 8h to 50 M H2O2 with or without 500 ng/ml
IL-1Ra. Apoptosis was induced 3.6-fold by H2O2, while
IL-1Ra failed to show any protective effect (data not
shown).
To exclude a matrix-dependent effect, we cultured iso-
lated human islets in suspension culture dishes, exposed
them for 3 d or 8h (H2O2) to the above described diabe-
togenicmilieuandanalyzed-cell apoptosis inbouin fixed
paraffin embedded islet sections. A similar induction of
-cell apoptosis was observed by all diabetogenic culture
conditions, linagliptin significantly reduced-cell apopto-
sis (1.9-, 2.0-, 2.3-, 1.5 and 1.2-fold
in 11.1 and 33.3 mM glucose, 0.5
mM palmitate, IL-1IFN and
H2O2, compared to vehicle, P .01;
Figure 1D). Sitagliptin, another
DPP-4 inhibitor tested in the same
experiments had similar protective
effects (Figure 1D; 1.4-, 1.9-, 4.7-,
2.5-, and 1.3-fold reduction of -cell
apoptosis in 11.1 and 33.3 mM glu-
cose, 0.5 mM palmitate, IL-
1IFN and H2O2, P  .01).
Linagliptin improves -cell
function and inhibits oxidative
stress
In addition to its protective effect
on -cell survival, linagliptin im-
proved glucose stimulated insulin se-
cretion (GSIS) in islets after long-
term culture of 4 d. In control
conditions, there was a 4-fold stim-
ulatory index when glucose was in-
creased from 2.8 mM to 16.7 mM
glucose (Figure 2D). All diabeto-
genic culture conditions significantly
reduced GSIS (P  .01; Figure
2A,D). At basal glucose, neither IL-
1Ra (Figure 2B,D) nor linagliptin
(Figure 2C,D) increased the stimula-
tory index, but under the diabeto-
genic conditionsGSISwas highly im-
proved (1.2-, 1.4-, 1.9-, 2.3-, and
1.8- fold by IL-1Ra, Figure 2B,D and
1.9-, 2.5-, 2.1-, 2.4- and 2.5- fold by
linagliptin, P  .05, Figure 2C,D).
To investigate the underlying
mechanisms of the protective effect
of the DPP-4 inhibitor, we hypothe-
sized that changes in nitrotyrosine, a
marker for oxidative stress, may occur during the long-
term exposure with diabetogenic conditions. Nitroty-
rosine production in islets during the 4-d culture period
wasmeasured and normalized towhole protein content of
the islet lysate. Nitrotyrosine content was increased by
glucose-, palmitate-, cytokine- and H2O2 exposure (P 
.05; Figure 2E). Both IL-1Ra and linagliptin decreased
nitrotyrosine under glucose, palmitate and cytokine treat-
ment (P .05), but not under conditions of H2O2 (Figure
2E).
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Figure 1. DPP-4 inhibition improves -cell survival Human pancreatic islets were
cultured on extracellular matrix coated dishes (A,B) or in suspension (C,D) at 5.5 mM (control),
11.1 or 33.3 mM glucose, 0.5 mM palmitate or 2 ng/ml IL-1/1000 IU IFN- for 96h (A,B) or
72h (C,D) or at 50 M H2O2 for 8h (A-D) in absence (control) or presence of IL-1Ra (500 ng/ml)
or linagliptin (50 nM). Apoptosis was analyzed either directly in the dishes (A) or in paraffin
embedded islet sections (C,D: red nuclei) by the TUNEL assay. Proliferation was analyzed in the
dishes (B) by the Ki67 antibody. All specimens were double-stained in green for insulin. Results
are means SEM of the TUNEL- or Ki67-positive -cells, normalized to control conditions at 5.5
mM glucose (in absolute numbers: 0.4%TUNEL- and 0.37%Ki67-positive -cells at 5.5 mM
glucose on the extracellular matrix and 1.0% TUNEL-positive -cells at 5.5 mM glucose in
suspension culture). The average number of -cells counted was 4175 for each treatment group
from three different experiments from three different organ donors. C shows a representative
staining picture of a palmitate treated human islet (upper panel: x200 magnification) with 2
TUNEL-positive nuclei (power panel: x600 magnification). *P  .05 compared to vehicle treated
control at 5.5 mM glucose, **P  .05 compared to vehicle under the same treatment condition.
4 linagliptin restores -cell function & survival J Clin Endocrinol Metab
Linagliptin stabilizes GLP-1 in the supernatants of
human islet cells
Since the main effect of DPP-4 is to stabilize GLP-1, we
next investigated whether total and active GLP-1 levels in
the culture medium were increased by linagliptin treat-
ment. Diabetogenic conditions (increasing glucose con-
centrations and cytokines) induced accumulation of total
GLP-1 (Figure3A) in the islet supernatants, and linagliptin
(30 nM) pretreatment resulted in approximately 2-fold
higher total GLP-1 (Figure 3A) and approximately 3-fold
higher activeGLP-1 (Figure 3B) in all conditions. Levels of
total and active GLP-1 were unchanged by IL-1Ra (data
not shown).
Next, the effect of linagliptin on the stabilization of an
exogenously added GLP-1 concentration was investi-
gated. 1h after linagliptin (30 nM) treatment, 0.5 nM
GLP-1 (a concentration similar to the secreted totalGLP-1
from islets treated with Linagliptin) was added to the islet
culture medium and immediately measured. Rapid deg-
radation of GLP-1 was observed during culture (Figure
3C,D), while addition of linagliptin inhibited such degra-
dation ofGLP-1. Total (Figure 3C) and activeGLP-1 (Fig-
ure 3D) accumulated during culture in the linagliptin
treated islet supernatants, which did not occur in the non-
treated islets.
GLP-1 stabilization was accompanied by restored
GLP-1 receptor levels. In confirmationwith earlier studies
(30, 31), GLP-1 receptor levelswere decreased in response
to glucotoxicity and cytokine exposure, compared to un-
treated control. In contrast, 30 nM linagliptin increased
GLP-1 receptor levels in all diabetogenic conditions (Fig-
ure 3E). To further prove whether the effect of linagliptin
is GLP-1 dependent, we cocultured linagliptin with Exen-
din- (9–39), an established inverse agonist of the GLP-1
receptor (32, 33).While 30 nM linagliptinwas effective in
improving glucose stimulated insulin secretion under cy-
tokine exposure, the addition of 100 nMExendin- (9–39)
inhibited the linagliptin effect (Figure 3F). To prove that
linagliptin was active, we also measured DPP-4 activity in
the islet cell supernatants. As expected, linagliptin inhib-
ited DPP-4 activity in culture (Figure 3G). The potential
GLP-1-SDF-1 synergism strongly promotes -cell sur-
vival (34). Since SDF-1 is another substrateofDPP-4 (35)
and an important prosurvival factor for -cells (36), we
tested whether increases in GLP-1 concentration and re-
duction in DPP-4 activity by linagliptin are also paralleled
with SDF1 mRNA production. Linagliptin strongly in-
creased SDF1 under basal as well as under diabetogenic
conditions (P .05, Figure 3H), while glucose and palmi-
tate themselves or IL-1Ra treatment of the islets had no
effect on SDF-1 (Figure 3H).
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Figure 2. Linagliptin improves -cell function and inhibits
oxidative stress Human pancreatic islets were cultured on
extracellular matrix coated dishes at 5.5 mM (control), 11.1 or 33.3
mM glucose, 0.5 mM palmitate or 2 ng/ml IL-1/1000 IU IFN- for 96h
or at 50 M H2O2 for 8h in the absence (control; A,D) or presence of
IL-1Ra (500 ng/ml; B,D) or linagliptin (50 nM; C,D). Basal and
stimulated insulin secretion indicates the amount secreted during 1h
incubations at 2.8 (basal) and 16.7 mM (stimulated) glucose following
the culture period and normalized to protein content (A-C),
stimulatory index was calculated as stimulated/basal insulin secretion
(D). Nitrotyrosine content (E) in the islet lysates was normalized to
whole islet protein content. Results are means SEM from triplicates
from three independent experiments from three donors, *P  .05
compared to vehicle treated control at 5.5 mM glucose, **P  .05
compared to vehicle under the same treatment condition.
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Figure 3. Linagliptin stabilizes GLP-1 in the supernatants of human islet cells Human pancreatic islets were cultured on
extracellular matrix coated dishes at 5.5 mM glucose (control) or 11.1 and 33.3 mM glucose, 0.5 mM palmitate or 2 ng/ml IL-1/1000 IU IFN- for
96h in the absence (control) or presence of linagliptin (50 nM, A,B) or 0.5 nM GLP-1 (C,D). Total (A,C) and active (B,D) GLP-1 secretion was
measured in the supernatants during the 4-d culture period. mRNA was isolated from treated islets after 4 d and RT-PCR analysis of GLP-1
receptor levels (E) was performed. The levels of gene expression were normalized to tubulin and 18S and presented as change of 5.5 mM glucose
control. Human pancreatic islets were cultured at 5.5 mM (control) glucose or 2 ng/ml IL-1/1000 IU IFN- for 96h in presence of 30 nM
linagliptin and an inverse agonist of the GLP-1 receptor Exendin- (9–39) (100 nM, F). Insulin stimulatory index as the ratio of the stimulated and
basal insulin secretion was calculated. (G) DPP-4 activity was measured at control conditions and with 30 and 100 nM linagliptin during culture.
(H) mRNA was isolated from treated islets after 4 d of culture and RT-PCR analysis of SDF-1 performed. The levels of gene expression were
normalized to tubulin and cyclophilin (with similar results) and presented as change of control. Results are means SEM from triplicates from three
independent experiments from three donors, except for (E): data are from one single donor (in triplicates) and (F): from 2 donors (each in
triplicates), *P  .05 compared to vehicle treated control at 5.5 mM glucose.
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Linagliptin inhibits cytokine secretion and
production from islets under diabetogenic
conditions
Since proinflammatory cytokines and chemokines are
elevated under a diabetogenic milieu, we tested whether
IL-1Ra and linagliptin exert their protective effects
through an inhibition of cytokine secretion. Cytokine and
chemokine secretion into the culture medium was mea-
sured simultaneously by theMSD© technique andmRNA
production by RT-PCR. The diabetogenic milieu which
included elevated glucose concentrations and palmitate
significantly increased IL-1 secretion (Figure 4A) and
mRNA production (Figure 4B), while IL-6 (Figure 4C,D)
and IL-8 (Figure 4E,F)were increasedby the cytokinemix-
ture IL-1 and IFN, but no significant effect was ob-
served in the other diabetogenic conditions.While IL-1Ra
and linagliptin had no effect on the minimal basal IL-1
secretion and production during the 4-d culture period,
they significantly decreased both IL-1 secretion and
mRNAproduction (Figure 4A,B) under diabetogenic con-
ditions. Similarly, IL-6 and IL-8,
which were elevated in response to
IL-1/IFN were decreased by IL-
1Ra and linagliptin (Figure 4C-F).
Discussion
Orally administered DPP-4 inhibi-
tors prevent the rapid cleavage of
GLP-1, and thus increase levels of ac-
tive GLP-1, resulting in increased in-
sulin and reduced glucagon secre-
tion, lowered glucose and reduced
HbA1c levels by 0.5–1.0% (2). Lina-
gliptin improves glycemic control
both as monotherapy (37) and in
combination therapy, e.g., withmet-
formin (38) or pioglitazone (39) and
also improves insulin sensitivity
(39). DPP-4 inhibitors mimic many
of the actions ascribed to GLP-1 in
rodents including preservation of
-cell mass through stimulation of
cell proliferation and inhibition of
apoptosis in rodents (15, 16, 17).
Besides GIP and GLP-1, many
gastrointestinal (GI) hormones, neu-
ropeptides, cytokines, and chemo-
kines are substrates for DPP-4 (40),
includingCXCL10andSDF1, both
ofwhich are involved in immune reg-
ulation, influence the inflammatory
response and have been associated with the regulation of
-cell turnover in diabetes (23, 34). Since cytokines and
chemokines are crucial for the survival of pancreatic
-cells (41), it remained to be investigated whether DPP-4
inhibitors in culture directly affect -cell survival and
function.
In the present study, the DPP-4 inhibitor linagliptin
effectively restored proliferation, survival and -cell func-
tion in a diabetic milieu. The concentrations of 30–50 nM
we used were higher than the average cmax plasma levels
but could be also obtained in patients taking therapeutic
doses of linagliptin (42). At all concentrations up to 1M,
which is 1000-fold the IC50 of the human enzyme, lina-
gliptin did not affect -cell survival at basal conditions in
culture.
Human-cells in culture have only a very limited, if any
(42), capacity to proliferate. Here we found 0.4% prolif-
erating -cells under basal conditions when islets were
plated on extracellular matrix coated dishes, and prolif-
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Figure 4. Linagliptin inhibits cytokine secretion from islets under diabetogenic
conditions Human pancreatic islets were cultured on extracellular matrix coated dishes at 5.5
mM (control), 11.1 or 33.3 mM glucose, 0.5 mM palmitate or 2 ng/ml IL-1/1000 IU IFN- for
96h in the absence (control) or presence of IL-1Ra (500 ng/ml) or linagliptin (50 nM). (B,D,F)
mRNA was isolated from treated islets after 4 d and RT-PCR analyses of IL-1 (B), IL-6 (D) and
IL-8 (F) were performed. The levels of gene expression were normalized to tubulin and cyclophilin
(with similar results) and presented as change of control. Cytokine and chemokine secretion of
IL-1 (A), IL-6 (C), IL-8 (E) from the culture medium of the same islets were analyzed in a
multiplex assay (Meso Scale Discovery©). Results are means SEM from three independent
experiments from three donors, *P  .05 compared to vehicle treated control at 5.5 mM
glucose, **P  .05 compared to vehicle under the same treatment condition.
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eration was further decreased by diabetogenic conditions
of chronically elevated glucose, free fatty acids, cytokines
or H2O2. Linagliptin improved cell survival by decreasing
apoptosis, andmaintained cells at a steady state level, even
under diabetogenic conditions.
The protective linagliptin effect seen in this study was
mediated by stabilization of GLP-1 in the islet superna-
tants, where total as well as active GLP-1 levels were re-
stored and accumulated during islet culture, providing a
similar mechanism as seen in vivo.
Active GLP-1 can be produced from islets (43). The
-cells express prohormone convertase PC1/3, which
cleaves preproglucagonpeptide to generateGLP-1.-cells
are an established islet source of secreted GLP-1 (44, 45,
46, 47) andmay provide a local protective paracrine effect
for -cell regeneration under diabetic conditions, espe-
cially during -cell injury (34). Sorted human -cells also
expressPC1/3but theGLP-1content couldnotbedetected
and thus itwas assumed that-cells donot produceGLP-1
(48), although it was found to be secreted from the rodent
-cell line, INS-1E (49).
We found high levels of active GLP-1 (3 ng/ml from
50 islets over 4 d of culture) were secreted from human
islets and accumulated only in the presence of a DPP-4
inhibitor, while high DPP-4 activity could only be mea-
sured in the absence of linagliptin.
GLP-1 is accumulated in the medium during the 4-d
culture period and provides in turn a paracrine protective
effect on the -cell. Diabetogenic conditions, e.g., the cy-
tokine cocktail IL-1/IFN enhanced IL-6 production.
This was counteracted by linagliptin, and paralleled with
increased GLP-1 in the medium. It can thus be hypothe-
sized, that higher GLP-1 concentrations in the culture me-
dium in turn inhibits IL-6 production; this would provide
anegative feedback loop to the IL-6 effect to induceGLP-1
in islets (44).
Hyperglycemia and a diabetic milieu decrease expres-
sion of -cell GLP-1 receptors in vivo and in vitro (30, 31,
50). In contrast, diabetogenic conditions significantly in-
creased total GLP-1 release from cultured islets. This was
also observed in islets from patients with T2D (51) and
from diabetic Psammomys obesus (47), which show
higher GLP-1 secretion than nondiabetic controls.
Slightly reduced GLP-1 secretion after a meal in pa-
tients with impaired oral glucose tolerance and more se-
verely impairedGLP-1 secretion in type 2diabetic patients
was observed (52), although controversial results have
been obtained in various studies (53). Differences occur
between tissue-specific GLP-1 levels and whether total or
active GLP-1 was measured (54). It is possible, that re-
ducedGLP-1 inT2Dpatients is a result of elevated plasma
DPP-4 activity (55), which can be induced by chronic hy-
perglycemia and is paralleled with reductions of active
GLP-1 (56).
Linagliptin strongly reduced DPP-4 activity in the hu-
man islet supernatant and stimulated GLP-1 stability. Ac-
tive DPP-4 rapidly degrades SDF-1 (1–68) to inactive
SDF-1 (3–68) (57) and thus, more active SDF1 is avail-
able upon DPP-4 inhibition. In turn SDF-1 acts like a
cytokine and induces its own production (34). This ex-
plains the increased SDF-1mRNA levels with linagliptin
treatment, found in the present study.
The regulation of DPP-4 in diabetes has not been fully
clarified, both increased (55, 56) and decreased (58)
DPP-4 activity have been reported in patients with diabe-
tes. DPP-4 release from adipose tissue is higher in obese
individuals and correlates with parameters of the meta-
bolic syndrome, where DPP-4 directly impairs insulin sig-
naling in fat and muscle cells (59). Elevated glucose ex-
posure leads to enhanced DPP-4 activity and mRNA
expression in endothelial cells (60). Also in human islets,
wedetected elevatedDPP-4mRNAin response to elevated
glucose and palmitate, while linagliptin inhibited this in-
duction (data not shown). One could speculate that in
islets under diabetogenic conditions, there is more DPP-4
produced, which inactivates the elevated GLP-1, and thus
it cannot fulfill its functions.
Recent human studies investigating the long-term treat-
ment with vildagliptin on -cell function were somehow
disappointing, because followingwashout periods the ob-
served-cell sparing effects disappeared, thus questioning
the disease modifying potential of this drug (6). However,
it remains to be elucidated whether this is caused by a
limited tissue penetration in vivo or limited availability of
the drugs in islets.
In summary, we show that linagliptin has a protective
effect on -cell turnover and function under diabetogenic
conditions, which is mediated through stabilized GLP-1
and an anti-inflammatory/antioxidative stress pathway.
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Abstract 
Chronic inflammation is consequential to the etiology of both T1D and T2D. 
Cytokine and chemokine production by infiltrating macrophages and by β-cells 
themselves in a diabetic milieu contributes to their destruction in inflamed islets 
and thus to progression of diabetes. In order to find potential targets for inhibition 
of this deleterious response of islets, the investigation of underlying mechanisms 
for triggering inflammation is essential.  
The expression of a novel family of adhesion molecules called Sialic acid-binding 
immunoglobulin-like lectins (Siglecs) in pancreatic islets was observed in a cell 
type specific manner. Siglec-7, expressed on the β-cells, was down-regulated in 
diabetes. Over-expression of Siglec-7 in cultured isolated islets prevented β-cell 
dysfunction and apoptosis under chronic diabetic stimuli and also in diabetic islets. 
The protective effect of Siglec-7 was mediated by the inhibition of the NF-κB 
pathway and the subsequent decrease in cytokine secretion. Also, activated 
immune cells showed loss of Siglec-7 expression. Ultimately, restoration of Siglec-
7 in stressed islets caused a reduction in the number of recruited migrating 
monocytes. 
Siglec-7 expression on β-cells contributes to the inhibition of pro-inflammatory 
activation of these cells in diabetes. Restoration of Siglec-7 expression or 
signaling may be a potential therapeutic strategy to preserve β-cell function and 
mass in the manifestation of diabetes. This strategy would not only rescue the β- 
cells, but also inhibit systemic inflammation observed in T2D. 
Introduction 
Diabetes mellitus is a syndrome of disordered glucose metabolism, usually due to 
a combination of hereditary and environmental causes, resulting in hyperglycemia. 
The ability of the β-cells to secrete adequate amounts of insulin to maintain 
normoglycemia depends on their function and mass. In both, Type 1 diabetes 
mellitus (T1D) and Type 2 diabetes mellitus (T2D), the major mechanism leading 
to decreased β-cell mass is increased β-cell apoptosis. T1D results from an 
absolute insulin deficiency due to the autoimmune destruction of the insulin 
producing β-cells [1]. β-cell destruction occurs through immune mediated 
processes such as mononuclear cell infiltration in the pancreatic islets and 
interaction between antigen presenting cells and T cells, which leads to high local 
concentrations of inflammatory cytokines, chemokines, reactive oxygen species 
(ROS) and other inflammatory products, and subsequently to β-cell apoptosis. 
T2D is characterized by chronic insulin resistance and a progressive decline in β-
cell function and mass. Obesity is strongly associated with the development of 
insulin resistance [2], and is the main risk factor for the development of T2D. A 
chronic, low-grade inflammatory state is present in obesity, with adipose tissue 
macrophage infiltration and pro-inflammatory activity of macrophages [3]. 
Epidemiological studies suggest that low-grade inflammation precedes and 
predicts the development of T2D [4]. Cytokines and chemokines are produced and 
secreted not only by activated infiltrating macrophages, but also by adipocytes and 
pancreatic β-cells themselves. Chronic elevated glucose and free fatty acid levels 
occurring in diabetes trigger pro-inflammatory responses in several tissues like 
adipose tissue, muscle, liver, immune cells and also the islets [5]. Pro-
inflammatory cytokines can cause insulin resistance [6], impair β-cell function [7], 
and anti-inflammatory mediators may reverse both [8, 9], implying that 
inflammation may be directly involved in the pathogenesis of T2D. Hence, 
activation of the innate immune system and triggering of local as well as systemic 
inflammation are hallmarks of both T1D and T2D. 
In the event of immune system activation, the signaling and activation of immune 
cells is brought by secreted stimulators as well as via cell-cell interactions. 
Different cell surface receptors and adhesion molecules play a role in the immune 
system activation. One such family of adhesion and signaling molecules are Sialic 
acid-binding immunoglobulin-like lectins (Siglecs) [10]. Siglecs are I-type lectins 
which recognize and interact via immunoglobulin (Ig)-like domains with sialylated 
glycan residues on same cell surface (cis-interaction) or on neighboring cell 
surface, extracellular matrix protein or secreted glycoproteins (trans-interactions). 
The siglecs can be divided into two groups: an evolutionarily conserved subgroup 
(Siglecs-1, -2, -4 and -15) and a rapidly evolving CD33/Siglec- 3-related subgroup 
(Siglecs-3, -5 to -11 and -14, -16 in primates) [11]. Only Siglec-4 (myelin-
associated glycoprotein, MAG) expressed on glial cells and placental Siglec-6 are  
siglecs present on non-hematopoetic cells. All other siglecs are expressed on the 
hematopoietic and immune cells, in a very cell-type specific manner. Every siglec 
recognizes specific sialic acid linkages, thus hinting towards their unique function 
[12]. Typically, cytoplasmic motifs of siglecs show presence of one or more 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These ITIMs recruit 
tyrosine phosphatases and eventually can inhibit activatory signals of other 
receptors. These cell-cell signaling interactions play a role in the immune system 
[13].  
To verify the presence and function of siglecs in the infiltrating immune cells in 
islets, we investigated expression levels of siglecs in the pancreas. Surprisingly, 
these investigations have brought to surface the presence of siglecs in non-
inflammatory cells in pancreatic tissue, opening a whole new perspective for the 
role of siglecs in general. Here, we show cell type specific siglec expression in the 
human endocrine pancreas. Because of its specific presence on β-cells, we 
focused our experimentation on Siglec-7. Cloned for the first time in 1999 [14], 
Siglec-7 is a CD-33 related siglec constitutively expressed on all natural killer (NK) 
cells, monocytes and also on a subset of T cells [15]. Structurally, it is 
characterized by 3 immunoglobulin-like extracellular domains (one NH 2-terminal 
V-type and two C2-type), a trans-membrane region and a cytoplasmic tail 
containing two tyrosine residues located in immunoreceptor tyrosine-based 
inhibitory motifs. Siglec-7 acts as an inhibitory receptor in human NK cells after 
engagement by antibodies [14] or binding with sialic acid-containing ligands [16]. 
Upon phosphorylation, it can recruit the SH2 domain-bearing protein tyrosine 
phosphatase (PTP) SHP-1 [14]. Anti-Siglec-7 Abs also inhibits the proliferation of 
myeloid cells [17]. Also, Siglec-7 inhibits the FcRI-mediated serotonin release from 
RBL cells following crosslinking. The ITIMs are essential for this inhibitory function, 
and facilitate tyrosine phosphorylation and recruitment of SHP-1 and SHP-2 
phosphatases [18]. Siglec-7 is also expressed on a subset of T-cells and 
negatively regulates T-cell receptor (TCR) signaling [19]. Thus, Siglec-7 can be 
considered as an inhibitory receptor, participating in the regulation of cell function 
and survival. 
The present study identifies the role of cell adhesion molecules, siglecs, in the 
manifestation and progression of T2D. We investigated, whether inhibitory signals 
by Siglec-7 can restore β-cell survival and function in a diabetic milieu and whether 
Siglec-7 expression can influence immune cell migration.  
 
Methods 
Islet culture. Human islets were isolated from ten pancreata of healthy and 3 
diabetic organ donors at the University of Lille or University of Leiden and cultured 
in CMRL-1066 medium (Invitrogen) as described previously [20]. Briefly, islets 
were cultured on extracellular matrix coated dishes derived from bovine corneal 
endothelial cells (Novamed Ltd., Jerusalem, Israel) for 2 days, allowing the cells to 
attach to the dishes and spread [21]. They were exposed to 5.5, 22.2 or 33.3 mM 
glucose, with or without 0.5 mM palmitate (dissolved as described previously [22]) 
or the mixture of 2 ng/ml recombinant human IL-1β (R&D Systems, Minneapolis, 
MN) +1,000 U/ml recombinant human IFN-γ (PeProTech, Rocky Hill, NJ, USA) for 
72h. 
Transfection. At 2 days post-isolation and culture on extracellular matrix coated 
dishes, isolated islets were transfected using Ca2+-KRH medium (KCl 4.74 mM, 
KH2PO4 1.19 mM, MgCl26H2O 1.19 mM, NaCl 119 mM, CaCl2 2.54 mM, NaHCO3 
25 mM, HEPES 10 mM). After 1h incubation lipoplexes (Lipofectamine2000, 
Invitrogen, Carlsbad, CA, USA)/DNA ratio 2.5:1, 5 μg CMV-Siglec-7 (Life 
technologies) or LacZ/GFP control plasmid DNA/100 islets or 100 nM siRNA to 
Siglec-7 (ON-TARGETplus SMARTpool against human Siglec-7, (Dharmacon, 
Lafayette CO, USA) and scramble siRNA (Dharmacon) were added to transfect 
the cells as described previously [23, 24]. After additional 6h incubation, CMRL 
1066 medium containing 20% FCS and L-Glutamine were added to the 
transfected islets. Transfection efficiency was determined using RT PCR.  
Glucose stimulated insulin secretion. Islets used to perform glucose-stimulated 
insulin secretion experiments were kept in culture medium on matrix-coated 
plates. For acute insulin release in response to glucose, islets were washed and 
pre-incubated (30 min) in Kreb’s Ringer bicarbonate buffer (KRB) containing 2.8 
mM glucose and 0.5% BSA. KRB was then replaced by KRB 2.8 mM glucose for 1 
h (basal), followed by an additional 1 h in KRB 16.7 mM glucose (stimulated). 
Islets were extracted with 0.18 N HCl in 70% ethanol for determination of insulin 
content. Islet insulin was determined using mouse insulin ELISA (ALPCO, Salem, 
NH, USA). 
RNA extraction and RT-PCR analysis. Total RNA was isolated from cultured 
human islets as described previously [20]. For gene expression analysis of siglecs, 
semi-quantitative Real Time-PCR was performed in the StepOne Plus Real Time 
PCR system (Applied Biosystems, Darmstadt, Germany) using Power SYBR 
Green PCR Master Mix (Applied Biosystems, Darmstadt,Germany).  cDNA based 
on RNA from human pancreatic tissues were analyzed for the genes cyclophilin, 
glucagon, SAT2, insulin and SN1. Amplification of the endogenous housekeeping 
gene cyclophilin as well as the genes glucagon, SAT2, insulin and SN1 consisted 
of an initial denaturation step at 95°C for 10 min, followed by 40 PCR cycles of 
denaturation by 95°C for 30 s, primer annealing by 60°C for 20 s, and elongation 
by 72°C for 10 s. All Siglecs were amplified carrying out the touchdown PCR with 
annealing temperatures from 57°C-53°C in each 5 cycles. Primers used for this 
RT-PCR were: (Siglec-7) 
5'AAGAAGCCACCAACAATGAG3'/5'CAGTTAGACAAGAGGAATAAGTTC3'; 
(Siglec-3) 5'TGGTGTGACTACGGAGAG3'/5'ATGAAGAAGATGAGGCAGAG3' 
(Siglec-10) 5'CATTATGCCACGCTCAAC3'/5'TCTTCAACCTCTTACTCTACC3'; 
(insulin) 5'CTACCTAGTGTGCGGGGAAC3'/5'GCTGGTAGAGGGAGCAGATG3'; 
(glucagon) 5'CATTCACAGGGCACATTCAC3'/5'CAGCTTGGCCTTCCAAATAA3'; 
(SN1) 5'TACGACGTGCTATCCAGCAG3'/5'CCAGGATTTTAGGGGTGGAT3'; 
(SAT2) 5'AGTTGCCTTTGGTGATCCAG3'/5'CAGGACACGGAACCTGAAAT3' and 
(PPIA) 5'TACGGGTCCTGGCATCTTGT3'/5'CCATTTGTGTTGGGTCCAGC3'. 
For analysis of PBMCS and isolated islets, we used the Applied Biosystems 
StepOne Real-Time PCR system (Applied Biosystems, Carlsbad, CA, USA) with a 
commercial kit (TaqMan(R) PCR Master Mix; Applied Biosystems). TaqMan(R) 
Primers used: Siglec-7 (Hs00255574_m1); Siglec-3 (Hs00233544_m1); ST8SIA1 
(Hs00268157_m1); PPIA (Hs99999904_m1); CD25 (Hs00907779_m1); Neu3 
(Hs00198406_m1). To analyze the relative changes in the gene expression the 
comparative ΔΔCt method was used. According to this method Ct values of the 
genes of interest were normalized the reference genes. The resulting ΔCt values 
of any sample were adjusted then to a ΔCt value of the control sample, using the 
formula 2-ΔΔCt in which ΔCt = Cttarget gene – Ctreference gene and ΔΔCt = ΔCt,sample –
ΔCt,control. 
Western Blot analysis. At the end of the incubation periods, islets were washed 
in ice-cold PBS and lysed in 40 ?l lysis buffer RIPA (20 mM Tris acetate, 0.27 M 
sucrose, 1 mM EDTA, 1 mM EGTA, 50mM NaF, 1% Triton X-100, 5 mM sodium 
pyrophosphate and 10 mM β-glycerophosphate) by repeated rounds of freezing 
and thawing on ice. Prior to use, the lysis buffer was supplemented with Protease- 
and Phosphatase-inhibitors (Pierce, Rockford, IL, USA). Protein concentration was 
measured using BCA assay (Pierce, Rockford, IL, USA). Equivalent amounts of 
protein from each treatment group were run on a NuPAGE 4-12% Bis-Tris gel 
(Invitrogen) and electrically transferred onto PVDF membranes. Membranes were 
incubated with rabbit anti- p-IκBα; rabbit anti- p-p65 rabbit anti-β-actin (Cell 
Signaling Technology, Danvers. MA, USA) antibodies, followed by horseradish-
peroxidase-linked anti-rabbit IgG. Membrane was developed using a 
chemiluminescence assay system (Pierce) and analyzed using DocIT®LS image 
acquisition 6.6a (UVP BioImaging Systems, Upland, CA, USA). Densitometric 
analysis of the blots was carried out using Vision Works LS Image Acquisition and 
Analysis software Version 6.8 (UVP BioImaging Systems, Upland, CA, USA). The 
gray scale values were normalized on the housekeeping genes as loading 
controls, and the fold change against control condition was plotted. 
Immunocytochemistry. Pancreas from 5 healthy controls and from 5 patients 
with T2DM were obtained from the National Disease Research Interchange 
(NDRI), approval for the studies were granted by the Ethical Commission of 
Bremen University. The tissues were fixed in 4% para-formaldehyde overnight and 
embedded in paraffin. Islets cultured in suspension were washed with PBS and 
were fixed in Bouin’s (Sigma, Hamburg, Germany) solution for 15 min, 
resuspended in 2% melted agarose in phosphate buffered saline (PBS), followed 
by short centrifugation and paraffin embedding. Both, islet agarose pellets and 
human tissue samples were washed overnight in 70% ethanol followed by 
dewatering in ethanol and xylol and paraffin embedding using Leica TP1020 tissue 
processor (Leica, Microsystems, Wetzlar, Germany). 4μm sections were cut using 
a microtome and mounted on slides. For immunohistochemical analysis of 
pancreatic and islet sections, they were deparaffinized and rehydrated by washing 
twice in toluene for 10 min, respectively, in 100%, 95% and 70% ethanol for 3 min, 
and then in water for 5 min. Slides were then exposed to antigen-retrieval using 
Antigen Unmasking Solution (Vector Laboratories, Inc. Burlingame, CA) pre-
warmed in a microwave at 600 Watt for 3 cycles each 5 min. and 1 min break in 
between each cycle. The sections were then cooled to room temperature and 
permeablized in soaking buffer (0.4% Triton X-100 in TBS) for 30 min.  After this, 
to minimize unspecific binding of antibodies, slides were incubated in blocking 
buffer containing 0.2% Tween 20, 3% IgG-free Bovine serum albumin (BSA), and 
0.5% Triton X-100 or 1 h RT. For Fc-chimera staining, Human Fc receptor 
blocking reagent (MACS #130-059-901) was used for 15-20 min room 
temperature. As a negative control for staining with Fc chimera, slides were 
treated with 10mU/ml V. cholerae sialidase (Roche) for 2h at 37°C. Primary 
antibodies were diluted  (1:50 or 1:100) in the antibody dilution buffer (0,2% Tween 
20, 3% IgG-free BSA in TBS) as recommended and incubated with the slides for 
either 1 h room temperature or overnight at 4°C. Antibodies used were:  polyclonal 
rabbit anti-Siglec-7 (Abcam, Cambridge, UK); rabbit anti-human CD22 (Abcam, 
Cambridge, UK); rabbit anti-human Sialoadhesin (Abcam, Cambridge, UK); 
monoclonal mouse anti- Siglec-7 (kindly provided by Prof. Paul Crocker), 
polyclonal sheep anti-Siglec-3,-5,-8,-7 and -10 (kindly provided by Prof. Paul 
Crocker); Siglec-7 Fc-chimera (kindly provided by Prof. Sørge Kelm); GD3 (R24; 
Abcam); guinea pig anti-insulin and mouse anti-glucagon. Secondary antibodies 
were against the primary antibody species and were either FITC- , Cy3- or AMCA-
conjugated antibodies (Dako, Hamburg, Germany). For bright field staining, the 
secondary antibodies conjugated to enzyme alkaline phosphatase were used, 
followed by development with BCPI/NBT substrate (Sigma, Steinheim, Germany) 
for 15 min at room temperature.  After the staining procedures, slides were 
mounted with Vectashield with 4’6-diamidino-2-phenylindole (DAPI) (Vector Labs) 
or Glycerogelatin.  Fluorescence was analyzed using a Nikon MEA53200 (Nikon 
GmbH, Dusseldorf, Germany) microscope and images were acquired using NIS-
Elements software (Nikon). Intensity and saturation of the staining was measured 
using Adobe Photoshop© Extended analysis software after an adapted model used 
by Pham et al [25]. Briefly, the insulin positive area in the green channel was 
manually marked and the selection was saved. By loading this selection onto the 
red channel image, the area positive for Siglec-7 or GD3 was assigned and 
measurements were recorded. The mean gray scale values were termed as the 
saturation and the integrated density values considered as intensities.     
For detection of β-cell apoptosis and proliferation, insulin and TUNEL (In Situ Cell 
Death Detection Kit -AP; Roche Diagnostics, Mannheim, Germany) or Ki67 
staining (Mouse anti-Ki67 (7B11) prediluted, Invitrogen, Camarillo, CA, USA)  were 
performed as described previously [26]. Dishes were analyzed using Nikon 
MEA53200 (Nikon GmbH, Dusseldorf, Germany) microscope and images were 
acquired using NIS-Elements software (Nikon).  
Cytokine quantification. The cell culture supernatants stored at -20°C were 
evaluated in a cytokine multiplex array system called Meso Scale Discovery®  
(Gaithersburg, MD, USA) using a kit (Human Pro-inflammatory II 4-plex assay) 
read at the Sector Imager 6000® as per manufacturer's instructions. The platform 
uses electrochemiluminescence technology, in which multiple specific capture 
antibodies are coated at corresponding spots on an electric wired microplate. The 
detection antibody is conjugated to a tag which is excited with emission beams in 
the electric field applied by the reading instrument. Co-reactants present in the 
“read buffer” amplify these electric signals [27]. Using a standard curve these 
signals are quantified and expressed as absolute concentrations. 
PBMC isolation. The isolation of PBMCs from buffy coats was adapted from 
Repnik U et.al.[28]. Briefly, buffy coats were obtained from the Central Institute for 
Transfusion Medicine, Hamburg (Germany) and WBCs were Purified using a Ficoll 
gradient (GE healthcare, Uppsala, Sweden), a subsequent hyperosmotic Percoll 
gradient (GE healthcare, Uppsala, Sweden) led to separation of monocytes from 
lymphocytes and a third iso-osmotic Percoll gradient to monocytes from platelets 
and dead cells. The pellet obtained after this gradient is the monocyte-enriched 
fraction, which we refer to as PBMCs. According to the forward and side scatter 
plots, this fraction contains about 55-80% monocytes along with 45-20% of 
lymphocytes.  
Flow cytometry. The PBMC fraction was cultured in RPMI supplemented with 
10% FCS, 2 mM L-Glutamine and 100 U/ml Penicillin-Streptomycin for 12 hours 
with or without 22.2 mM glucose and 0.5 mM Palmitate. For flow cytometry of 
these PBMCS, they were fixed in freshly-prepared in 1% para-formaldehyde for 10 
min at RT. After washing, cells were incubated in polyclonal rabbit anti-Siglec-7 Ab 
(Abcam) followed by incubation with FITC/Alexa 488 labeled donkey anti-rabbit 
secondary antibody (Dako, Hamburg, Germany). Rabbit IgG was used as isotype 
control. For CD25 and CD14 labeling, the PE conjugated anti-CD25 Antibody 
(Beckman and Coulter A0 7774) and PE-Cy5 conjugated anti-CD14 (Beckman 
and Coulter A0 7765) were incubated for 30 min at 37°C. The fractions analyzed 
by FACS were: unstained, control with only secondary, single labeled Siglec-7, 
CD14 and CD25 and a triple stained fraction. Statistical analysis has been 
performed on the cell populations in all the different quadrants of the dot plots of 
CD14 vs. Siglec-7 and CD25 vs. Siglec-7 in the triple stained samples, and the 
data represented in the graphs signify quantifications of the co-stained 
populations.  
Migration assay. After processing buffy coats through a single Ficoll gradient, the 
purified leukocyte fraction is plated on cell culture inserts with 0.1 μm pore size 
membranes, placed in 24 well plates (BD biosciences). The lower chamber 
contained 1:10 diluted conditioned media obtained from transfected and treated 
islets and migration was allowed at 37°C for 4 hours. Post the duration of 
migration, the membrane was cut off and mounted on slides in fluorescein di-
acetate solution which renders live cells fluorescent. The slides are analyzed with 
a Nikon MEA53200 (Nikon GmbH, Dusseldorf, Germany) microscope and images 
were acquired and quantified using NIS-Elements software (Nikon).  
Statistical analysis. Samples were evaluated in a randomized manner by G.D, 
who was blinded to the treatment conditions. Data are presented as means +/- SE 
and were analyzed by Student’s t- tests.  
 
Results 
Siglecs are differentially expressed in human pancreatic islets  
Siglecs are classically expressed in the cells of the hematopoietic system and 
regulate the inflammatory cell response. Since many pattern recognition receptors 
and cytokine receptors are highly expressed on ?-cells, we assessed expression 
levels of the 10 classical siglecs in the human pancreas. Immunofluorescent 
labeling of siglecs, insulin and glucagon revealed the presence of siglecs 
predominantly in the endocrine pancreas. The evolutionarily conserved siglecs 
Siglec-1 (Sialoadhesin) and Siglec-2 (CD22); as well as Siglec-7 and -10 were 
expressed exclusively in the β-cells (Fig.1A-D) and Siglec-3,-5, and -8 were 
expressed solely by the α-cells (Fig.1E-G). In contrast, Siglec-4, -6 and -9 were 
not expressed in the pancreatic islets. The cellular localization was confirmed by 
carrying out Confocal Laser Scanning Microscopy (data not shown). Cell surface 
expression of Siglec-7 in islets was confirmed by flow cytometric analysis of 
dispersed islets (Supp. Fig. 1A). In addition to this, the presence of Siglec-7 was 
tested using two different polyclonal antibodies and a monoclonal antibody (data 
not shown), which validated our observations in human pancreas sections.  
Siglec-7 and -3 are oppositely regulated in type 2 diabetes  
In order to understand the role of siglec expression in the endocrine pancreas, we 
investigated whether siglecs are regulated in T2D. Semi-quantitative real time 
PCR analysis was performed on cDNAs obtained from non-diabetic and diabetic 
human pancreas from autopsy. In addition to housekeeping genes, expression 
levels of siglecs were normalized on cell specific markers of β- and α-cells i.e. 
insulin and glucagon, to account for the changes in their mass in diabetic 
individuals. In addition, pancreatic siglec expression was normalized to the β- and 
α-cell specific glutamate receptors SN1 and SAT2, whose expression is 
unregulated in diabetes [29]. Siglec-7 expressed on β-cells was drastically 
decreased in diabetic individuals when normalized on expression levels of 
cyclophylin (PPIA), insulin and SN1 (Fig.2A; reduced by 94%, 85%, 94% 
respectively in individuals with T2D). Also, Siglec-10 was significantly down-
regulated in T2D as compared to cyclophylin (PPIA) and SN1 and showed similar 
tendency when normalized on insulin (Supp.Fig.1B). On the other hand, the α-cell 
specific Siglec-3 showed substantial increase in diabetes upon normalization with 
cyclophylin (PPIA), glucagon and SAT2 (Fig.2A; induced to 5.15-, 4.29-, 5.52-fold, 
respectively in individuals with T2D, vs. non-diabetic controls). A decrease in 
insulin mRNA was confirmed in T2D (Fig.2B), while glucagon mRNA showed an 
increase in T2D (Fig.2C) and β- and α-cell specific SN1 and SAT2 remained 
unchanged in T2D (Fig.2D, E). 
The down-regulation of β-cell siglecs was confirmed in freshly isolated human 
islets from organ donors with T2D and controls. Siglec-7 showed 87% reduction vs 
non-diabetic control islets (Fig.2F) and Siglec-10 showed a similar decrease 
(Suppl.Fig.1C). Because of the β-cell specific expression and significant regulation 
in diabetes, we focused our research on the presence and implication of Siglec-7 
in the progression of diabetes.  
Siglecs bind to different linkages of the terminal sialic acid to its underlying glycan 
with varying affinities [30]. Siglec-7 has a binding preference for α2,8-linked disialic 
acid, which leads to downstream signaling via its cytoplasmic inhibitory motifs [31]. 
In contrast to Siglec-7, the sialyl-transferase responsible for α2-8 linkage 
formation, St8Sia1 showed a tendency of up-regulation in the diabetic islets 
(Fig.2G), suggestive of a compensatory mechanism. The membrane-associated 
sialic acid-cleaving enzyme sialidase Neu3 (Fig.2H), which may unmask Siglec-7 
residues and thus induce Siglec-7 mediated inhibition of cell death [16], was 
significantly down-regulated in T2D islets, which is a further deleterious signal in 
the inflammation-initiation cascade. 
GD3 is one of the endogenous ligands for Siglec-7 which displays 2,8-linked 
disialic acids [32]. High levels of GD3 reverse the Siglec-7 protective functions in 
cell survival [16]. Its constitutive expression was detected in β-cells in human 
pancreas sections by immunofluorescent labeling. As compared to non-diabetic 
individuals GD3 was more strongly expressed in patients with T2D. Quantification 
of the staining showed a 1.50-fold and 3.27-fold increase in intensity and 
saturation respectively in non-diabetic controls vs. patients with T2D (Fig.2I, J). 
The loss in Siglec-7 expression was confirmed in the same sections from autopsy 
and showed a 60% and 63% decrease in intensity and saturation respectively in 
patients with T2D vs. non-diabetic controls (Fig.2K, L).  
We further confirmed the opposite regulation of Siglec-7 ligands by another 
biochemical approach. Chimeric proteins consisting of the IgG like V-set domain 
attached to an Fc-region were constructed, expressed and purified from the Cho-
lec1 cell line [33]. They were used as probes to detect the presence of their 
binding partners. As a negative control, slides treated with sialidase were probed, 
in which there was no detection of ligands. Bright field staining of the chimeras 
revealed the presence of Siglec-7 ligands in both α- and β-cells (Fig.2M), which 
was increased in pancreatic sections of patients with T2D. These findings hint 
towards a disruption of Siglec-7 engagement in diabetic islets, and the cells 
attempt to counteract this by up-regulating its ligands.   
 
Siglec-7 over-expression improves β-cell survival and function  
In order to understand the physiological impact of decreased Siglec-7 expression 
in diabetes, we used an in vitro model of human islets exposed to a diabetic milieu 
of elevated glucose (22.2-33.3 mM) (HG) and free fatty acid (0.5 mM 
palmitate)(Pal) levels or the cytokine mixture of IL-1β and IFNγ (IL/IF) and 
subsequently investigated whether re-expression of Siglec-7 can restore ?-cell 
function and survival under diabetogenic conditions. Siglec-7 was restored by 
liposome-mediated transfection of human islets isolated from non-diabetic and 
diabetic (T2D) organ donors. Plasmid over-expression of Siglec-7 was analysed 
using flow cytometry following over-expression in HEK293T cells (Supp.Fig.1D). 
β-cell function (Fig.3A-D) and survival (Fig.3E-F) were impaired by all diabetogenic 
culture conditions (Fig.3A,C,D) as well as in islets isolated from patients with T2D 
(3B,D,F). In contrast, Siglec-7 over-expression improved β-cell function and 
survival at all diabetic conditions (3A-F) in healthy non diabetic islets as well as in 
islets isolated from T2D organ donors, where Siglec-7 over-expression completely 
normalized β-cell function and survival in these islets (Fig. 3B, D and F). 
Treatment of diabetic islets with a diabetic milieu did not further impair the β-cells. 
In line with our observation in the diabetic pancreas, diabetogenic conditions in 
vitro led to a loss in Siglec-7 expression (Fig.3G). Down-regulation of Siglec-7 by 
siRNA shows that a loss of Siglec-7 alone impairs β-cell function in vitro (Fig.3H, I; 
60% reduction in GSIS, as compared to scramble transfected control islets). 
Furthermore, the deleterious effects of glucolipotoxicity and cytokines impair 
insulin secretion in β-cells; loss of Siglec-7 adds to it as seen by a tendency of 
lower stimulatory indices in cytokine treated islets. This down-regulation may 
directly influence β-cell survival and function under these conditions. We checked 
for possible mechanisms by which Siglec-7 can bring about inhibition of 
destruction of β-cells.  
Siglec-7 over-expression inhibits NF-κB activation and cytokine production   
Islets exposed to elevated glucose and palmitate or cytokines are triggered to 
secrete pro-inflammatory cytokines. As Siglec-7 is an inhibitory cell adhesion 
molecule on immune cells [34], we hypothesized that the protective role of Siglec-
7 was mediated via the inhibition of inflammation. Expression and secretion of 
both IL-1β and IL-6 were induced by exposure of islets to elevated glucose and 
palmitate as well as by the cytokine mixture; this was strongly inhibited on islets 
over-expressing Siglec-7 (Fig. 4A-D).  
In order to identify the underlying signaling cascades of Siglec-7 mediated β-cell 
protection, downstream inflammatory pathways were investigated. Western blot 
analysis of isolated islets treated with elevated glucose and palmitate and the 
cytokine mixture revealed the activation of the NF-κB pathway, as observed by the 
induction of phosphorylation of IκB-α and p65 phosphorylation at Ser536, both 
core components leading to NF-κB activation (Fig.4E,F). This induction could at 
least be partially prevented by over expression of Siglec-7 shown by subsequent 
decrease in IκB-α phosphorylation (Fig.4E, H, I). p65 phosphorylation at Ser536 
merely enhances its transcription factor activity and is known to be independent of 
IκB-α [35]. Nevertheless, also the induction of p65 phosphorylation upon cytokine 
treatment was inhibited upon Siglec-7 over-expression (Fig.4F, J, K). These 
observations consolidated the immunosuppressive role of Siglec-7 in the 
prevention of triggering islet inflammation observed in diabetes. 
Since also PBMCs showed induction of phosphorylation of IκB-α and p65 
phosphorylation at Ser536 in response to elevated glucose and palmitate and the 
cytokine mixture IL/IF (Fig.4G), we subsequently analyzed Siglec-7 expression in 
PBMCs under a diabetogenic milieu. 
Loss of Siglec-7 is a hallmark of LPS and Gluc/Pal mediated monocyte 
activation. 
Since Siglec-7 is classically expressed by cells of the immune system, we 
investigated whether diabetogenic conditions would also affect Siglec-7 
expression in enriched monocytes. The monocyte-enriched fraction of peripheral 
blood mononuclear cells (PBMCs) was isolated from human buffy coats using 
sequential Ficoll-Percoll gradients and exposed to control media, 
Lipopolysaccharide (LPS, 20 μg/ml) as known activator of the immune cells or the 
mixture of 22.2 mM glucose and 0.5 mM palmitate. The activated state of these 
cells was analyzed at 2h and 12h after treatment by real time PCR analysis of the 
expression of CD25 and the cytokine IL-6. The activation of the canonical NF-κB 
pathway in PBMCs after the chronic treatments was seen by western blot analysis 
of the cell lysates (Fig.4G). LPS elucidated rapid (after 2h) and sustained (after 
12h) activation of immune cells, as seen by the induction of IL-6 expression after 
2h exposure (Fig.5A, B; ~22-fold/~390-fold at 2 and 12h as compared to control). 
Elevated glucose/palmitate induced a similar activation pattern in monocytes but to 
a lesser extent (Fig.5A, B; ~4-fold/~50-fold at 2 and 12h as compared to control). 
Both LPS and glucose/palmitate induced the expression of CD25 after 2h and, 
similar to IL-6, CD25 expression was much higher induced after 12h, with LPS 
showing a stronger effect (Fig.5C, D; ~45-fold, ~3-fold at LPS and Gluc/Pal 
respectively, as compared to control). In parallel, Siglec-7 m-RNA expression was 
down-regulated already after 2h treatment with LPS and glucose/palmitate 
(Fig.5E, F; 45% reduction as compared to control). While LPS-induced Siglec-7 
down-regulation was only transient, glucose/palmitate induced a sustained Siglec-
7 down-regulation (Fig.5F; 47% reduction as compared to control), suggesting the 
chronic nature of activation of these cells under conditions of glucolipotoxicity. In 
line with our findings that Neu3 is decreased in islets in T2D, there was marked 
down-regulation of Neu3 gene expression in the activated PBMCs at both acute 
and chronic treatments (Fig.5G, H). For confirming the changes in mRNA, we 
carried out flow cytometric analysis of the treated PBMCs (Fig.5I). The mean 
fluorescence intensity of Siglec-7 staining of cells treated with LPS and 
glucose/palmitate was decreased by 21.38% and 28.49%, respectively, as 
compared to control (Fig.5J), along with increased expression of CD25 
(Supp.Fig.3). 
To assess the Siglec-7 expression in activated cell population, cell surface 
expression of CD25 and CD14 was checked along with Siglec-7. By plotting the 
intensity of Siglec-7 vs intensity of either CD14 or CD25, followed by quadrant 
analysis, we determined the Siglec-7 intensity in these cells. The CD25 and 
Siglec-7 population increases upon exposure to LPS or Gluc/Pal, and the Siglec-7 
expression in these cells decreased. On the other hand CD14+ Sig7+ cells showed 
a decline in these conditions, with Siglec-7 staying stably expressed in these cells. 
Thus, loss of Siglec-7 expression was observed only in activated PBMCs, 
indicating the decreased immune-suppression in these conditions (supplementary 
figure 2). 
Immune cell migration into inflamed islets is inhibited by Siglec-7  
Increased infiltration of macrophages has been observed in islets in T2D [36]. To 
elaborate on the immune-regulatory role of Siglec-7, we evaluated the migration of 
monocytes in vitro in response to conditioned media obtained from isolated human 
islets, which had been exposed to diabetogenic conditions. For this, we 
established an in vitro migration assay wherein leukocytes isolated from human 
buffy coats were allowed to migrate over a period of 4h through a 0.1μm 
membrane to the lower compartment containing the conditioned islet media. The 
membranes were mounted in fluorescein diacetate solution, which rendered the 
live cells fluorescent upon excitation and enabled quantification by fluorescence 
microscopy (Fig.5M). Induced migration of immune cells was observed under 
conditions of elevated glucose/palmitate (Fig.5K, 9.61-fold as compared to 
control), which demonstrates the triggering of inflammation in islets upon chronic 
exposure to elevated glucose/palmitate. Conditioned media from islets 
overexpressing Siglec-7 majorly inhibited cell migration of immune cells (Fig.5K, 
74% reduction as compared to glucose/palmitate-treated, LacZ-transfected control 
islets). We also analysed the migratory response of the cells towards isolated 
islets obtained from patients with T2D. Islet supernatants from T2D islets induced 
significantly higher migration of the immune cells (Fig. 5L, ~ 2.2-fold induction as 
compared to non-diabetic islet supernatants, p<0.05) which could also be blocked 
by restoring Siglec-7 expression in these islets (Fig. 5L 54%, reduction as 
compared to lacz-transfected control T2D islets, p<0.05). Treatment with glucose 
and palmitate could not further induce the migration in diabetic islets, but Siglec-7 
over-expressing islets showed a decreased tendency of immune cell migration 
(data not shown). These findings elaborate on the anti-inflammatory role and the 
inhibition of immune cell stimulation by Siglec-7 in β-cells. 
 
Discussion  
The present study investigated the role of sialic acid-binding immunoglobulin-like 
lectins (Siglecs), a novel, and still-expanding family of cell adhesion molecules, in 
islet inflammation observed in T2D. Siglecs, previously known to be majorly 
expressed in the hematopoietic cells, are also expressed, in a cell type specific 
manner, in the endocrine pancreas. Of the evolutionarily evolving CD-33 related 
siglecs which were investigated, Siglec-7 and -10 were expressed solely in the β-
cells, whereas Siglec-3, -5 and -8 were expressed only in the α-cells. Although 
Siglec-7 shares around  84% sequence homology with Siglec-9 [37], its presence 
was undetectable in the endocrine pancreas as assessed by real-time PCR and 
immunohistochemical analyses. The β-cell specific Siglec-7 and -10 were 
markedly down-regulated in pancreas of individuals with T2D. In contrast, Siglec-3 
was significantly up-regulated in α-cells in T2D.  
Owing to the significant, drastic regulation of Siglec-7 in diabetes, we focused our 
research on its role in the β-cells. A marked decrease in the surface expression of 
Siglec-7 is the foremost marker of the aberrant NK-cell dysregulation in patients 
with chronic HIV-1 viremia [38]. Similarly, we saw down-regulation of Siglec-7 in β-
cells, in T2D. Thus, we hypothesized that the loss of Siglec-7 in the β-cells 
contributed to their dysfunction and apoptosis. Indeed, restoring surface Siglec-7 
expression protected the β-cells from deleterious effects of a diabetic milieu. 
Siglec-7 could not only maintain glucose stimulated insulin secretion even under 
diabetogenic conditions, but also inhibit β-cell apoptosis. This rescue of function 
and survival was also evident in in vitro studies of freshly isolated T2D islets. 
Additionally, depletion of Siglec-7 in healthy isolated control islets impaired β-cell 
function.  Hence, we could conclude that loss of Siglec-7 in the β-cells contributed 
to their destruction observed in T2D. Siglec-3 also has cytoplasmic ITIMs, but its 
functional significance in α-cells needs to be further investigated. Also, it is one 
C2-set domain shorter than Siglec-7, and might vary its interactions within the 
islets.    
Siglec-7 has an unusual binding preference for α-2,8-linked disialic acids and 
weaker interactions with branched α-2,6 sialyl residues [31]. Subsequently, we 
immunohistochemically investigated the presence of these binding partners in the 
human pancreas using Siglec-7 Fc-chimeras, and found them to be expressed in 
islets. Interaction partners were present in both α- and β-cells, indicating possibility 
of intra-islet trans interactions of Siglec-7 with its ligands on both these cell types.  
An endogenous ligand of Siglec-7, ganglioside GD3, was strongly up-regulated in 
diabetes. The disialoganglioside GD3 is an acidic glycosphingolipid, generated 
downstream of the ceramide-driven ganglioside biosynthesis, by sialylation of its 
immediate precursor GM3 by the GD3 synthase (α-2,8-sialyltransferase or ST8Sia 
I or SAT II) [39]. In freshly isolated islets obtained from autopsy of patients with 
T2D, we could detect a tendency of increase in ST8SiaI expression, which 
supported our observed up-regulation of GD3 in diabetic individuals. GD3 
activates Fas and ceramide mediated apoptosis, directly targets mitochondria and 
disrupts mitochondrial trans-membrane potential [40],  leading to the release of 
apoptotic factors such as cytochrome c, production of ROS and activation of AIF 
and caspase-9 [41]. Its induced expression in diabetes, thus, hints not only 
towards feedback up-regulation of ligand upon loss of Siglec-7 expression, but 
also gives an indirect proof of activation of the pro-apoptotic signaling like that of 
the Fas receptor, previously reported in the context of glucotoxicity as well as 
immune mediated ?-cell destruction in islets [42, 43]. Increased levels of GD3 in 
serum have also been implicated in inflammatory processes such as 
atherosclerosis [44] and lipopolysaccharide triggered inflammation in brain, 
wherein the microglial cells are activated and secrete GD3 leading to apoptosis of 
oligodendrocytes [45]. Parallels can be drawn between cytokines (e.g. IL-1β) and 
GD3, as both at low concentrations, stimulate cell proliferation while at high 
concentration triggers apoptosis [7, 46]. Also, GD3 expression has been observed 
specifically in the islets of a T1D mouse model i.e. NOD mice, whereas its 
precursor GM3 is expressed in the wild type islets [47]. Hence, increased GD3 
expression reiterates the pro-apoptotic inflamed state of islets in T2D.  
While we observed increased GD3 synthase, the membrane-associated sialidase, 
specific for ganglioside, NEU3 [48] was decreased in islets isolated from 
individuals with T2D. NEU3 cleaves off the surface sialic acid residues, which can 
unmask Siglec-7 and induce its inhibitory signaling cascade [16]. This unmasking 
may be diminished in T2D, as observed by significantly lower levels of NEU3 
consequently leasing to increased Siglec-7 ligand expression in diabetic islets.  
Tissue specific effects of NEU3 were observed previously; mice over-
expressing NEU3 mainly in muscles develop severe insulin-resistant diabetes [49], 
but, hepatic NEU3 over-expression improves insulin sensitivity and glucose 
tolerance through modification of ganglioside composition and Peroxisome 
Proliferator-activated Receptor gamma (PPAR-γ) signaling [50]. In islets, PPAR-γ 
activation restores β-cell function under conditions of hyperglycemia and cytokine 
stress [51] and also regulates β-cell transcription factors PDX-1 and Nkx6.1[52]. 
Decreased NEU3 expression in T2D islets may thus lead to reduced PPAR-γ 
signaling, and hence might contribute to β-cell dysfunction under diabetogenic 
conditions.  
Activated and insulin resistant immune cells have been observed in obesity [53]. 
Also, chronic exposure to FFAs leads to activation of monocytes, along with up-
regulation of toll-like receptors TLR2 and TLR4 [54], which leads to impaired 
glucose metabolism on the level of insulin sensitive as well as insulin producing 
cells. As Siglec-7 is endogenously expressed mainly by natural killer cells and 
monocytes and balances the immune response, the observed loss of Siglec-7 in 
PBMCs was a hallmark of activated monocytes under diabetogenic conditions. 
Acute exposure to LPS as well as elevated glucose and palmitate was sufficient to 
inhibit Siglec-7 expression. In spite of that, chronic exposure to LPS led to 
restoration of the messenger RNA, but maintained reduced cell surface expression 
of Siglec-7. Glucose and palmitate chronically kept both the mRNA and protein 
levels down, proving their chronic effect on the activation of the immune cells 
under circumstances when also IL-6 was induced. CD25, an atypical marker for 
activated macrophages [55] was induced after chronic treatment with the diabetic 
milieu, reiterating the activation of these cells. 
The down-regulation of Siglec-7 in activated PBMCs goes in hand with the 
decreased expression in islets under conditions of inflammation, which highlights 
its anti-inflammatory role in both these cell types. Ultimately, we investigated the 
effect of restoration of the siglecs in the islets on the actual infiltration of the 
immune cells.   
Maintaining Siglec-7 expression in stressed islets under glucolipotoxic conditions 
could inhibit the recruitment and migration of the immune cells. The increased 
number of macrophages per islet observed in vivo in diabetes [36] could, for the 
first time, be confirmed in vitro using a leukocyte migration assay, which also be 
prevented by restoring Siglec-7 expression in these islets. Hence, Siglec-7 
expression in islets is essential for maintaining an anti-inflammatory environment 
in islets, which prevents subsequent immune system activation. Summarizing the 
findings, we detected the presence of a novel family of cell adhesion molecules- 
Siglecs, expressed in the endocrine cells of the pancreas. One of its β-cell specific 
members, Siglec-7 was lost in diabetes. Restoration of Siglec-7 in these cells 
could protect them from the harmful effects of diabetic milieu, and help preserve β-
cell function and survival under these conditions by inhibition of pro-inflammatory 
cytokine secretion by suppressing NF-κB activity. Not only was this immune-
modulatory function evident in the cytokine profile of the β-cells, but also the 
PBMCs showed loss of Siglec-7 expression upon activation. Taken together, 
Siglec-7 plays a substantial role in the maintenance of immune-suppressive anti-
inflammatory microenvironment, which is lost in diabetes, and may contribute to 
the manifestation and progression of this metabolic syndrome (Suppl.Fig.4). Thus, 
preserving Siglec-7 expression and function on β-cells as well as immune cells 
may be a novel therapeutic strategy which could help target both, the sensitization 
and pro-inflammatory activation of the immune system as well as the islets, 
thereby being beneficial to effectively halt the deterioration of islets in T2D.     
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Figure legends 
Figure 1. Siglecs are differentially expressed in the human Islets of 
Langerhans.  
Triple immunostaining for insulin (blue), glucagon (green) and siglecs (red) was 
carried out on human pancreatic sections obtained at autopsy of healthy non-
diabetic controls and patients with T2DM, all with documented fasting plasma 
glucose >150 mg/dl. (A) Siglecs 1, (B) -2, (C) -7and (D) -10 were expressed in β- 
cells. (E) Siglecs 3, (F) -5, (G) -8 were expressed solely in α-cells. Representative 
analyses from 5 pancreases from patients with T2D and 5 controls are shown.  
Figure 2. Siglec-7 and -3 are oppositely regulated in type 2 diabetes  
Semi quantitative real time PCR analysis was performed on cDNAs obtained from 
non-diabetic (n=9) and diabetic human pancreas (n=5) from autopsy. (A) Siglec-7 
expression was normalized on cyclophilin (PPIA), insulin (ins) and SN1; whereas 
Siglec-3 expression was normalized on cyclophylin, glucagon (gluc) and SAT2. (B-
E) Insulin; Glucagon; SN1 and SAT2 were normalized on cyclophylin. (F-H) Real 
time PCR analysis of isolated islets obtained from autopsy of T2D patients (n=5) 
were compared to that of nondiabetic individuals (n=3) of (F) Siglec-7; (G) St8Sia1 
and (H) Neu3 (I,J) Immunohistochemical analysis was carried out on human 
pancreatic sections obtained at autopsy of healthy non-diabetic controls (n=3) and 
patients with T2DM (n=3) for (I) GD3 and (K) Siglec-7; (J,L) staining saturation 
and intensity were quantified using Photoshop; each data point represents 
saturation and intensity of the protein signal of islets from 3 donors, 2 sections per 
donor, average 7 islets per section. (M) Bright field staining using Siglec-7 Fc-
chimeras; along with glucagon (red) and insulin (green) of pancreas sections 
obtained from autopsies of healthy non-diabetic controls (n=3) and patients with 
T2DM (n=3); along with control slides treated with sialidase treatment. (*p<0.05 to 
5.5 mM glucose control). 
Figure 3. Siglec-7 over-expression improves β-cell survival and function  
Freshly isolated human islets of nondiabetic individuals as well as from patients 
with T2D were cultured on extracellular matrix-coated dishes and exposed to 
elevated glucose (22.2 or 33.3 mM) (HG) with or without palmitate (HGPal), 
palmitate alone (Pal) or the cytokine mixture IL-1β (2 ng/ml) and IFNγ (1,000 U/ml) 
(IL/IF) for 72 h with or without over-expression by lipofectamine-mediated Siglec-7 
plasmid transfection. Glucose stimulated insulin secretion assays were performed 
after the 72h culture period. (A,B) Basal (2.8 mM) and glucose stimulated 
(16.7mM) insulin secretion was expressed as percent change of control condition 
basal insulin levels. (C,D) Stimulatory index denotes the amount of glucose 
stimulated (16.7 mM glucose) divided by the amount of basal insulin secretion. 
Fold changes in stimulatory indices of treated islets were plotted, compared to 
stimulatory index of control islets (E,F) Apoptosis was analyzed by the TUNEL 
assay in dishes. Islets were triple-stained for insulin and counterstained for DAPI 
(not shown). Results are means ± SE of the percentage of TUNEL-positive β-cells. 
The average number of β-cells counted was 8124 for each treatment group in 3 
separate experiments from 3 separate dishes per treatment from 3 different organ 
donors. (G) Isolated human islets were treated with 22.2 mM glucose and 0.5 mM 
palmitate; or the cytokine mixture IL/IF, followed by immunohistochemical analysis 
of paraffin-embedded islet sections. Representative images show glucagon 
(green), Siglec-7 (red) and DAPI (blue). (A-D) Data are shown from parallel 
experiments as mean ? SE from 3 islet isolations from 3 different donors. For 
control islets; *p<0.05 to 5.5 mM glucose treated LacZ transfected islets, **p<0.05 
to diabetic stimuli treated LacZ transfected islets For T2D analysis, #p<0.05 to 5.5 
mM glucose treated LacZ transfected nondiabetic control islets. 
Figure 4. Siglec-7 inhibits NF-κB activation and cytokine secretion. 
Human pancreatic islets were cultured on extracellular matrix-coated dishes and 
exposed to  elevated glucose (22.2 mM) and palmitate (Gluc/Pal) or the cytokine 
mixture IL-1? (2 ng/ml) and IFNγ (1,000 U/ml) (IL/IF) for 72 h with or without over-
expression by lipofectamine-mediated Siglec-7 plasmid transfection. (A-D) The 
cytokine profiles of the supernatants of transfected and treated islets were 
assessed using protein microarray ELISAs. Western blot analysis was performed 
after Siglec-7 over-expression in islets and 72h treatment with (E) 22.2mM glucose 
and palmitate or (F) IL1β and IFNγ; and analyzed for p-p65, p-IKBα and actin. (G) 
PBMCs purified from buffy coats were exposed to 22.2mM glucose and palmitate 
or IL1β and IFNγ for 12h followed by western blotting. The blots were probed for p-
p65, p-IκBα and actin. (H-K) Densitometry was carried on blots, protein of interest 
i.e. p- IκBα and p-p65, normalized on housekeeping, and plotted as fold change of 
islets at control condition. The graphs and blots are representative of 3-4 
independent experiments. *p<0.05 to 5.5 mM glucose treated LacZ transfected 
control islets, **p<0.05 to diabetic stimuli treated LacZ transfected control islets.  
Figure 5. Immune cell migration into inflamed islets is inhibited by Siglec-7. 
PBMCs purified from buffy coats of blood donors (n=6) were treated with Lipo 
polysaccharide (LPS) or elevated glucose and palmitate (Gluc/Pal) for (A,C,E,G) 
2h or (B,D,F,H) 12h. Real time PCR analysis of these treated cells was carried out 
for (A-B) IL6, (C-D) CD25, (E,F) Siglec-7 and (G,H) Neu-3. Cell surface 
expression of Siglec-7 in the treated PBMCs was determined using flow cytometry. 
(I) Histograms for intensity of Siglec-7 (FL1 filter) was plotted and overlayed to 
observe the effect of these treatments. (J) Histograms were quantified and Siglec-
7 expression was plotted as % mean fluorescent intensity as compared to 
untreated control fraction. The migration of leukocytes (n=3 buffy coat donors) in 
response to conditioned media obtained from transfected and treated islets (n=3 
separate dishes from 3 independent experiments from 3 donors), was quantified 
after 4h using an in vitro migration assay. (K) The fold induction of migration as 
compared to untreated control islet supernatants was plotted. (L) Migration of 
mononuclear cells (n=3) with respect to cultured islets from diabetic donors (n=3), 
with or without Siglec-7 over-expression, was plotted as fold change of migrated 
cells compared to untreated control islets of a nondiabetic individual. (M)The 
images are representative of fluorescent microscopic analysis of live cells 
migrating through membranes observed in green. For PBMC treatments; *p<0.05 
to 11.1mM glucose treated monocyte fraction. For migration assay, *p<0.05 to 
monocyte fraction treated with 5.5 mM glucose, LacZ transfected control islets, 
**p<0.05 to monocyte fraction treated with Gluc/Pal, LacZ transfected control 
islets.   
 
Supplementary Figure 1: (A) Islets were dispersed using accutase and cultured 
overnight for recovery. These dispersed cells were stained with Siglec-7 and 
analyzed by flow cytometry. Histograms indicate the intensity of FL1 for unstained, 
isotype control and Siglec-7 stained cells. (B) Semi quantitative real time PCR 
analysis was performed on cDNAs obtained from non-diabetic (n=9) and diabetic 
human pancreas (n=6) from autopsy. Siglec-10 expression was normalized on 
cyclophilin (PPIA), insulin and SN1 (C) Real time PCR analysis for Siglec-10 of 
isolated islets obtained from autopsy of T2D patients (n=3) were compared to that 
of nondiabetic individuals (n=3). (D) HEK293T cells were transfected with LacZ or 
Siglec-7 plasmids were stained for Siglec-7 and analyzed using flow cytometry. 
(*p<0.05 to 5.5 mM glucose control) 
Supplementary Figure 2: (A) PBMCs purified from buffy coats of blood donors 
(n=6) were treated with elevated glucose and palmitate for 12h. They were triple 
stained for Siglec-7, CD-14 and CD-25 and analyzed using flow cytometry. Their 
intensities were plotted against each other, and the quadrants were analyzed for 
number of positive cell and signal intensities. (B)The % cells co-labeled for CD25 
and Siglec-7 were quantified, and also the (C) % mean fluorescent intensities of 
Siglec-7 in these cells was plotted. (D) % cells co-labeled for CD14 and Siglec-7 
were quantified, and the (E) % mean fluorescent intensities of Siglec-7 in these 
cells were plotted. *p<0.05 to 11.1mM glucose treated monocyte fraction.  
Supplementary Figure 3: Cell surface expression of CD25 in  elevated glucose 
and palmitate treated PBMCs (n=6) after 12h was determined using flow 
cytometry. Histograms for intensity of CD25 (FL2 filter) were plotted and overlayed 
to observe the effect of these treatments. *p<0.05 to 11.1mM glucose treated 
monocyte fraction. 
Supplementary Figure 4: This model illustrates the role of Siglec-7 as 
investigated in this paper. In healthy individuals, Siglec-7 helps to maintain a pro-
survival anti-inflammatory signaling in monocytes as well as β-cells. In diabetes 
however, chronic elevated glucose along with palmitate and cytokines cause loss 
of Siglec-7 in these cells. This leads to triggering of apoptotic and pro-
inflammatory signals, activation of macrophages and ultimately to β-cell death. 
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Discussion and Outlook 
This thesis is a compilation of three mutually exclusive investigations which drive 
towards the sole aim of understanding the mechanisms and players in β-cell survival. 
The thread joining these investigations was to put forth therapeutic targets or strategies 
to rescue and preserve the β-cell mass and function in diabetes. The investigations 
could be broadly classified into three categories: preservation of β-cell mass, 
maintenance of β-cell function and amelioration of the pro-inflammatory environment in 
the islets. Thus, one study was aimed at identifying a molecule TOSO, which could act 
as a switch to drive the apoptosis of these cells into a proliferative mode, thus protecting 
the β-cell from Fas induced apoptosis. The second study looked deeper into effects of 
one of the existing medications: DPP4-inhibitors on β-cell function and survival. Third 
and the major research carried out during this thesis, was exploring β-cell function and 
survival under conditions of inflammation with a focus on the cell surface expression 
and signaling of siglecs. This section of the thesis will discuss each of these 
investigations in detail, always keeping in mind the basic aim of protecting the β-cells 
from deleterious events taking place in diabetes.  
 
Target for induction of β-cell proliferation 
TOSO switches Fas-induced β-cell apoptosis into proliferation [1]. 
The activation of inflammatory pathways has been discovered as a causal event for β-
cell destruction in diabetes [2, 3], which is also mediated by TLR activation [4, 5]. 
Thereby, not only pro-inflammatory molecules are induced (e.g. IL-1β, Fas), but also the 
anti-inflammatory cytokine interleukin-1 receptor antagonist and the anti-apoptotic cFLIP 
are down-regulated in β-cells in diabetes [2, 6, 7]. Also, TOSO down-regulation was 
reported in response to TLR activation [8]. Thus, attempts to block Fas-induced 
apoptosis and the activation of pro-inflammatory cytokines could be a strategy to 
prevent diabetes. Here we show that down-regulation of another protective factor in 
T2D and its loss promotes β-cell destruction. 
TOSO was first cloned and characterized in hematopoietic cells as a novel 
immunoglobulin domain-containing type I transmembrane protein, exhibiting potent 
pathway-specific anti-apoptotic effect [9]. The name TOSO was given after a Japanese 
liquor that is drunk on New Year's Day to celebrate long life and eternal youth [9], 
reflecting its pro-survival effect. TOSO inhibited apoptosis induced by 
Fas, TNFα, FADD, and PMA/ionomycin; but not staurosporine- or ceramide-
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induced apoptosis. The mechanism of inhibition and its specificity were hypothesized to 
be due to inhibition of caspase-8 processing, through induction of cFLIP expression. 
The role of TOSO in maintaining cFLIP expression during Fas mediated apoptosis of 
lymphocytes and hepatocytes has been elucidated using TOSO-/- mice [10]. B-cells and 
thymocytes from these mice show increased sensitivity to Fas-triggered apoptosis, and 
these mice suffer greater mortality and exhibit exacerbated liver damage in response to 
Fas engagement in vivo. TOSO modulates Fas-mediated apoptosis by influencing the 
expression of c-FLIP and regulating the physical binding of caspase-8 to Fas receptor. 
The anti-apoptotic function of TOSO depends on ubiquitination of an adaptor kinase, 
RIP1, and involves the recruitment of the death adaptor FADD to a TOSO/RIP1 protein 
complex. Upon activation by FasL and TNFα, TOSO promotes the activation of pro-
survival signaling pathways and protects from liver damage [11]. TLR activation leads to 
decreased TOSO expression shown in leukemic B-cells [8]. 
In this study, I showed that TOSO expression correlated positively with β-cell 
proliferation; both the proliferation-inducing treatments, i.e., acute high glucose and low 
dose IL-1β positively regulated TOSO expression. On the other hand, pro-apoptotic 
stimuli, i.e., chronic elevated glucose and high dose of IL-1β almost depleted TOSO 
mRNA expression. Thus, depletion of TOSO coincides with activation of β-cell 
apoptosis under conditions of stress. TOSO, when over-expressed, not only rescued β-
cells from apoptosis but also triggered proliferation. This pro-survival signaling has also 
been observed in TOSO over-expressing Jurkat cells in which CD95L- and TNFα- 
stimulation readily induced the activation of Erk1/2 [11]. While TNFα potentiates cell 
death, it is insufficient to cause apoptosis in β-cells [12]. Since TOSO promotes the 
TNFα -induced signaling cascade, it is possible that TNFα would induce β-cell apoptosis 
in the absence of TOSO, but there is no experimental proof for this hypothesis so far. 
Intact Fas receptor signaling is also necessary for β-cell secretory function [13]. Hence, 
we investigated whether TOSO expression can also contribute to glucose stimulated 
insulin secretion. While TOSO over-expression was not effective at basal glucose 
levels, our results show that TOSO protected the inhibition of insulin secretion by 
elevated glucose and cytokines and restored β-cell function.  
Mature human β-cells have only a very limited capacity to undergo proliferation [14]. To 
control and foster β-cell proliferation has become a long-term goal in β-cell research. 
With the goal to find a subpopulation of β-cells with a higher proliferative capacity, I 
over-expressed TOSO and investigated the nature of the induced proliferation by using 
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the technique of sequential thymidine analogue labelling, previously developed in mice 
by Teta et al. [15]. I optimized the method so that it could be used in a similar fashion in 
vitro in human islets, to detect multiple rounds of proliferation. TOSO over-expression 
induced an early round of proliferation in the isolated human islets, irrespective of 
sequence of analogue administration or time after transfection. However, only in a very 
limited number of islets (maximum 0.08 %), more than one round of proliferation was 
observed during the 6-day culture period. Such limited proliferation capacity is in 
confirmation with the results from mouse β-cells in vivo. In summary, TOSO is a novel 
anti-apoptotic protein, which interferes with the Fas triggered apoptosis by regulating 
FLIP and thereby initiating a pro-survival signaling cascade (see chapter 3.1.1 for our 
model). Thus, TOSO hints to be a promising therapeutic target to rescue β-cells from 
apoptosis induced by elevated glucose and cytokines and hence, intervening in the 
progression of diabetes. However, with the means of TOSO, we were unable to develop 
a β-cell, which would undergo multiple rounds of replication during culture.  
 
Target for prevention of β-cell apoptosis and improvement of function 
The DPP4- inhibitor Linagliptin improves β-cell function and survival by stabilising GLP-
1 [16]  
Orally administered DPP-4 inhibitors prevent the rapid cleavage of GLP-1 and thus 
increase levels of active GLP-1, resulting in increased insulin and reduced glucagon 
secretion, lowered glucose and reduced HbA1c levels by 0.5 – 1.0% [17]. Linagliptin 
improves glycemic control both as monotherapy [18] and in combination therapy, e.g., 
with metformin [19] or pioglitazone [20] and also improves insulin sensitivity [20]. DPP-4 
inhibitors mimic many of the actions ascribed to GLP-1 including preservation of β-cell 
mass through stimulation of cell proliferation and inhibition of apoptosis in rodents [21-
23]. 
Besides GIP and GLP-1, many gastrointestinal hormones, neuropeptides, cytokines, 
and chemokines are substrates for DPP-4 [24], including CXCL10 and SDF1α, both of 
which are involved in immune regulation, influence the inflammatory response and have 
been associated with the regulation of β-cell turnover in diabetes [5, 25]. Since 
cytokines and chemokines are crucial for the survival of pancreatic β-cells [26], it 
remained to be investigated whether DPP-4 inhibitors in culture directly affect β-cell 
survival and function. In the present study, the DPP-4 inhibitor linagliptin effectively 
restored proliferation, survival and β-cell function in a diabetic milieu. The 
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concentrations of 30 – 50 nM used in the study were higher than the average Cmax 
plasma levels but could be also obtained in patients taking therapeutic doses of 
linagliptin [27]. At all concentrations up to 1 μM, which is 1000-fold the IC50 of the 
human enzyme, linagliptin did not affect β-cell survival at basal conditions in culture. 
Human β-cells in culture have only a very limited if any [28] capacity to proliferate. Here 
we found 0.4% proliferating β-cells under basal conditions when islets were plated on 
extracellular matrix coated dishes, and proliferation was even further decreased by 
diabetogenic conditions of chronically elevated glucose, free fatty acids, cytokines or 
H2O2. Linagliptin improved cell survival by decreasing apoptosis, and maintained cells 
at a steady state level, even under diabetogenic conditions.  
The protective linagliptin effect seen in this study was mediated by stabilization of   
GLP-1 in the islet supernatants, where total as well as active GLP-1 levels were 
restored and accumulated during islet culture, providing a similar mechanism of the 
protective effect of DPP-4 inhibition on β-cell survival as in vivo. 
Active GLP-1 can be produced from islets [29]. The β-cells express pro-hormone 
convertase PC1/3, which cleaves preproglucagon peptide to generate GLP-1. β-cells 
are an established islet source of secreted GLP-1 [30-33] and may provide a local 
protective paracrine effect for β-cell regeneration under diabetic conditions, especially 
during β-cell injury [25]. Sorted human β-cells also express PC1/3 but the GLP-1 
content could not be detected and thus it was assumed that β-cells do not produce 
GLP-1 [34], although it was found to be secreted from the rodent β-cell line, INS-1E 
[35]. We found high levels of active GLP-1 (3 ng/ml from 50 islets over 4 days of culture) 
were secreted from human islets and accumulated only in the presence of a DPP-4 
inhibitor, while high DPP-4 activity could only be measured in the absence of linagliptin.  
GLP-1 is accumulated in the medium during the 4-day culture period and provides in 
turn a paracrine protective effect on the β-cell. Diabetogenic conditions like the cytokine 
cocktail IL-1β/IFNγ enhanced IL-6 production, which was counteracted by linagliptin, 
paralleled with increased GLP-1 in the medium. It can thus be hypothesized, that higher 
GLP-1 concentration in the culture medium in turn inhibits elevations in IL-6; this would 
provide a negative feedback loop to the IL-6 effect to induce GLP-1 in islets [30].   
Hyperglycemia and a diabetic milieu decrease expression of β-cell GLP-1 receptors in 
vivo and in vitro [36-38]. In contrast, diabetogenic conditions significantly increased total 
GLP-1 release from cultured islets. This was also observed in islets from patients with 
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T2D [31] and from diabetic Psammomys obesus [33], which show higher GLP-1 
secretion than non-diabetic controls. 
Slightly reduced GLP-1 secretion after a meal in patients with impaired oral glucose 
tolerance and more severely impaired GLP-1 secretion in type 2 diabetic patients was 
observed [39], although controversial results have been obtained in various studies [40]. 
Differences occur between tissue-specific GLP-1 levels and whether total or active 
GLP-1 was measured [41]. It is possible, that reduced GLP-1 in T2D patients is a result 
of elevated plasma DPP-4 activity [42], which can be induced by chronic hyperglycemia 
and is paralleled with reductions of active GLP-1 [43].  
Linagliptin strongly reduced DPP-4 activity in the human islet supernatant and stimulate 
GLP-1 stability. Active DPP-4 rapidly degrades SDF-1α(1-68) to inactive SDF-1α(3-68) 
[44] and thus, more active SDF-1α is available upon DPP-4 inhibition. In turn SDF-1α 
acts like a cytokine and induces its own production [25]. This explains the increased 
SDF-1α mRNA levels upon linagliptin treatment, found in the present study. 
The regulation of DPP-4 in diabetes has not been fully clarified, both increased [42, 43] 
and decreased [45] DPP-4 activity has been reported in patients with diabetes.  DPP-4 
release from adipose tissue is higher in obese individuals and correlates with 
parameters of the metabolic syndrome, where DPP-4 directly impairs insulin signaling in 
fat and muscle cells [46]. Elevated glucose exposure leads to enhanced DPP-4 activity 
and mRNA expression in endothelial cells [47]. Also in human islets, we detected 
elevated DPP-4 mRNA in response to elevated glucose and palmitate, while linagliptin 
inhibited an induction. One could speculate that in islets under diabetogenic conditions, 
there is more DPP-4 produced, which inactivates GLP-1 and thus it cannot fulfil its 
functions.  
Recent human studies investigating the long-term treatment with vildagliptin on β-cell 
function were somehow disappointing, because following wash out periods the 
observed β-cell sparing effects disappeared, thus questioning the disease modifying 
potential of this drug [48]. However, it remains to be elucidated whether this is caused 
by a limited tissue penetration in vivo or limited availability of the drugs in islets. In 
summary, I show that linagliptin has a protective effect on β-cell turnover and function, 
which is mediated through stabilized GLP-1 and an anti-inflammatory/anti-oxidative 
stress pathway. 
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Target for amelioration of inflammation-induced β-cell death  
Siglec-7 inhibits pro-inflammatory signaling in stressed β-cells, and improves their 
survival and function 
The present study investigated the role of sialic acid-binding immunoglobulin-like lectins 
(Siglecs), a novel, still-expanding family of cell adhesion molecules, in islet inflammation 
observed in T2D. Here, we show for the first time, that some of the Siglecs, previously 
known to be majorly expressed in the haematopoietic cells, are also expressed, in a cell 
type specific manner, in the endocrine pancreas. Of the evolutionarily evolving CD-33 
related siglecs which were investigated, Siglec-7 and Siglec-10 were expressed solely 
in the β-cells, whereas siglecs 3, 5 and 8 were expressed only in the α-cells. Although, 
Siglec-7 shares around  84 % sequence homology with Siglec-9 [49], its presence was 
undetectable in the endocrine pancreas as assessed by real-time PCR and 
immunohistochemical analyses. The non-hematopoietic siglecs, Siglec-4 (myelin 
associated) and Siglec-6 (placental) were also not detected in the islets. Out of the 
siglecs which are evolutionarily conserved within species, siglecs 1 and 2 are expressed 
in the β-cells. Siglecs being cell adhesion molecules, this differential expression could 
imply their involvement in intra-islet cellular cross talk.  
After having confirmed their presence in islets, we checked whether expressions of any 
of these siglecs were affected in diabetic islets. The β-cell specific siglecs 7 and 10 
were markedly down-regulated in pancreas of individuals with T2D. In contrast, Siglec-3 
was significantly up-regulated in α-cells in T2D.  
Owing to the significant, drastic regulation of Siglec-7 in diabetes, we focused our 
research on its role in the β-cells. Previously, it has been shown by Brunetta E. et al. 
that a marked decrease in the surface expression of Siglec-7 is the foremost marker of 
the aberrant NK-cell dysregulation in patients with chronic HIV-1 viremia [50]. We saw 
strong correlation between incidence of T2D and down-regulation of Siglec-7 in the β-
cells. Also, in vitro down-regulation of Siglec-7 in the β-cells was sufficient to impair the 
β-cell function. Thus, we hypothesized that the loss of Siglec-7 in the β-cells contributed 
to their dysfunction and apoptosis. Indeed, restoring surface Siglec-7 expression 
protected the β-cells from deleterious effects of a diabetic milieu. Siglec-7 could not only 
restore the glucose stimulated insulin secretion under these conditions, but it also 
inhibited β-cell apoptosis. This rescue of function and survival was also evident in in 
vitro studies of freshly isolated T2D islets. Hence, we could conclude that loss of Siglec-
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7 in the β-cells contributed to their destruction observed in T2D. Nevertheless, one 
needs to take into consideration the fact that over-expression in islets in the present 
study could occur in all its different cell types. Further experiments using an insulin 
promoter driven plasmid might be useful in confirming the β-cell specific role of Siglec-
7.Another fact that needs to be focused on is that, Siglec-3 also has cytoplasmic ITIMs, 
but its functional significance in α-cells needs to be further investigated. Also, it is one 
C2-set domain shorter than Siglec-7, and might vary its interactions within the islets. 
Siglec-7 has an unusual binding preference for α-2,8-linked disialic acids and weaker 
interactions with branched α-2,6 sialyl residues [51]. Subsequently, we 
immunohistochemically investigated the presence of these binding partners in the 
human pancreas using Siglec-7 Fc-chimeras, and found them to be expressed in islets. 
Interaction partners were present in both α- and β-cells, indicating the possibility of 
intra-islet trans interactions of Siglec-7 with its ligands on both these cell types.  
An endogenous ligand of Siglec-7, ganglioside GD3, was strongly upregulated in 
diabetes. The disialoganglioside GD3 is an acidic glycosphingolipid, generated 
downstream of the ceramide-driven ganglioside biosynthesis, by sialylation of its 
immediate precursor GM3 by the GD3 synthase (α- 2,8-sialyltransferase or ST8Sia I or 
SAT II). In freshly isolated islets obtained from autopsy of patients with T2D, we could 
detect a tendency of increase in ST8SiaI expression, which supported our observed 
upregulation of GD3 in diabetic individuals. As early as in 1979, GD3 has been first 
described as a tumor-associated antigen, with its overexpression observed in different 
melanomas [52].  More than two decades later, its involvement in the Fas and ceramide 
mediated apoptosis in haematopoietic cells was reported [53]. GD3 directly targets 
mitochondria and disrupts mitochondrial trans-membrane potential [53], leading to the 
release of apoptotic factors such as ROS, cytochrome c, AIF and caspase-9 [54]. Its 
induced expression in diabetes, thus, hints not only towards feedback up-regulation of 
ligand upon loss of Siglec-7 expression, but also gives an indirect proof of activation of 
the pro-apoptotic signaling like that of the Fas receptor, previously reported by us in the 
context of glucotoxicity in the islets [7]. Increased levels of GD3 in serum have also 
been implicated in inflammatory processes such as atherosclerosis [55]. GD3 acts as 
an extracellular messenger of cell death in the lipopolysaccharide triggered 
inflammation in brain, wherein the microglial cells are activated and secrete GD3 
leading to apoptosis of oligodendrocytes [56]. Islet inflammation in T2D has been 
elucidated by induction of cytokine and chemokine secretion upon chronic exposure to 
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elevated glucose and free fatty acids [57]. We have previously shown induced IL1β 
expression by the β-cell as a result of chronic elevated glucose concentrations resulting 
in β-cell apoptosis [2]. Parallels can be drawn between the cytokine IL1β and GD3, as 
both at low concentrations, stimulate cell proliferation while at high concentration 
triggers apoptosis [2, 58]. Hence, increased GD3 expression reiterates the pro-apoptotic 
inflamed state of islets in T2D.  
Together with the increased GD3 synthase, we also observed decreased Neu3 
expression in islets isolated from individuals with T2D. Neu3 is the membrane-
associated sialidase which is specific for gangliosides [59]. It has been reported that 
mice over-expressing NEU3 mainly in muscles develop severe insulin-resistant diabetes 
[60]. However, hepatic NEU3 overexpression paradoxically improves insulin sensitivity 
and glucose tolerance through modification of ganglioside composition and Peroxisome 
Proliferator-activated Receptor gamma (PPAR-γ) signaling [61]. In islets, PPAR-γ 
activation restores β-cell function under conditions of hyperglycemia and cytokine stress 
[62] and its agonist are used in pharmacological treatment of T2D. In line with these 
observations, decreased Neu3 expression in T2D islets can lead to reduced PPAR- γ 
signaling, and hence might contribute to the β-cell dysfunction under diabetogenic 
conditions. In addition to this, Neu3 can cleave off the surface sialic acid residues, 
which can unmask Siglec-7 and induce its inhibitory signaling cascade [63]. This 
unmasking is also diminished in T2D, as observed by significantly lower levels of Neu3 
and increased ligand expression in diabetic islets.  
Along with the observed induced pro-apoptotic glycosylation machinery, loss of the 
inhibitory receptor Siglec-7 further accentuates loss of β-cell function and survival. We 
investigated underlying mechanisms of the protective effect of Siglec-7 by performing 
western blot analysis of transfected and treated islets, and checked for activation of the 
classical pathway. Chronic exposure of islets to diabetic stimuli led to increased 
phosphorylation of IKBα, marking it for proteosomal degradation. Once free, p65/p50 
NF-κB heterodimer could translocate to the nucleus where it would be phosphorylated, 
thus enhancing its transcriptional activity. Diabetic milieu could also induce this p65 
phosphorylation. Siglec-7 over-expression blocked this signaling cascade by inhibiting 
phosphorylation of IκBα and p65. The consequent secretion of cytokines after the NF-
κB activation was investigated, which revealed decreased expression and secretion of 
cytokines Il1b and IL-6 upon Siglec-7 restoration in islets treated with a diabetic milieu 
of elevated glucose and palmitate as well as mixture of cytokines IL1β/IFNγ. This 
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demonstrates the immuno-suppresive effect of Siglec-7, which can protect the β-cells 
from cytokine-mediated apoptosis. 
Chronic activation of the innate immune system is observed in both T1D and T2D. 
Metabolic changes in glucose homeostasis have been shown to affect the inflammatory 
state of the immune system It has been shown in the context of T1D, soluble form 
Interleukin receptor 7-α is increased, and it has been attributed to effect of 
hyperglycemia on the T-cells [64]. We wanted to check the regulation of Siglec-7 in the 
immune cells. As Siglec-7 is endogenously expressed mainly by natural killer cells and 
monocytes, we checked for its regulation upon acute and chronic treatment of freshly 
isolated peripheral blood monocytes (PBMCs) with elevated glucose and palmitate as 
well as cytokine mixture. Siglec-7 down-regulation was seen to be a hallmark of the 
activated monocytes. Acute exposure to LPS as well as elevated glucose and palmitate 
was sufficient to inhibit Siglec-7 expression. In spite of that, chronic exposure to LPS led 
to restoration of the messenger RNA, but maintained reduced cell surface expression of 
Siglec-7. On the other hand, glucose and palmitate chronically kept both the mRNA and 
protein levels down, proving their chronic effect on the activation of the immune cells. In 
both acute and chronic treatment, cytokine IL-6 was induced. CD25, an atypical marker 
for activated macrophages [65] was induced after chronic treatment with the diabetic 
milieu, reiterating the activation of these cells. The down-regulation of Siglec-7 in 
activated PBMCs goes in hand with the decreased expression in islets under conditions 
of inflammation, which highlights its anti-inflammatory role in both these cell types. 
Ultimately, we investigated the effect of restoration of siglecs in the islets on the actual 
infiltration of the immune cells. The increased number of macrophages per islet 
observed in vivo in diabetes [66] could, for the first time, be confirmed in vitro using a 
leukocyte migration assay, wherein we could quantify the glucolipotoxicity induced 
migration of immune cells towards the islets. Maintaining Siglec-7 expression in these 
stressed islets could inhibit the recruitment and migration of the immune cells. Hence, 
Siglec-7 expression in islets is essential for maintaining an anti-inflammatory 
environment in islets which prevents subsequent immune system activation.  
Summarizing the findings, we detected the presence of a novel family of cell adhesion 
molecules- Siglecs, expressed in the endocrine cells of the pancreas. One of its β-cell 
specific members, Siglec-7 was lost in diabetes. Restoration of Siglec-7 in these cells 
could protect them from the harmful effects of diabetic milieu, and help preserve β-cell 
function and survival under these conditions by inhibition of pro-inflammatory cytokine 
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secretion by suppressing NF-κB activity. Not only was this immune-modulatory function 
evident in the cytokine profile of the β-cells, but also the PBMCs showed loss of Siglec-
7 expression upon activation.  
As a therapeutic agent, Siglec-7 is a very lucrative target as it can rescue both the 
activated immune system as well as the inflamed islet. Restoration of Siglec-7 signaling 
both in islets and immune cells may halt the progression of the pro-inflammatory state in 
diabetes. Crosslinking the siglecs using synthetic ligands may be able to restore the 
inhibitory signals. The binding of synthetic sialic acid derivative with high affinity to 
Siglec-2 have been shown to modulate the inhibitory activity of its ITIM [67]. 
Development of similar high affinity ligands for Siglec-7 can be a strategy for treatment 
of diabetes (Figure 1).  
Taken together, Siglec-7 plays a substantial role in the maintenance of immune-
suppressive anti-inflammatory microenvironment, which is lost in diabetes, and may 
contribute to the manifestation and progression of this metabolic syndrome. Thus, 
preserving Siglec-7 expression and function on β-cells as well as immune cells may be 
a novel therapeutic strategy which could help target both, the sensitisation and pro-
inflammatory activation of the immune system as well as the islets, thereby being 
beneficial to effectively halt the progress of islet destruction in diabetes. 
  
Figure 1.Siglec-7 in diabetes: summary and outlook (adapted from [68]). (A) In healthy 
individuals, inhibitory signaling by Siglec-7 supports the survival of β-cells. (B) However, 
in diabetes, Siglec-7 expression is lost on β-cells as well on macrophages; inhibition of 
NFκB is lost, leading to macrophage activation, cytokine secretion and apoptosis of β-
cells. (C) Restoration of inhibitory signals may be brought about by ligands which would 
cluster Siglec-7, preventing immune cell activation and β-cell death. 
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Zooming out to view the bigger picture 
At first glance, this thesis might come across as a collage of three different 
investigations, without focus on any one particular aspect in islet research. Without 
refuting such claims, I would like to point out the fine points of similarities between the 
three projects, which clarified their purpose during my thesis.  
Diabetes manifests from multi-organ failure, at the crux of which lies the loss of β-cell 
function and survival. In spite of that, there is a lack of treatments targeted to maintain 
endogenous β-cell mass. Current therapies aim at reducing postprandial 
hyperglycemia. Pharmacological interventions currently in use are insulin 
secretagogues (sulfonylureas and meglitinides), which bind to β-cells to induce insulin 
secretion, insulin sensitizers (thiazolidinediones), which improve insulin response, 
Biguanides like metformin, which act primarily to reduce hepatic gluconeogenesis, and 
α-glucosidase and SGLT2 inhibitors, which reduce carbohydrate reabsorption from the 
intestine and kidney [69-72], but none of the current treatments provides a cure for 
diabetes, namely restoration of the β-cells, only a cure of the symptoms.  
β-cell death is a complex phenomenon, wherein multiple triggers act via simultaneous 
activation of several pathways. Therefore, it is essential to not only focus on specific 
stimuli and its consequences, but also the general tissue specific impact of a mixture of 
stimuli which mimic the scenario in vivo. 
This thesis brings forth two different molecules which may be pursued further as 
potential targets for restoring β-cell function and mass in T2D. Even though the modes 
of action of both TOSO and Siglec-7 are diverse, their β-cell protective function needs 
to be further investigated in order to understand the full extent of their role in these 
systems. Additionally, this thesis contributes to the mechanistic understanding of the 
DPP-4 inhibitor linagliptin. Taken together, my dissertation is a part of a body of 
research which aims to prevent and/or cure diabetes by directly solving the central 
failure in overt diabetes: loss of β-cell function and mass.  
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Kathrin Maedler†, Gitanjali Dharmadhikari, Desiree M Schumann &  
Joachim Størling
†University of Bremen, Centre for Biomolecular Interactions, Bremen, Germany
Since having been cloned in 1984, IL-1? has been the subject of over 22,000 
citations in Pubmed, among them over 800 reviews. This is because of its 
numerous effects. IL-1? is a regulator of the body’s inflammatory response 
and is produced after infection, injury, and antigenic challenge. It plays a 
role in various diseases, including autoimmune diseases such as rheumatoid 
arthritis, inflammatory bowel diseases and type 1 diabetes, as well as in 
diseases associated with metabolic syndrome such as atherosclerosis, chronic 
heart failure and type 2 diabetes. Macrophage are the primary source of 
IL-1, but epidermal, epithelial, lymphoid and vascular tissues also synthesize 
IL-1. IL-1? production and secretion have also been reported from pancre-
atic islets. Insulin-producing ?-cells within pancreatic islets are specifically 
prone to IL-?-induced destruction and loss of function. Macrophage-derived 
IL-1? production in insulin-sensitive organs, leads to progression of inflam-
mation and induction of insulin resistance in obesity. We summarize the 
mechanisms involved in inflammation and specifically the IL-1? signals that 
lead to the progression of insulin resistance and diabetes. We highlight 
recent clinical studies and experiments in animals and isolated islets using 
IL-1? as a potential target for the therapy of type 2 diabetes.
Keywords: diabetes, IL-1Ra, IL-1?, ?-cell
Expert Opin. Biol. Ther. (2009) 9(9):1177-1188
??? ????????????
During the 25 years after IL-1? was cloned in the lab of Charles Dinarello [1], 
production and secretion of IL-1? have been linked not only to various autoim-
mune and auto-inflammatory diseases, but also to metabolic dysregulation [2]. 
Meanwhile, 11 ligands and 10 receptors of the IL-1 family have been discovered. 
The pro-inflammatory and agonistic ligands are IL-1?, IL-1?, IL-18, family of 
interleukin 1 (FIL-1)?, IL-1H2, IL-1?, IL-33 and the anti-inflammatory ligands 
IL-1Ra, FIL1?, IL-1H4, IL-1Hy2 [2]. IL-1?, IL-1? and IL-1Ra bind to IL-1R1, 
IL-1? and the IL-1? precursor bind to IL-1R2, IL-33 binds to IL-1R4, IL-18 and 
IL-1H4 to IL-1R5, FIL-1?, IL-1H2, IL-1? to IL-1R6. IL-1R8, 9 and toll-interleukin 
1 receptor 8 (TIR8) remain orphan receptors and IL-1RAcP and IL-18? are co-
receptors [3]. In the pancreatic islet, IL-1R1 is present on the ?-cells [4] and not the 
?-cells [5] and thus the ?-cells are a target for IL-1?, IL-1? and IL-1Ra. This review 
summarizes signaling pathways of IL-1? which lead to impaired insulin secretion 
and insulin action. Clearly, other cytokines and chemokines are involved in the 
inflammatory responses; however, we focus here on the possibility of blocking only 
IL-1? as a target for improving glycemia in type 2 diabetes mellitus (T2DM).
??? ?????????????????????????????
Soon after the cloning of IL-1?, Mandrup-Poulsen and colleagues observed that 
IL-1? impairs ?-cell function [6,7]. In addition to impaired insulin secretion, 
1.  Introduction
2.  IL-1? signaling in the ?-cell
3.  IL-1? secretion
4.  Blocking IL-1? signals protects 
the ?-cell from IL-1?- and 
glucose-induced cell death
5.  IL-1? links obesity and diabetes
6.  IL-1? in adipocytes
7.  IL-1? in the liver
8.  IL-1? in the brain
9.  Lessons from the IL-1 mouse 
models
10.  Blocking IL-1? signals in vivo 
inhibits diabetes progression
11.  Expert opinion
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IL-1? was found to induce ?-cell death, which was potentiated 
by the cytokines IFN? and TNF? [8,9]. Blocking IL-1? with 
specific IL-1?-neutralizing antibodies conferred protection from 
the cytotoxic effects induced by activated-mononuclear-cell- 
conditioned medium [10], indicating that IL-1? plays an 
important role in the molecular mechanisms underlying 
autoimmune ?-cell destruction.
Since then, IL-1? signaling and the underlying mecha-
nisms of IL-1?-induced ?-cell destruction have been investi-
gated. Importantly, IL-1? induces its own expression and 
the expression of other cytokines, for example IL-2, -3, -6 
and interferons [11]. In turn, cells that produce IL-1? also 
respond to IL-1? [12]. IL-1? initiates signal transduction by 
binding to IL-1R1 on the ?-cell. This leads to docking of 
the interleukin 1 receptor accessory protein (IL-1RAcP) to 
the IL-1–IL-1R1 complex, which is followed by recruitment 
of the adaptor protein myeloid differentiation primary 
response gene 88 (MyD88). interleukin-1 receptor-associated 
kinase (IRAK)-4, Tollip and IRAK-1 are then recruited, allow-
ing IRAK-1 to activate TNF-receptor-associated factor 6 
(TRAF6), which in turn triggers activation of TGF-beta 
activated kinase 1 (TAK1). TAK1 is able to stimulate two 
main pathways; the inhibitor of NF-?B kinase (IKK)–NF-?B 
pathway, and the MAPK/stress-activated protein kinase (MAPK/
SAPK) pathway [13]. In addition to TAK1, MAPK/extracellular-signal 
regulated kinase(ERK) kinase kinase 1 (MEKK1) seems to partici-
pate in the activation of both NF?B and SAPK in ?-cells [14]. 
Phosphorylation of I-?B, a cytosolic inhibitor of NF-?B, by 
IKK leads to I-?B degradation and NF-?B translocation to 
the nucleus, thus regulating the transcription of many target 
genes, such as iNOS expression and production of NO, a 
toxic reactive radical. Consistently interfering with NF-?B 
activation decreases IL-1?-induced ?-cell death [15,16].
IL-1? can also activate protein kinase C?, which leads to 
?-cell apoptosis presumably through iNOS expression [17,18]. 
Notably, IL-1? induces Fas expression on ?-cells [19,20], 
increasing their sensitivity to FasL and accelerating apoptosis 
via cleavage of downstream caspases (Figure 1 and reviewed 
in [21]). A distal consequence of IL-1? signaling in ?-cells is 
the induction of endoplasmic reticulum (ER) stress. IL-1? 
depletes ER Ca2+, leading to ER stress and induction of sev-
eral ER stress markers including CCAAT/enhancer-binding 
protein homologous protein (CHOP). The induction of ER 
stress by IL-1? can be prevented by inhibition of iNOS, sug-
gesting that NO mediates ER stress [22]. This is consistent 
with the notion that a chemical NO donor causes ER Ca2+ 
depletion and ER stress [23]. What is currently unclear is the 
importance of ER stress in IL-1?-induced ?-cell impairment. 
Studies addressing the role of ER stress-induced CHOP so 
far indicates that ER stress and CHOP do not contribute to 
cytokine-induced ?-cell death [24]. Thus, while there is little 
doubt that ER stress is induced in ?-cells by IL-1?, it is 
uncertain whether ER stress contributes to apoptosis or 
whether it may simply be a secondary effect and thus only 
plays a minor role, if any, in IL-1?-mediated apoptosis.
The MAPK/SAPK pathways consist of ERK1/2, p38 and 
JNK1/2, all of which are activated by IL-1? in ?-cells [25,26]. 
Using both pharmacological and molecular inhibitor 
approaches, NF-?B, ERK1/2, p38 and JNK1/2 have been 
demonstrated to be involved in IL-1?-induced ?-cell 
apoptosis [25,27-30].
Another target of IL-1? signaling in ?-cells is the survival 
kinase pathway PI3K–Akt. IL-1? reduces both PI3K [31] and 
Akt [32] activation. Since Akt is a negative regulator of JNK/
SAPK in ?-cells [33], reduced Akt signaling may allow 
increased and sustained pro-apoptotic JNK activation.
In general, signal transduction initiated by a ligand bind-
ing to membrane receptors leads to activation or induction 
of a negative feedback mechanisms to ensure only transient 
signaling. This is also true for signal transduction evoked by 
pro-inflammatory cytokines such as IL-1?. IL-1? induces 
expression of suppressor of cytokine signaling (SOCS)-3 in 
?-cells [31,34]. SOCS-3 is a member of a family of proteins that 
function to terminate cytokine signaling thereby constituting a 
negative feedback loop [35]. Although IL-1? induces SOCS-3 
expression in ?-cells, this induction seems to be insufficient to 
completely terminate IL-1? signal transduction, since pro-
longed NF-?B and MAPK/SAPK signaling is observed in 
?-cells exposed to IL-1? [25,33,36]. Putatively, either the amount 
of SOCS-3 induced by IL-1? in ?-cells is too low to effec-
tively block signaling or the kinetics of SOCS-3 induction by 
IL-1? is abnormally slow in ?-cells. In any case, forced 
SOCS-3 overexpression effectively inhibits IL-1? signaling at 
the level of TRAF6, leading to dampening of both the NF-?B 
and MAPK/SAPK pathways thus protecting against apopto-
sis [13,37]. Interestingly, IL-1? induced endogenous SOCS-3 
targets insulin signaling in the ?-cell by associating with the 
insulin receptor (IR) thereby preventing activation of insulin 
receptor substrate (IRS) and PI3K [31]. By this mechanism, 
SOCS-3 induction is likely to contribute to IL-1?-induced 
desensitization of insulin signaling which is important for 
optimal ?-cell function. One may speculate whether IL-1?-induced 
SOCS-3 expression is preferentially directed towards IR signals 
while leaving the IL-1? signaling cascade unaffected. The 
IL-1? signaling pathways are summarized in Figure 1.
??? ???????????????
The primary sources of IL-1? are blood monocytes, tissue 
macrophages, and dendritic cells. B lymphocytes and NK 
cells also produce IL-1? [2]. The release of the leaderless 
cytokine, IL-1?, cannot be initiated through the Golgi appa-
ratus. IL-1? precursor accumulates in the cytosol, and is 
processed by caspase-1 (also named Interleukin converting 
enzyme (ICE)) into the mature secreted IL-1?. This is 
triggered by ATP activating the P2X7 receptor, which forms 
a pore in response to ligand stimulation and regulates cell 
permeability and cytokine release [38].
Resident islet macrophages are fundamental in the 
development of autoimmune diabetes [39,40] and it has 
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been postulated that IL-1? secreted from such intra-islet 
macrophages results in ?-cell destruction [39]. More recent 
studies show that the ?-cells themselves are able to secrete 
IL-1? which is induced by double stranded RNA, a mecha-
nism by which viral infection may mediate ?-cell damage [41] 
or by elevated glucose concentrations [42,43]. Upregulation of 
the Fas receptor plays a central role in the mediation of 
?-cell death [44,45]. IL-1? rapidly induces Fas upregulation, 
whereas glucose only induces Fas in chronic conditions [46].
In two animal models, Psammomys obesus and Goto-Kakizaki 
(GK) rat, it has been observed that pancreatic ?-cells express 
IL-1? under hyperglycemic conditions [42,47]. In Psammomys 
obesus, normalizing hyperglycemia with phlorizin, an inhibitor 
of the renal tubular glucose re-uptake, inhibited intra-islet 
IL-1? expression [42]. In contrast, Jorns et al. found no IL-1? 
expression within the islets [48]. IL-1? production by islet cells 
was confirmed in several studies [49,43]. While glucose-induced 
IL-1? mRNA production was not found in human islets that 
had been preincubated in suspension for 3 – 5 days, 
Boni-Schnetzler et al. showed that glucose response in islets is 
negatively correlated with basal IL-1? expression levels [43]. 
These studies show that IL-? may mediate ?-cell destruction 
also in T2DM (reviewed in [44]). It is tempting to suggest 
IL-1? as a target for the treatment of diabetes. However, 
whether changes in circulating cytokines are physiologically 
relevant in the face of locally produced inflammatory mediators 
remains unknown.
??? ???????????????????????????????????????????
??????????????????????????????????????????
As described above, IL-1? has been shown to impair insulin 
release, to induce Fas expression thus enabling Fas-triggered 
apoptosis in rodent and human islets [15,50-59], and to share 
similarities with glucose-induced apoptosis. In parallel with the 
essential role of glucose in mediating insulin secretion and 
proliferation, a low concentration of IL-1? also stimulates 
insulin release and proliferation in rat and human islets [60-64]. 
The beneficial IL-1? effects seem to be partly mediated by the 
increased secretion of the naturally occurring anti-inflammatory 
cytokine and antagonist of IL-1? and IL-1?, the interleukin-1-
receptor antagonist. IL-1Ra was discovered in 1987 [65-77]. Four 
forms of IL-1Ra have been described, three of them are intrac-
ellular proteins (icIL-1Ra I, II and III) and one is secreted 
(sIL-1Ra) [68]. Similar to IL-1?, IL-1Ra binds to type 1 and 2 
IL-1 receptors but lacks a second binding domain. Therefore, 
IL-1Ra does not recruit the IL-1 receptor accessory protein, the 
second component of the receptor complex.
Endogenous production and secretion of IL-1Ra limits 
inflammation and tissue damage [2]. In vivo, exogenous 
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IL-1Ra counteracts low dose streptozotocin-induced diabe-
tes [69], autoimmune diabetes [70] and promotes graft 
survival [71-83] and islet survival after transplantation [74].
We have recently shown that IL-1Ra is secreted from the 
?-cell and expressed in ?-cell granules [75]. IL-1Ra protects 
cultured human islets from the deleterious effects of glu-
cose [42] as well as IL-1? [57,71,72,76,77]. Inhibition of IL-1Ra 
with small interfering RNAs or long term treatment with 
leptin lead to ?-cell apoptosis and impaired function, which 
may provide a further link between obesity and diabetes.
The definite secretion and regulation mechanisms of 
IL-1Ra are unknown. Like IL-1?, IL-1Ra may also be 
secreted by a leaderless pathway via activation of the P2X7 
receptor [78,79]. In pancreatic islets from obese individuals 
P2X7 receptors are highly expressed and these receptors were 
almost undetectable in T2DM [79]. In accordance with the 
P2X7 receptor expression levels, increased IL-1Ra serum 
levels correlate with obesity and insulin resistance [80-83], but 
IL-1Ra is decreased in T2DM [84]. Recent results from the 
Whitehall Study show that IL-1Ra levels are increased before 
the onset of T2DM [85], which are consistent with findings 
in mice fed with a high fat/high sucrose diet (HFD). IL-1Ra 
levels were increased after 4 and 8 weeks of diet together 
with an increase in ?-cell mass and body weight. Serum 
concentrations of IL-1Ra are influenced by adipose tissue, 
which is a major source of IL-1Ra [86]. After 16 weeks, 
when the HFD-fed mice displayed glucose intolerance and 
?-cell apoptosis, IL-1Ra levels were lower than in the 
normal-diet-fed mice. Mice deficient for the P2X7-receptor, 
were unable to increase ?-cell mass in compensation in 
response to the HFD feeding and had no adaptive increase 
in IL-1Ra levels [79].
The increased IL-1Ra could be an attempt by the body to 
counteract the deleterious effects of IL-1? and to preserve 
?-cell survival, insulin secretion and insulin sensitivity. It has 
been suggested that IL-1Ra has an additional metabolic 
effect, which leads to insulin resistance. However, when we 
treated mice daily for 12 weeks with IL-1Ra we did not 
observe changes in insulin sensitivity at any time point [87].
Whether serum IL-1Ra levels would explain the progression 
of diabetes in obese individuals and whether serum IL-1Ra 
affects IL-1Ra expression in the ?-cell is not known. We sug-
gest that a decreased ?-cell IL-1Ra expression could trigger the 
progression from obesity to diabetes and high IL-1Ra expression 
could protect the ?-cell and enable it to adapt to conditions of 
higher insulin demand, this is illustrated in Figure 2.
??? ????????????????????????????????
Chronic sub-clinical inflammation is present in obesity, insu-
lin resistance and T2DM. The diseases related to metabolic 
syndrome are characterized by abnormal cytokine produc-
tion, including elevated circulating IL-1?, increased acute-
phase proteins, e.g., CRP [88] and activation of inflammatory 
signaling pathways [89].
Proinflammatory cytokines can cause insulin resistance in 
adipose tissue, skeletal muscle and liver by inhibiting insulin 
signal transduction. The sources of cytokines in insulin-resistant 
states are the insulin target tissues themselves, primarily fat 
and liver, but to a larger extent the activated tissue-resident 
macrophages [90].
While macrophage infiltration in adipose and brain tissue 
has been shown in many studies [85], increased islet mac-
rophage infiltration has only recently been observed in pan-
creatic sections from patients with T2DM [86], and in 
T2DM animal models, such as the GK rat [91], the HFD 
and db/db mouse [86], and the hyperglycemic Cohen dia-
betic rat [92]. While IL-1? signals induce destruction and 
impaired insulin secretion in the ?-cells, insulin signaling is 
disturbed in the insulin target tissues (Figure 3).
Insulin receptor signaling is complex. To summarize 
shortly, signaling downstream of the insulin receptor involves 
phosphorylation of IRS1/2 and the activation of the PI3K–
AKT pathway (responsible for insulin action on glucose 
uptake) and the Ras–MAPK pathway (responsible for sup-
pression of gluconeogenesis, reviewed in [93]). Due to inflam-
mation, IRS1 can be alternatively phosphorylated on serine 
307, which leads to downstream activation of the NF-?B 
pathway, phosphorylation of Jnk1, activation of the JNK/
activator protein 1 (AP-1) pathway and thus disturbed insu-
lin signaling. Furthermore, IL-1? induces SOCS signaling 
which leads to degradation of IRS proteins [94].
??? ???????????????????
Infiltration of macrophages in adipose tissue is tightly corre-
lated with obesity in mice and humans [95,96]. Important 
modulators of inflammation are the adipocytokines, such as 
leptin, resistin and adiponectin which play a central role in 
the regulation of insulin resistance and ?-cell function [97,98].
In obesity, not only circulating free fatty acids (FFA), and 
lipids, but also leptin and resistin are increased, whereas adi-
ponectin, which is known to prevent inflammation [98] and 
which is negatively correlated with insulin resistance, is 
decreased [99]. Leptin has been shown to exert pro- as well as 
anti-inflammatory properties, probably dependent on its dose 
and exposure time. While in vivo, leptin overexpression nor-
malizes glycemia in the diabetic NOD mice as well as in 
streptozotocin- and alloxan-induced diabetes [100], chronic lep-
tin incubation in vitro leads to impaired ?-cell function and 
survival [75,101,102]. Leptin has been shown to manipulate levels 
of IL-1? and IL-1Ra. While acutely, leptin induces IL-1Ra 
expression in islets and monocytes [75,103], there is a chronic 
reduction of IL-1Ra and induction of IL-1? secretion.
IL-1Ra expression is increased in white adipose tissue 
in obese individuals with increased circulating FFA and 
lipids [104]. In contrast, daily IL-1Ra injections in HFD-fed 
mice normalizes circulating FFA, lipids as well as adipok-
ines. Although the percentage of macrophages in a given 
adipose tissue depot is positively correlated with adiposity 
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and adipocyte size [95], the normalization of lipids and 
adipokines by IL-1Ra seems to be independent of fat mass, 
since IL-1Ra treatment neither influences fat mass nor adi-
pocyte size. In contrast, mRNA levels of the inflammatory 
cytokines IL-1? and TNF-?, the macrophage marker F4/80 
and the pro-inflammatory macrophage marker CD11c are 
increased by the HFD in wild-type mice but reduced by 
IL-1Ra overexpression [87]. Interestingly, specifically the 
marker of the ‘classically activated’ macrophages M1 [105] is 
highly induced by the HFD and normalized by IL-1Ra. 
Thus, the HFD-induced pro-inflammatory state of adipocytes 
may be the reason for the increased adipokines (resistin and 
leptin) and lipid production.
Undoubtedly, the effect of IL-1Ra on adipocyte-derived 
factors plays a protective role at the level of the ?-cell.
??? ??????????????????
The bone marrow–derived macrophage cells in the liver are 
the Kupffer cells. Kupffer cells secrete cytokines, among 
them IL-1?, NO and free radicals, which could, by them-
selves, induce ?-cell failure [106]. This is specifically deleteri-
ous in the environment of transplanted islets in the liver. 
Cytokines (IL-1?, IFN-? and TNF-?) are particularly ele-
vated after islet transplantation [107], and liver tissue mac-
rophages participate in cell injury and graft failure [108,109]. 
Strategies to inhibit IL-1?-induced ?-cell failure, for exam-
ple by salicylate treatment of the islets [110,111] may therefore 
improve graft survival.
Similar to the role of macrophages in obese adipose tis-
sue, secretion of IL-1? by the Kupffer cells could be central 
to hepatic insulin resistance in obesity. Cytokine-induced 
JNK phosphorylation and activation of the NF-?B pathway 
are indicative of insulin resistance in the liver, for example 
depletion of JNK in myeloid cells (including Kupffer cells) 
in mice leads to HFD-induced hepatic steatosis without an 
increase in inflammatory markers in the liver and no devel-
opment of insulin resistance [112]. Furthermore, hepatocyte 
specific inhibition of NF-?B [113] or of IKK? [114] in myel-
oid cells improves hepatic insulin sensitivity. These studies 
show that independent of obesity, the inflammatory status 
in the liver primarily regulates insulin sensitivity.
??? ??????????????????
In the healthy brain, members of the IL-1 family are 
expressed at low or undetectable levels [115]. During 
neuro-inflammation, IL-1? is dramatically upregulated by 
various local and systemic brain insults including ischaemia, 
trauma, hypoxia and neurotoxic inflammatory stimuli [116].
IL-1? in the brain is produced primarily by microglia, 
which also express caspase 1 [116]. To a lesser extent, astro-
cytes, oligodendroglia, neurons, cerebrovascular cells and cir-
culating immune cells after infiltrating the brain under 
inflammatory conditions, produce IL-1? [117].
IL-1? has a number of diverse actions in the CNS to modify 
feeding behavior, fever [118], central pain modulation [119], stress 
responses [120] memory [121] and neuroendocrine responses, 
mainly through actions in the hypothalamus [122].
There is evidence of a hypothalamic control of insulin sensi-
tivity which is disturbed when elevated levels of pro-inflammatory 
cytokines are circulating. Studies in mice show that HFD pro-
motes hypothalamic resistance to the main anorexigenic hor-
mones, leptin and insulin, leading to the progressive loss of the 
balance between food intake and thermogenesis and, therefore, 
resulting in body mass gain [123-125].
Also, the structural and metabolic damage found in 
Alzheimer`s disease, is in part due to sustained elevation of 
IL-1? [126-128]. It upregulates expression of ?-amyloid precur-
sor protein (?-APP) and stimulates the processing of ?-APP 
resulting in amyloidogenic fragments in neurons [129]. Simi-
larly, the ?-APP deposits found in the Alzheimer brain share 
the same molecular structure as the amylin oligomer deposits 
found in the pancreatic ?-cells in T2DM and are equally 
neurotoxic [130]. Based on observations in the human islet 
amyloid polypeptide transgenic rat [131], we have observed 
IL-1? expression within the islets after the induction of 
severe hyperglycemia (unpublished observation), indicating 
that IL-1? expression can only be observed at high glucose 
levels. It remains to be elucidated if the toxicity of amylin 
oligomers on the ?-cell involves IL-1? signals.
Possibly, the activation of cytokine-induced pro-inflammatory 
pathways (e.g., JNK) plays a major role in the modulation of 
neurodegeneration [132]. In line with this hypothesis, JNKs are 
negatively regulating insulin sensitivity in the obese state.
Four different pathways are shown in the brain as a conse-
quence of diet-induced activation of inflammatory signaling; 
i) induction of suppressor of cytokine signaling-3 (SOCS3) 
expression [133]; ii) activation of JNK and IKK [123]; iii) induc-
tion of protein tyrosine phosphatase 1B (PTP1B) [134]; and 
iv) activation of TLR4 signaling [124]. Thus, obesity and HFD 
induce activation of pro-inflammatory pathways in the brain 
which may directly develop insulin resistance and lead to 
diminished glucose regulation by the insulin target tissues.
??? ?????????????????????? ????? ?????
Having shown the deleterious effects of IL-1? on the ?-cell, 
one would suppose that the IL-1? knockout mouse would 
be the ideal model for improved ?-cell survival and function. 
Conversely, IL-1?-KO mice show impaired glucose tolerance, 
decreased ?-cell mass and decreased expression of ?-cell tran-
scription factors (e.g., PDX-1, Pax-4) [61], indicating that 
IL-1? has a dual role in the ?-cell and activated pathways for 
example Fas-linked interleukin 1-B converting enzyme-like 
protease inhibitor protein (FLIP), Fas and NF-?B might be 
needed for insulin secretion and survival [61,136,137]. In line 
with these data, Caspase 8-knockout [136] and Fas-deficient 
mice [137] show impaired glucose tolerance. Especially the 
dual role of NF-?B, which was long known to be responsible 
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for IL-1?-induced ?-cell destruction [138] is shown through 
NF-?B-induced activation of the antiapoptotic gene A20, 
which protects against cell death [139], promotion of insulin 
secretion [140] and ?-cell specific NF-?B depletion accelerates 
diabetes in the NOD mouse [16]. In contrast and despite 
their basally impaired glucose tolerance, IL-1?-KO mice are 
protected against the diabetogenic effects of the HFD as well 
as against glucotoxicity [61], which supports the concept that 
IL-? mediates nutrient-induced ?-cell dysfunction during the 
development of T2DM.
In NOD mice, IL-1R deficiency slows but does not pre-
vent diabetes progression [141], and caspase 1 (interleukin 
converting enzyme) deficiency has no effect on diabetes pro-
gression [142], although both IL-1R subtype 1 and caspase 1 
are highly expressed in islets from wild type NOD mice [143]. 
It is possible that pathways other than IL-1? signals are 
involved in diabetes in NOD mice since it has been shown 
that IL-10 promotes diabetes in NOD mice independent of 
Fas, perforin, TNFR 1 and TNFR 2 [144].
???? ???????????????????????in vivo??????????
????????????????????
Recently, the hypothesis that blocking IL-1? would be a 
successful strategy for the therapy of T2DM has been proven 
by several studies. Daily injection of IL-1Ra in mice fed a 
HFD improved glycemia, glucose stimulated insulin secre-
tion and survival [87], reduced hyperglycaemia and reversed 
the islet inflammatory phenotype in the GK rat [145]. 
Treatment with an IL-1? antibody also improved glycemic 
control in diet-induced obesity in mice [146,147].
Importantly, results from a recent clinical study in patients 
with T2DM showed that IL-1Ra improved glycemic control 
and ?-cell function [148]. After 13 weeks of treatment, C-peptide 
secretion was increased and inflammatory markers, for example 
IL-6 and C-reactive protein were reduced in the IL-1Ra 
group. HbA1c was significantly lower in the IL-1Ra group 
compared with the placebo group, which correlated with the 
body-surface area in the IL-1Ra group. The dose of 100 mg 
IL-1Ra was given daily to the patients without weight adjust-
ment. Currently ongoing trials, which include dose adjust-
ment to body weight, may result in better glycemic control 
in the higher body surface area group. The effect of IL-1 
antagonism on ?-cell function is currently being tested in 
patients with recent onset of T1DM [149]. Both, IL-1Ra as 
well as anti-IL-1? antibody Xoma 052 do not completely 
block IL-1? signaling. While IL-1Ra is a competitive antago-
nist to IL-1?, XOMA 052 has a novel mechanism of action 
that reduces IL-1? activity by 40 – 50-fold rather than com-
pletely blocking it [146,150]. Given the dual effect of IL-1? on 
?-cell survival and insulin secretion, this may be an impor-
tant characteristic of both drugs.
As shown by these recent studies, blocking IL-1? signaling 
may be a powerful new treatment for T2DM which does 
not rely on replacing insulin exogenously but acts at the 
level of the ?-cell to improve ?-cell survival and to improve 
endogenous insulin secretion and action. Moreover, blocking 
IL-1? may also improve insulin sensitivity. Further studies 
will be necessary to clarify the contradiction of IL-1Ra`s 
modulation of insulin sensitivity and the impact of IL-? on 
?-cell survival in T2DM.
???? ??????????????
To maintain ?-cell mass and function to achieve normo-
glycemia is the major aim for diabetes therapy. Such strategy 
involves ?-cell replacement through islet or pancreas 
transplantation or triggering their regeneration, a develop-
ment which is still far away from a general application for 
diabetes therapy.
In any case, the remaining ?-cell mass as well as any 
newly transplanted or formed ?-cells need to be protected 
from further destruction. Secreted IL-1? into the proximity 
of the ?-cell induces their destruction and impairs insulin 
secretion. Several recent studies show that intra-islet 
inflammation contributes to the decreased ?-cell mass in 
T2DM. Blocking such deleterious signals through binding 
and inactivation of IL-1? may therefore be a successful way 
towards long-term survival of insulin-producing ?-cells.
???????????????????????
This work was supported by the German Research 
Foundation (DFG, Emmy Noether Programm, MA4172/1-1), 
the Juvenile Diabetes Research Foundation (JDRF 26-2008-
861) and the European Foundation for the Study of Diabetes 
(EFSD)/Merck Sharp & Dohme (MSD) European Studies 
on Beta Cell Function and Survival. The authors thank the 
members of the Islet Biology laboratory in Bremen for 
critical discussion.
Ex
pe
rt 
O
pi
n.
 B
io
l. 
Th
er
. D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Su
U
B
 B
re
m
en
 o
n 
07
/1
8/
13
Fo
r p
er
so
na
l u
se
 o
nl
y.
???????????????????????????????????????????????????????
????? ????????????????????????????????????
Bibliography
1. Auron PE, Webb AC, Rosenwasser LJ, 
et al. Nucleotide sequence of human 
monocyte interleukin 1 precursor cDNA. 
Proc Natl Acad Sci USA 1984;81:7907-11
2. Dinarello CA. Immunological and 
inflammatory functions of the interleukin-1 
family. Annu Rev Immunol 
2009;27:519-50
3. Boraschi D, Tagliabue A. The interleukin-1 
receptor family. Vitam Horm 
2006;74:229-54
4. Deyerle KL, Sims JE, Dower SK,  
Bothwell MA. Pattern of IL-1 receptor  
gene expression suggests role in 
noninflammatory processes. J Immunol 
1992;149:1657-65
5. Scarim AL, Arnush M, Hill JR, et al. 
Evidence for the presence of type I IL-1 
receptors on ?-cells of islets of Langerhans. 
Biochim Biophys Acta 
1997;1361(3):313-20
6. Mandrup-Poulsen T, Bendtzen K,  
Nielsen JH, et al. Cytokines cause 
functional and structural damage to 
isolated islets of Langerhans. Allergy 
1985;40:424-9
7. Mandrup-Poulsen T, Bendtzen K, Nerup J, 
et al. Affinity-purified human interleukin I 
is cytotoxic to isolated islets of Langerhans. 
Diabetologia 1986;29:63-7
8. Eizirik DL. Interleukin-1 induced 
impairment in pancreatic islet  
oxidative metabolism of glucose is 
potentiated by tumor necrosis factor.  
Acta Endocrinol (Copenh) 1988;119:321-5
9. Pukel C, Baquerizo H, Rabinovitch A. 
Destruction of rat islet cell monolayers by 
cytokines. Synergistic interactions of 
interferon-gamma, tumor necrosis factor, 
lymphotoxin, and interleukin 1. Diabetes 
1988;37:133-6
10. Bendtzen K, Mandrup-Poulsen T, Nerup J, 
et al. Cytotoxicity of human pI 7 
interleukin-1 for pancreatic islets of 
Langerhans. Science 1986;232:1545-7
11. Dinarello CA. Biology of interleukin 1. 
Faseb J 1988;2:108-15
12. Warner SJ, Auger KR, Libby P. Human 
interleukin 1 induces interleukin 1 gene 
expression in human vascular smooth 
muscle cells. J Exp Med 1987;165:1316-31
13. Frobose H, Ronn SG, Heding PE, et al. 
Suppressor of cytokine signaling-3 inhibits 
interleukin-1 signaling by targeting the 
TRAF-6/TAK1 complex. Mol Endocrinol 
2006;20:1587-96
14. Mokhtari D, Myers JW, Welsh N. The 
MAPK kinase kinase-1 is essential for 
stress-induced pancreatic islet cell death. 
Endocrinology 2008;149:3046-53
15. Giannoukakis N, Mi Z, Rudert WA, et al. 
Prevention of beta cell dysfunction and 
apoptosis activation in human islets by 
adenoviral gene transfer of the insulin-like 
growth factor I. Gene Ther 
2000;7:2015-22
16. Kim S, Millet I, Kim HS, et al. NF-?B 
prevents ? cell death and  
autoimmune diabetes in NOD mice.  
Proc Natl Acad Sci USA 2007;104:1913-8
17. Carpenter L, Cordery D, Biden TJ. Protein 
kinase C? activation by interleukin-1? 
stabilizes inducible nitric-oxide synthase 
mRNA in pancreatic ?-cells. J Biol Chem 
2001;276:5368-74
18. Carpenter L, Cordery D, Biden TJ. 
Inhibition of protein kinase C ? protects 
rat INS-1 cells against interleukin-1? and 
streptozotocin-induced apoptosis. Diabetes 
2002;51:317-24
19. Augstein P, Dunger A, Heinke P, et al. 
Prevention of autoimmune diabetes  
in NOD mice by troglitazone is  
associated with modulation of ICAM-1 
expression on pancreatic islet cells and 
IFN-? expression in splenic T cells. 
Biochem Biophys Res Commun 
2003;304:378-84
20. Stassi G, Todaro M, Richiusa P, et al. 
Expression of apoptosis-inducing CD95 
(Fas/Apo-1) on human beta-cells sorted by 
flow-cytometry and cultured in vitro. 
Transplant Proc 1995;27:3271-5
21. Donath MY, Storling J, Maedler K, 
Mandrup-Poulsen T. Inflammatory 
mediators and islet ?-cell failure: a link 
between type 1 and type 2 diabetes.  
J Mol Med 2003;81:455-70
22. Cardozo AK, Ortis F, Storling J, et al. 
Cytokines downregulate the 
sarcoendoplasmic reticulum pump  
Ca2+ ATPase 2b and deplete endoplasmic 
reticulum Ca2+, leading to induction of 
endoplasmic reticulum stress in pancreatic 
?-cells. Diabetes 2005;54:452-61
23. Oyadomari S, Araki E, Mori M. 
Endoplasmic reticulum stress-mediated 
apoptosis in pancreatic ?-cells. Apoptosis 
2002;7:335-45
24. Akerfeldt MC, Howes J, Chan JY, et al. 
Cytokine-induced ?-cell death is 
independent of endoplasmic reticulum 
stress signaling. Diabetes 2008;57:3034-44
25. Larsen CM, Wadt KA, Juhl LF, et al. 
Interleukin-1?-induced rat pancreatic islet 
nitric oxide synthesis requires both the p38 
and extracellular signal-regulated kinase 1/2 
mitogen-activated protein kinases.  
J Biol Chem 1998;273:15294-300
26. Welsh N. Interleukin-1?-induced ceramide 
and diacylglycerol generation may lead to 
activation of the c-Jun NH2-terminal 
kinase and the transcription factor ATF2 in 
the insulin-producing cell line RINm5F.  
J Biol Chem 1996;271:8307-12
27. Abdelli S, Abderrahmani A, Hering BJ, 
et al. The c-Jun N-terminal kinase JNK 
participates in cytokine- and isolation 
stress-induced rat pancreatic islet apoptosis. 
Diabetologia 2007;50:1660-9
28. Bonny C, Oberson A, Negri S, et al. 
Cell-permeable peptide inhibitors of JNK: 
novel blockers of ?-cell death. Diabetes 
2001;50:77-82
29. Pavlovic D, Andersen NA,  
Mandrup-Poulsen T, Eizirik DL. Activation 
of extracellular signal-regulated kinase 
(ERK)1/2 contributes to cytokine-induced 
apoptosis in purified rat pancreatic ?-cells. 
Eur Cytokine Netw 2000;11:267-74
30. Saldeen J, Lee JC, Welsh N. Role of p38 
mitogen-activated protein kinase  
(p38 MAPK) in cytokine-induced rat islet 
cell apoptosis. Biochem Pharmacol 
2001;61:1561-9
31. Emanuelli B, Glondu M, Filloux C, et al. 
The potential role of SOCS-3 in the 
interleukin-1?-induced desensitization of 
insulin signaling in pancreatic beta-cells. 
Diabetes 2004;53:S97-103
32. Storling J, Binzer J, Andersson AK, et al. 
Nitric oxide contributes to  
cytokine-induced apoptosis in pancreatic 
beta cells via potentiation of JNK activity 
and inhibition of Akt. Diabetologia 
2005;48:2039-50
33. Aikin R, Maysinger D, Rosenberg L. 
Cross-talk between phosphatidylinositol 
3-kinase/AKT and c-jun NH2-terminal 
kinase mediates survival of isolated human 
islets. Endocrinology 2004;145:4522-31
34. Karlsen AE, Ronn SG, Lindberg K, et al. 
Suppressor of cytokine signaling 3 
(SOCS-3) protects ?-cells against 
interleukin-1?- and interferon-?-mediated 
toxicity. Proc Natl Acad Sci USA 
2001;98:12191-6
Ex
pe
rt 
O
pi
n.
 B
io
l. 
Th
er
. D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Su
U
B
 B
re
m
en
 o
n 
07
/1
8/
13
Fo
r p
er
so
na
l u
se
 o
nl
y.
???????????????????????????????????????????
? ????????????????????????????????????? ????
35. Ronn SG, Billestrup N, Mandrup-Poulsen T. 
Diabetes and suppressors of cytokine 
signaling proteins. Diabetes 2007;56:541-8
36. Ortis F, Cardozo AK, Crispim D, et al. 
Cytokine-induced proapoptotic gene 
expression in insulin-producing cells is 
related to rapid, sustained, and 
nonoscillatory nuclear factor-?B activation. 
Mol Endocrinol 2006;20:1867-79
37. Ronn SG, Borjesson A, Bruun C, et al. 
Suppressor of cytokine signalling-3 
expression inhibits cytokine-mediated 
destruction of primary mouse and rat 
pancreatic islets and delays allograft 
rejection. Diabetologia 2008;51:1873-82
38. Narcisse L, Scemes E, Zhao Y, et al. The 
cytokine IL-1? transiently enhances P2X7 
receptor expression and function in human 
astrocytes. Glia 2005;49:245-58
39. Arnush M, Heitmeier MR, Scarim AL, 
et al. IL-1 produced and released 
endogenously within human islets inhibits 
beta cell function. J Clin Invest 
1998;102(3):516-26
40. Lacy PE. The intraislet macrophage and 
type I diabetes. Mt Sinai J Med 
1994;61:170-4
41. Heitmeier MR, Arnush M, Scarim AL, 
Corbett JA. Pancreatic ?-cell damage 
mediated by ?-cell production of IL-1: A 
novel mechanism for virus-induced 
diabetes. J Biol Chem 2001;276:11151-8
42. Maedler K, Sergeev P, Ris F, et al. 
Glucose-induced ?-cell production of 
interleukin-1? contributes to glucotoxicity 
in human pancreatic islets.  J Clin Invest 
2002;110:851-60
43. Boni-Schnetzler M, Thorne J, Parnaud G, 
et al. Increased interleukin (IL)-1? 
messenger ribonucleic acid expression in 
beta -cells of individuals with type 2 
diabetes and regulation of IL-1? in human 
islets by glucose and autostimulation.  
J Clin Endocrinol Metab 2008;93:4065-74
44. Donath MY, Ehses JA, Maedler K, et al. 
Mechanisms of ?-Cell death in  
type 2 diabetes. Diabetes  
2005;54(Suppl 2):S108-13
45. Cnop M, Welsh N, Jonas JC, et al. 
Mechanisms of pancreatic ?-cell death in 
type 1 and type 2 diabetes: many 
differences, few similarities. Diabetes 
2005;54(Suppl 2):S97-107
46. Elouil H, Cardozo AK, Eizirik DL, et al. 
High glucose and hydrogen peroxide 
increase c-Myc and haeme-oxygenase 1 
mRNA levels in rat pancreatic islets 
without activating NF?B. Diabetologia 
2005;48:496-505
47. Mine T, Miura K, Okutsu T, et al. Gene 
expression profile in the pancreatic islets of 
Goto-Kakizaki (GK) rats with repeated 
postprandial hyperglycemia. Diabetes 
2004;53(Suppl 2):2475A
48. Jorns A, Rath KJ, Bock O, Lenzen S. Beta 
cell death in hyperglycaemic Psammomys 
obesus is not cytokine-mediated. 
Diabetologia 2006;49:2704-12
49. Welsh N, Cnop M, Kharroubi I, et al. Is 
there a role for locally produced 
interleukin-1 in the deleterious effects  
of high glucose or the type 2 diabetes 
milieu to human pancreatic islets?  
Diabetes 2005;54:3238-44
50. Maedler K, Spinas GA, Lehmann R, et al. 
Glucose induces ?-cell apoptosis via 
upregulation of the Fas-receptor in human 
islets. Diabetes 2001;50:1683-90
51. Corbett JA, Sweetland MA, Wang JL, et al. 
Nitric oxide mediates cytokine-induced 
inhibition of insulin secretion by  
human islets of Langerhans.  
Proc Natl Acad Sci USA 1993;90:1731-5
52. Giannoukakis N, Rudert WA,  
Ghivizzani SC, et al. Adenoviral gene 
transfer of the interleukin-1 receptor 
antagonist protein to human islets prevents 
IL-1?-induced ?-cell impairment and 
activation of islet cell apoptosis in vitro. 
Diabetes 1999;48:1730-6
53. Loweth AC, Watts K, McBain SC, et al. 
Dissociation between Fas expression and 
induction of apoptosis in human islets of 
Langerhans. Diabetes Obes Metab 
2000;2:57-60
54. Loweth AC, Williams GT, James RF, et al. 
Human islets of Langerhans express Fas 
ligand and undergo apoptosis in response 
to interleukin-1? and Fas ligation.  
Diabetes 1998;47:727-32
55. Mandrup-Poulsen T, Bendtzen K, Nerup J, 
et al. Affinity-purified human interleukin I 
is cytotoxic to isolated islets of Langerhans. 
Diabetologia 1986;29:63-7
56. Mandrup-Poulsen T, Bendtzen K, et al. 
Cytokines cause functional and structural 
damage to isolated islets of Langerhans. 
Allergy 1985;40:424-9
57. Mandrup-Poulsen T, Zumsteg U, Reimers J, 
et al. Involvement of interleukin 1 and 
interleukin 1 antagonist in pancreatic ?-cell 
destruction in insulin-dependent diabetes 
mellitus. Cytokine 1993;5:185-91
58. Rabinovitch A, Sumoski W, Rajotte RV, 
Warnock GL. Cytotoxic effects of  
cytokines on human pancreatic islet  
cells in monolayer culture.  
J Clin Endocrinol Metab 1990;71:152-6
59. Stassi G, De Maria R, Trucco G, et al. 
Nitric oxide primes pancreatic ? cells  
for Fas-mediated destruction in  
insulin-dependent diabetes mellitus.  
J Exp Med 1997;186:1193-200
60. Schumann DM, Maedler K, Franklin I, 
et al. The Fas pathway is involved in ?-cell 
secretory function. Proc Natl Acad Sci USA 
2007;104:2861-6
61. Maedler K, Schumann DM, Sauter N, 
et al. Low concentration of interleukin-1? 
Induces FLICE-inhibitory  
protein-mediated ?-cell proliferation in 
human pancreatic islets. Diabetes 
2006;55:2713-22
62. Spinas GA, Hansen BS, Linde S, et al. 
Interleukin 1 dose-dependently affects the 
biosynthesis of (pro)insulin in isolated rat 
islets of Langerhans. Diabetologia 
1987;30:474-80
63. Spinas GA, Mandrup-Poulsen T, Molvig J, 
et al. Low concentrations of interleukin-1 
stimulate and high concentrations inhibit 
insulin release from isolated rat islets of 
Langerhans. Acta Endocrinol (Copenh) 
1986;113:551-8
64. Spinas GA, Palmer JP, Mandrup-Poulsen T, 
et al. The bimodal effect of interleukin 1 on 
rat pancreatic beta-cells – stimulation 
followed by inhibition – depends upon dose, 
duration of exposure, and ambient glucose 
concentration. Acta Endocrinol (Copenh) 
1988;119:307-11
65. Dinarello CA. The role of the  
interleukin-1-receptor antagonist in 
blocking inflammation mediated by 
interleukin-1. N Engl J Med 
2000;343:732-4
66. Seckinger P, Lowenthal JW, Williamson K, 
et al. A urine inhibitor of interleukin 1 
activity that blocks ligand binding.  
J Immunol 1987;139:1546-9
67. Seckinger P, Williamson K, Balavoine JF, 
et al. A urine inhibitor of interleukin 1 
activity affects both interleukin 1 alpha and 
1 beta but not tumor necrosis factor alpha. 
J Immunol 1987;139:1541-5
68. Arend WP, Guthridge CJ. Biological role of 
interleukin 1 receptor antagonist isoforms. 
Ann Rheum Dis 2000;59(Suppl 1):i60-4
69. Sandberg JO, Andersson A, Eizirik DL, 
Sandler S. Interleukin-1 receptor antagonist 
Ex
pe
rt 
O
pi
n.
 B
io
l. 
Th
er
. D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Su
U
B
 B
re
m
en
 o
n 
07
/1
8/
13
Fo
r p
er
so
na
l u
se
 o
nl
y.
???????????????????????????????????????????????????????
????? ????????????????????????????????????
prevents low dose streptozotocin  
induced diabetes in mice.  
Biochem Biophys Res Commun 
1994;202:543-8
70. Nicoletti F, Di Marco R, Barcellini W, et al. 
Protection from experimental autoimmune 
diabetes in the non-obese diabetic mouse 
with soluble interleukin-1 receptor.  
Eur J Immunol 1994;24:1843-7
71. Sandberg JO, Eizirik DL, Sandler S. IL-1 
receptor antagonist inhibits recurrence of 
disease after syngeneic pancreatic islet 
transplantation to spontaneously diabetic 
non-obese diabetic (NOD) mice.  
Clin Exp Immunol 1997;108:314-7
72. Stoffels K, Gysemans C, Waer M, et al. 
Interleukin-1 receptor antagonist inhibits 
primary non-function and prolongs graft 
survival time of xenogeneic islets 
transplanted in spontaneously diabetic 
autoimmune NOD mice. Diabetologia 
2002;45(Suppl 2):424
73. Tellez N, Montolio M, Estil-Les E, et al. 
Adenoviral overproduction of interleukin-1 
receptor antagonist increases beta cell 
replication and mass in syngeneically 
transplanted islets, and improves metabolic 
outcome. Diabetologia 2007;50:602-11
74. Satoh M, Yasunami Y, Matsuoka N, et al. 
Successful islet transplantation to two 
recipients from a single donor by targeting 
proinflammatory cytokines in mice. 
Transplantation 2007;83:1085-92
75. Maedler K, Sergeev P, Ehses JA, et al. 
Leptin modulates ? cell expression of IL-1 
receptor antagonist and release of IL-1? in 
human islets. Proc Natl Acad Sci USA 
2004;101:8138-43
76. Sandberg JO, Eizirik DL, Sandler S, et al. 
Treatment with an interleukin-1 receptor 
antagonist protein prolongs mouse 
islet allograft survival. Diabetes 
1993;42:1845-51
77. Tellez N, Montolio M, Biarnes M, et al. 
Adenoviral overexpression of interleukin-1 
receptor antagonist protein increases 
beta-cell replication in rat pancreatic islets. 
Gene Ther 2005;12:120-8
78. Wilson HL, Francis SE, Dower SK, 
Crossman DC. Secretion of intracellular 
IL-1 receptor antagonist (type 1) is 
dependent on P2X7 receptor activation.  
J Immunol 2004;173:1202-8
79. Glas  R, Sauter NS, Schulthess FT, et al. 
Purinergic P2X7 receptors regulate 
secretion of interleukin-1 receptor 
antagonist and beta cell function and 
survival. Diabetologia 2009. (In Press)
80. Abbatecola AM, Ferrucci L, Grella R, et al. 
Diverse effect of inflammatory markers on 
insulin resistance and insulin-resistance 
syndrome in the elderly. J Am Geriatr Soc 
2004;52:399-404
81. Meier CA, Bobbioni E, Gabay C, et al. 
IL-1 receptor antagonist serum levels are 
increased in human obesity: a possible  
link to the resistance to leptin? J Clin 
Endocrinol Metab 2002;87:1184-8
82. Ruotsalainen E, Salmenniemi U, 
Vauhkonen I, et al. Changes in 
inflammatory cytokines are related to 
impaired glucose tolerance in offspring of 
type 2 diabetic subjects. Diabetes Care 
2006;29:2714-20
83. Salmenniemi U, Ruotsalainen E, 
Pihlajamaki J, et al. Multiple abnormalities 
in glucose and energy metabolism and 
coordinated changes in levels of 
adiponectin, cytokines, and adhesion 
molecules in subjects with metabolic 
syndrome. Circulation 2004;110:3842-8
84. Marculescu R, Endler G, Schillinger M, 
et al. Interleukin-1 receptor antagonist 
genotype is associated with coronary 
atherosclerosis in patients with type 2 
diabetes. Diabetes 2002;51:3582-5
85. Herder C, Brunner EJ, Rathmann W, et al. 
Elevated levels of the anti-inflammatory 
interleukin-1 receptor antagonist (IL-1Ra) 
precede the onset of type 2 diabetes 
(Whitehall II Study). Diabetes Care 2008
86. Juge-Aubry CE, Somm E, Giusti V, et al. 
Adipose tissue is a major source of 
interleukin-1 receptor antagonist: 
upregulation in obesity and inflammation. 
Diabetes 2003;52:1104-10
87. Sauter NS, Schulthess FT, Galasso R,  
et al. The antiinflammatory cytokine 
interleukin-1 receptor antagonist protects 
from high-fat diet-induced hyperglycemia. 
Endocrinology 2008;149:2208-18
88. Koenig W, Khuseyinova N, Baumert J, 
et al. Increased concentrations of C-reactive 
protein and IL-6 but not IL-18 are 
independently associated with incident 
coronary events in middle-aged men and 
women: results from the MONICA/KORA 
Augsburg case-cohort study, 1984-2002. 
Arterioscler Thromb Vasc Biol 
2006;26:2745-51
89. Wellen KE, Hotamisligil GS. 
Inflammation, stress, and diabetes.  
J Clin Invest 2005;115:1111-19
90. de Luca C, Olefsky JM. Inflammation  
and insulin resistance. FEBS Lett 
2008;582:97-105
91. Schenk S, Saberi M, Olefsky JM. Insulin 
sensitivity: modulation by nutrients  
and inflammation. J Clin Invest 
2008;118:2992-3002
92. Ehses JA, Perren A, Eppler E, et al. 
Increased number of islet-associated 
macrophages in type 2 diabetes. Diabetes 
2007;56:2356-70
93. Homo-Delarche F, Calderari S,  
Irminger JC, et al. Islet inflammation  
and fibrosis in a spontaneous model of 
type 2 diabetes, the GK rat. Diabetes 
2006;55:1625-33
94. Weksler-Zangen S, Raz I, Lenzen S, et al. 
Impaired glucose-stimulated insulin 
secretion is coupled with exocrine 
pancreatic lesions in the Cohen diabetic  
rat. Diabetes 2008;57:279-87
95. Taniguchi CM, Emanuelli B, Kahn CR. 
Critical nodes in signalling pathways: 
insights into insulin action. Nat Rev Mol 
Cell Biol 2006;7:85-96
96. Rui L, Yuan M, Frantz D, et al. SOCS-1 
and SOCS-3 block insulin signaling by 
ubiquitin-mediated degradation of IRS1 
and IRS2. J Biol Chem 2002;277:42394-8
97. Weisberg SP, McCann D, Desai M, et al. 
Obesity is associated with macrophage 
accumulation in adipose tissue.  
J Clin Invest 2003;112:1796-808
98. Xu H, Barnes GT, Yang Q, et al. Chronic 
inflammation in fat plays a crucial role in 
the development of obesity-related insulin 
resistance. J Clin Invest 2003;112:1821-30
99. Koerner A, Kratzsch J, Kiess W. 
Adipocytokines: leptin–the classical, 
resistin–the controversical, adiponectin–the 
promising, and more to come. Best Pract 
Res Clin Endocrinol Metab 
2005;19:525-46
100. Tilg H, Moschen AR. Adipocytokines: 
mediators linking adipose tissue, 
inflammation and immunity.  
Nat Rev Immunol 2006;6:772-83
101. Rasouli N, Kern PA. Adipocytokines and 
the metabolic complications of obesity.  
J Clin Endocrinol Metab 2008;93:S64-73
102. Yu X, Park BH, Wang MY, et al. Making 
insulin-deficient type 1 diabetic rodents 
thrive without insulin. Proc Natl Acad  
Sci USA 2008;105:14070-5
103. Seufert J, Kieffer TJ, Leech CA, et al. 
Leptin suppression of insulin secretion  
Ex
pe
rt 
O
pi
n.
 B
io
l. 
Th
er
. D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Su
U
B
 B
re
m
en
 o
n 
07
/1
8/
13
Fo
r p
er
so
na
l u
se
 o
nl
y.
???????????????????????????????????????????
? ????????????????????????????????????? ????
and gene expression in human pancreatic 
islets: implications for the development  
of adipogenic diabetes mellitus. J Clin 
Endocrinol Metab 1999;84:670-6
104. Roduit R, Thorens B. Inhibition of 
glucose-induced insulin secretion by 
long-term preexposure of pancreatic islets 
to leptin. FEBS Lett 1997;415:179-82
105. Gabay C, Dreyer M, Pellegrinelli N, et al. 
Leptin directly induces the secretion of 
interleukin 1 receptor antagonist in human 
monocytes. J Clin Endocrinol Metab 
2001;86:783-91
106. Lumeng CN, Bodzin JL, Saltiel AR. 
Obesity induces a phenotypic switch in 
adipose tissue macrophage polarization.  
J Clin Invest 2007;117:175-84
107. Barshes NR, Wyllie S, Goss JA. 
Inflammation-mediated dysfunction and 
apoptosis in pancreatic islet transplantation: 
implications for intrahepatic grafts.  
J Leukoc Biol 2005;77:587-97
108. Bottino R, Fernandez LA, Ricordi C, et al. 
Transplantation of allogeneic islets of 
Langerhans in the rat liver: effects of 
macrophage depletion on graft survival and 
microenvironment activation. Diabetes 
1998;47:316-23
109. Kaufman DB, Platt JL, Rabe FL, et al. 
Differential roles of Mac-1+ cells, and 
CD4+ and CD8+ T lymphocytes in 
primary nonfunction and classic  
rejection of islet allografts. J Exp Med 
1990;172:291-302
110. Kaufman DB, Gores PF, Field MJ, et al. 
Effect of 15-deoxyspergualin on immediate 
function and long-term survival of 
transplanted islets in murine recipients  
of a marginal islet mass. Diabetes 
1994;43:778-83
111. Tran PO, Gleason CE, Robertson RP. 
Inhibition of interleukin-1beta-induced 
COX-2 and EP3 gene expression by 
sodium salicylate enhances pancreatic  
islet beta-cell function. Diabetes 
2002;51:1772-8
112. Zeender E, Maedler K, Bosco D, et al. 
Pioglitazone and Sodium Salicylate  
Protect Human {beta}-Cells against 
Apoptosis and Impaired Function Induced 
by Glucose and Interleukin-1{beta}.  
J Clin Endocrinol Metab 2004;89:5059-66
113. Solinas G, Vilcu C, Neels JG, et al. JNK1 
in hematopoietically derived cells 
contributes to diet-induced inflammation 
and insulin resistance without affecting 
obesity. Cell Metab 2007;6:386-97
114. Cai D, Yuan M, Frantz DF, et al.  
Local and systemic insulin resistance 
resulting from hepatic activation of 
IKK-beta and NF-kappaB. Nat Med 
2005;11:183-90
115. Arkan MC, Hevener AL, Greten FR,  
et al. IKK-beta links inflammation to 
obesity-induced insulin resistance.  
Nat Med 2005;11:191-8
116. Allan SM, Tyrrell PJ, Rothwell NJ. 
Interleukin-1 and neuronal injury.  
Nat Rev Immunol 2005;5:629-40
117. Touzani O, Boutin H, Chuquet J,  
Rothwell N. Potential mechanisms of 
interleukin-1 involvement in cerebral 
ischaemia. J Neuroimmunol 
1999;100:203-15
118. Rothwell NJ, Luheshi GN. Interleukin 1  
in the brain: biology, pathology and 
therapeutic target. Trends Neurosci 
2000;23:618-25
119. Dinarello CA, Wolff SM. Molecular  
basis of fever in humans. Am J Med 
1982;72:799-819
120. Wolf G, Yirmiya R, Goshen I, et al. 
Impairment of interleukin-1 (IL-1) 
signaling reduces basal pain sensitivity  
in mice: genetic, pharmacological and 
developmental aspects. Pain 
2003;104:471-80
121. Goshen I, Yirmiya R, Iverfeldt K, 
Weidenfeld J. The role of endogenous 
interleukin-1 in stress-induced adrenal 
activation and adrenalectomy-induced 
adrenocorticotropic hormone 
hypersecretion. Endocrinology 
2003;144:4453-8
122. Schneider H, Pitossi F, Balschun D, et al. A 
neuromodulatory role of interleukin-1beta 
in the hippocampus. Proc Natl Acad  
Sci USA 1998;95:7778-83
123. Sims JE, Dower SK. Interleukin-1 
receptors. Eur Cytokine Netw 
1994;5:539-46
124. De Souza CT, Araujo EP, Bordin S, et al. 
Consumption of a fat-rich diet activates a 
proinflammatory response and induces 
insulin resistance in the hypothalamus. 
Endocrinology 2005;146:4192-9
125. Milanski M, Degasperi G, Coope A, et al. 
Saturated fatty acids produce an 
inflammatory response predominantly 
through the activation of TLR4 signaling  
in hypothalamus: implications for the 
pathogenesis of obesity. J Neurosci 
2009;29:359-70
126. Munzberg H, Flier JS, Bjorbaek C. 
Region-specific leptin resistance within  
the hypothalamus of diet-induced obese 
mice. Endocrinology 2004;145:4880-9
127. Vandenabeele P, Fiers W. Is amyloidogenesis 
during Alzheimer’s disease due to an  
IL-1-/IL-6-mediated ‘acute phase response’ 
in the brain? Immunol Today 
1991;12:217-19
128. Holden RJ, Mooney PA. Interleukin-1 
beta: a common cause of Alzheimer’s 
disease and diabetes mellitus.  
Med Hypotheses 1995;45:559-71
129. Zuliani G, Ranzini M, Guerra G, et al. 
Plasma cytokines profile in older subjects 
with late onset alzheimer’s disease or 
vascular dementia. J Psychiatr Res 
2007;41:686-93
130. Goldgaber D, Harris HW, Hla T, et al. 
Interleukin 1 regulates synthesis of amyloid 
beta-protein precursor mRNA in human 
endothelial cells. Proc Natl Acad Sci USA 
1989;86:7606-10
131. Haataja L, Gurlo T, Huang CJ, Butler PC. 
Islet amyloid in type 2 diabetes, and the 
toxic oligomer hypothesis. Endocr Rev 
2008;29:303-16
132. Butler AE, Jang J, Gurlo T, et al. Diabetes 
due to a progressive defect in beta-cell mass 
in rats transgenic for human islet amyloid 
polypeptide (HIP Rat): a new model for 
type 2 diabetes. Diabetes 2004;53:1509-16
133. Borsello T, Forloni G. JNK signalling: a 
possible target to prevent 
neurodegeneration. Curr Pharm Des 
2007;13:1875-86
134. Howard JK, Cave BJ, Oksanen LJ, et al. 
Enhanced leptin sensitivity and attenuation 
of diet-induced obesity in mice with 
haploinsufficiency of Socs3. Nat Med 
2004;10:734-8
135. Bence KK, Delibegovic M, Xue B, et al. 
Neuronal PTP1B regulates body weight, 
adiposity and leptin action. Nat Med 
2006;12:917-24
136. Liadis N, Salmena L, Kwan E, et al. 
Distinct in vivo roles of caspase-8 in 
beta-cells in physiological and diabetes 
models. Diabetes 2007;56:2302-11
137. Schumann DM, Maedler K, Franklin I, 
et al. The Fas pathway is involved in 
pancreatic {beta} cell secretory function. 
Proc Natl Acad Sci USA 2007;104:2861-6
138. Flodstrom M, Welsh N, Eizirik DL. 
Cytokines activate the nuclear factor kappa 
B (NF-kappa B) and induce nitric oxide 
Ex
pe
rt 
O
pi
n.
 B
io
l. 
Th
er
. D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Su
U
B
 B
re
m
en
 o
n 
07
/1
8/
13
Fo
r p
er
so
na
l u
se
 o
nl
y.
???????????????????????????????????????????????????????
????? ????????????????????????????????????
production in human pancreatic islets. 
FEBS Lett 1996;385:4-6
139. Liuwantara D, Elliot M, Smith MW, et al. 
Nuclear factor-kappaB regulates beta-cell 
death: a critical role for A20 in beta-cell 
protection. Diabetes 2006;55:2491-501
140. Hammar E, Parnaud G, Bosco D, et al. 
Extracellular matrix protects pancreatic 
{beta}-cells against apoptosis: role of  
short- and long-term signaling pathways. 
Diabetes 2004;53:2034-41
141. Thomas HE, Irawaty W, Darwiche R, et al. 
IL-1 receptor deficiency slows progression 
to diabetes in the NOD mouse. Diabetes 
2004;53:113-21
142. Schott WH, Haskell BD, Tse HM, et al. 
Caspase-1 is not required for type 1 
diabetes in the NOD mouse. Diabetes 
2004;53:99-104
143. Jafarian-Tehrani M, Amrani A,  
Homo-Delarche F, et al. Localization and 
characterization of interleukin-1 receptors 
in the islets of Langerhans from control and 
nonobese diabetic mice. Endocrinology 
1995;136:609-13
144. Balasa B, La Cava A, Van Gunst K, et al.  
A mechanism for IL-10-mediated diabetes 
in the nonobese diabetic (NOD) mouse: 
ICAM-1 deficiency blocks accelerated 
diabetes. J Immunol 2000;165:7330-7
145. Ehses JA, Giroix M-H, Coulaud J, et al. 
IL-1?-MyD88 signaling is central to islet 
chemokine secretion in response to 
metabolic stress: evidence from a 
spontaneous model of type 2 diabetes,  
the GK rat. Diabetologia  
2008;50(Suppl 1):S177
146. Owyang AM, Gross L, Yin J, et al.  
XOMA 052, an anti-IL-1? antibody, 
improves glucose control, ?-Cell function, 
and insulin resistance in the diet-induced 
obesity mouse model. Diabetes 
2009;58(S1):A82
147. Osborn O, Brownell SE, Sanchez-Alavez M, 
et al. Treatment with an Interleukin 1 beta 
antibody improves glycemic control in 
diet-induced obesity. Cytokine 
2008;44:141-8
148. Larsen CM, Faulenbach M, Vaag A, et al. 
Interleukin-1-receptor antagonist in type 2 
diabetes mellitus. N Engl J Med 
2007;356:1517-26
149. Pickersgill LM, Mandrup-Poulsen TR.  
The anti-interleukin-1 in type 1 diabetes 
action trial--background and rationale. 
Diabetes Metab Res Rev  
2009;25:321-4
150. Donath MY, Weder C, Brunner A, et al. 
XOMA 052, a potential disease modifying 
anti-IL-10 antibody shows sustained 
HbA1c reductions 3 months after single 
injection with no increases in safety 
parameters in subjects with T2DM. 
Diabetes 2008;58S1:A30
Affiliation
Kathrin Maedler†1, Gitanjali Dharmadhikari1, 
Desiree M Schumann2 & Joachim Størling3
†Author for correspondence
1University of Bremen, 
Centre for Biomolecular Interactions Bremen, 
Islet Biology Laboratory, 
Leobener Straße NW2, Room B2080, 
28359 Bremen, Germany 
Tel: +49 42121863290; Fax: +49 4212184279; 
E-mail: kmaedler@uni-bremen.de
2Boehringer-Ingelheim, 
Cardiometabolic Diseases Research, 
Biberach, Germany
3Hagedorn Research Institute, 
Gentofte, Denmark
Ex
pe
rt 
O
pi
n.
 B
io
l. 
Th
er
. D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Su
U
B
 B
re
m
en
 o
n 
07
/1
8/
13
Fo
r p
er
so
na
l u
se
 o
nl
y.
Neutralizing Interleukin-1 (IL-1) Induces -Cell Survival by
Maintaining PDX1 Protein Nuclear Localization*□S
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The transcription factor PDX1 plays a critical role during
-cell development and in glucose-induced insulin gene tran-
scription in adult-cells. Acute glucose exposure leads to trans-
localization of PDX1 to the nucleoplasm, whereas under condi-
tions of oxidative stress, PDX1 shuttles from the nucleus to the
cytosol. Here we show that cytosolic PDX1 expression corre-
lated with -cell failure in diabetes. In isolated islets from
patients with type 2 diabetes and from diabetic mice, we found
opposite regulation of insulin and PDX1 mRNA; insulin was
decreased in diabetes, but PDX1 was increased. This suggests
that elevated PDX1mRNA levelsmay be insufficient to regulate
insulin. In diabetic islets, PDX1 protein was localized in the
cytosol, whereas in non-diabetic controls, PDX1 was in the
nucleus. In contrast, overexpression of either IL-1 receptor
antagonist or shuttling-deficient PDX1 restored -cell survival
and function and PDX1 nuclear localization. Our results show
that nuclear localization of PDX1 is essential for a functional
-cell andprovides a novelmechanismof the protective effect of
IL-1 receptor antagonist on -cell survival and function.
New therapies for diabetes that lead to protection of the insu-
lin-producing -cell are urgently needed. Only when the -cell
compensates for the higher insulin demand during insulin
resistance can normoglycemia be maintained. Recent studies
suggest that the low grade inflammation in type 2 diabetesmel-
litus (T2DM)3 contributes to-cell failure (1). Especially, inter-
leukin-1 (IL-1), whose secretion has been postulated from
intraislet macrophages (2) and from -cells themselves when
exposed to double-stranded RNA (3), to elevated glucose con-
centrations (4–6), or to free fatty acids (7), initiates -cell
destruction.
The receptor for IL-1, IL-1R1, is highly expressed in the
-cell, and more than 10-fold higher expression of IL-1R1
mRNA was observed in isolated islets than in total pancreas,
which is attributed to the expression in -cells (7). This may
explain the high sensitivity of the-cell to IL-1. A recent study
shows that glucose-induced IL-1 secretion involves caspase 1
activationmediated by the NALP3 inflammasome. The inflam-
masome is activated by bacterial toxins or endogenous stress
signals (e.g.ATP and -amyloid (8–10)) through the formation
of reactive oxygen species (6, 11). Glucose-induced IL-1 secre-
tion by the -cell is prevented in NALP3/ mice, indicating
that IL-1 is generated through glucose-induced reactive oxy-
gen species production and oxidative stress (6). The thiore-
doxin-interacting protein, which has been linked to insulin
resistance (12), functions as an activator of NALP3. In line with
these data, another recent study shows that thioredoxin-inter-
acting protein is highly increased by elevated glucose in -cells
and that thioredoxin-interacting protein-deficient islets are
protected against glucose toxicity (13). Although glucose-in-
duced IL-1 production in the -cell was not observed in all
studies (14), IL-1 expression in islets from patients with
T2DM has been confirmed (5, 15), supporting the concept of
blocking IL-1 signals as a target for diabetes treatment.
Indeed, daily injection of IL-1Ra in mice fed a high fat diet
(HFD) improves glycemia, glucose-stimulated insulin secre-
tion, and survival (16); reduces hyperglycemia; and reverses the
islet inflammatory phenotype in the GK rat (17). Treatment
with an IL-1 antibody also improves glycemic control in diet-
induced obesity inmice (18, 19). Results from a clinical study in
patients with T2DM showed that IL-1Ra improves glycemic
control and -cell function (20–22). Blocking IL-1 signals
reduces expression of inflammatory marker in fat tissue and in
islets (16). None of the studies have studied the mechanisms of
the protective effect of IL-1Ra at the level of -cell gene regu-
lation. IL-1 affects expression of the transcription factor
PDX1 (pancreatic duodenal homeobox-1, previously called
IPF1, IDX1, STF1, or IUF1) (23), a key factor in pancreas devel-
opment and function. Reduced PDX1 expression levels nega-
tively regulates insulin expression and secretion and predispose
islets to apoptosis (24–26). Its homozygous mutations result in
* This work was supported by Deutsche Forschungsgemeinschaft Emmy
Noether Programm Grant MA4172/1-1, Juvenile Diabetes Research Foun-
dation Grant 40-2011-9, and European Research Council Grant 260336.
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1 and S2.
1 Both authors contributed equally to this work.
2 To whom correspondence should be addressed: Islet Biology Laboratory,
Centre for Biomolecular Interactions Bremen, University of Bremen, Leo-
bener Strasse NW2, Rm. B2080, 28359 Bremen, Germany. Tel.: 49-421-218-
63290; Fax: 49-421-218-4279; E-mail: kmaedler@uni-bremen.de.
3 The abbreviations used are: T2DM, type 2 diabetes mellitus; HFD, high fat
diet; ND, normal diet; NES, nuclear export signal; IL-1Ra, IL-1 receptor
antagonist; PARP, poly(ADP-ribose) polymerase; OE, overexpressing; JNKi,
JNK inhibitor.
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pancreas agenesis associated with neonatal diabetes (27, 28).
PDX1 directly binds to the promoter and controls expression of
important -cell genes, which are vital for -cell function, such
as insulin, Glut2, and glucokinase (27). PDX1 deficiency con-
tributes to impaired proliferation and enhanced apoptosis via
transcriptional mechanisms in models of type 2 diabetes,
such as Psammomys obesus and the leptin receptor-deficient
(Leprdb/db) db/db mice (29). Overexpression of PDX1 restores
-cell mass and function, thereby preventing the onset of dia-
betes in IRS2 knock-outmice, showing the critical role of PDX1
in -cell survival (30).
Complicated signaling networks control PDX1 regulation,
and nucleo-cytoplasmic shuttling plays a major role in the reg-
ulation of PDX1 function (31, 32). Well characterized PDX1
nuclear import signal and nuclear export signal (NES) suggest
that PDX1might be regulated at the level of cellular localization
(31, 33). Post-translational modification of proteins is the most
abundant form of cellular regulation, affecting many cellular
signal pathways, includingmetabolism, growth, differentiation,
and apoptosis. In response to acute elevation of glucose and
survival factors, such as insulin, PDX1 is phosphorylated and
translocates to the nucleus (34, 35). By contrast, stimuli associ-
ated with diabetes, such as oxidative stress (31) and free fatty
acids (36), cause nuclear exclusion of PDX1 (36). This suggests
that cytoplasmic accumulation may represent a mechanism to
reduce the nuclear action of PDX1 under pathologic conditions
rather than to promote a specific cytoplasmic function.
We have shown previously that a diet enriched with fat and
sucrose (“Surwit”; HFD) induces impaired glucose tolerance
after 4 weeks of feeding, impaired fasting glucose after 8 weeks,
and hyperglycemia after 12 weeks in C57Bl/6J mice (16, 19, 37).
These changes in glycemia were accompanied by fluctuations
in -cell mass. Despite the reduction in -cell proliferation and
the increase in -cell apoptosis, islets showed a compensatory
increase in -cell mass up to 12 weeks of diet. After 16 weeks,
apoptosis was increased, and -cell mass was reduced in the
HFD-treated mice. IL-1 antagonism by anti-IL-1 antibody
treatment, IL-1Ra injections, or overexpression restored nor-
moglycemia and -cell function and survival (16, 19, 37), but
also changes in the inflammatory state of the fat tissue were
involved in the protective effects of IL-1 antagonism. There-
fore, we asked how IL-1 signals regulate gene transcription in
the -cell. We tested the effect of IL-1Ra on regulating glucose
homeostasis in another animal model, the obese diabetic leptin
receptor-deficient Leprdb/db mice (db/db). Commonly, we
detected that IL-1Ra was able to maintain the cellular localiza-
tion of PDX1. A diabetic milieu in vitro as well as T2DM in vivo
induced a switch of PDX1 from the nucleus to the cytosol,
which was accompanied by a loss in -cell mass and function.
Whether PDX1 is altered in its localization in -cells during
the progression to diabetes and whether these changes may
affect -cell function in different levels was previously un-
known. Because PDX1 regulates insulin and specific -cell
genes, altered localization may contribute to -cell death and
loss of function. In the short term, this stressful response may
be tolerated, but under chronic situations in T2DM, prolonged
stress conditions ultimately affect -cell survival.
EXPERIMENTAL PROCEDURES
Animals—Transgenic mice overexpressing IL-1Ra (IL-1Ra-
OE) were kindly provided by Dr. Emmet Hirsch (Northwestern
University, Evanston, IL) (38). Beginning at 5 weeks of age and
continuing for 12weeks, transgenic animals as well as their wild
type littermateswere fed a normal diet (WTNDand IL-1Ra-OE
ND) or a high fat/high sucrose diet (WT HFD and IL-1Ra-OE
HFD, Surwit (Research Diets, New Brunswick, NJ), containing
58, 26, and 16% calories from fat, carbohydrate, and protein,
respectively (39)) or were treated daily with IL-1Ra from the
starting day of the diets (NDIL-1Ra and HFDIL-1Ra;
Kineret, Amgen (Thousand Oaks, CA), intraperitoneal injec-
tion of 10 mg/kg body weight) as described previously (16).
Four independent experiments with a total of 16 mice (4 mice/
cage) in each group were performed, respectively.
Heterozygous leptin receptor deficient mice on the
C57BLKS/J background (Leprdb/, db/) were purchased from
Jackson Laboratory. By cross-breeding these mice to C57BL/
6J-IL-1Ra-overexpressing mice (OE), we obtained diabetic
Leprdb/db (db/db) as well as non-diabetic Lepr/ (WT) with
endogenous overexpression of IL-1Ra (OE-db/db and OE) as
well as littermates without IL-1Ra as appropriate negative con-
trols (db/db and WT) with the same mixed background. In all
experiments, littermates from the F2 breeding were used. All
animals were housed in a temperature-controlled room with a
12-h light/dark cycle and were allowed free access to food and
water in agreement with National Institutes of Health animal
care guidelines and Section 8 of the German animal protection
law.
Intraperitoneal Glucose and Insulin Tolerance Tests—After
4, 8, and 12 weeks of diet (HFD) or at the age of 6 and 10 weeks
(db/db), all animals underwent in vivo studies (intraperitoneal
glucose and insulin tolerance tests) as described before (16).
Islet Isolation and Culture—Islets from all groups were iso-
lated as described previously (40). Human islets were isolated
from eight pancreases of healthy organ donors and from eight
with T2DM at the University of Illinois (Chicago, IL), Lille Uni-
versity, or Pisa University as described previously (41) and cul-
tured inCMRL-1066mediumas described previously (42). Islet
purity was greater than 95% as judged by dithizone staining (if
this degree of puritywas not achieved by routine isolation, islets
were hand-picked). Islets were exposed to 5.5, 11.1, 22.2, or 33.3
mM glucose or 5.5 mM plus 2 ng/ml recombinant human IL-1
(R&D Systems, Minneapolis, MN), with or without 500 ng/ml
recombinant human IL-1Ra (R&D Systems) or 10 M JNKi
(kindly provided byXigen S.A., Lausanne, Switzerland) for 72 h.
Transfections—At 2 days postisolation and culture on extra-
cellular matrix-coated dishes, isolated islets were exposed to
transfection Ca2-KRH medium (4.74 mM KCl, 1.19 mM
KH2PO4, 1.19 mM MgCl26H2O, 119 mM NaCl, 2.54 mM CaCl2,
25 mM NaHCO3, 10 mM HEPES). After 1 h of incubation, lip-
oplexes (Lipofectamine2000 (Invitrogen)/DNA ratio 2.5:1, 5g
of DNA/100 islets) were added to transfect the islets. After an
additional 6 h of incubation, CMRL 1066 medium containing
20% FCS and L-glutamine was added to the transfected islets.
Efficient transfection was evaluated based on enhanced GFP-
positive cells, which resulted in 60% transfection efficiency in
PDX1 Localization in Diabetes
MAY 13, 2011•VOLUME 286•NUMBER 19 JOURNAL OF BIOLOGICAL CHEMISTRY 17145
 at U
N
IV
E
R
S
ITÄ
T B
R
E
M
E
N
, on January 30, 2013
w
w
w
.jbc.org
D
ow
nloaded from
 
-cells through the whole islets, analyzed by fluorescence and
confocal microscopy.
Glucose-stimulated Insulin Secretion and Insulin Content—
Islets used to perform glucose-stimulated insulin secretion
experiments were kept in culture medium on matrix-coated
plates derived from bovine corneal endothelial cells (Novamed
Ltd., Jerusalem, Israel) for 4 days, allowing the cells to attach to
the dishes and spread (43). These experimental conditions
allowed direct comparison with our previous studies in human
and mouse islets pretreated with IL-1Ra in vitro (4, 16). There-
after, islets were washed with PBS and extracted with HCl (0.18
N) in 70% ethanol for 24 h at 4 °C. The acid-ethanol extracts
were collected for determination of insulin content. Insulin was
determined using a human insulin ELISA kit (Alpco).
-Cell Mass and Histochemical Analyses—Pancreatic sec-
tions from seven healthy controls and from seven patients with
T2DM were obtained from the National Disease Research
Interchange (NDRI) and from Kangnam St. Mary’s Hospital
(Seoul, Korea) as described (44); approval for the studies was
granted by the Kangnam St. Mary’s Hospital and by the Ethical
Commission of Bremen University.
Mouse pancreases and sections from isolated islets were
obtained as described (16). To determine -cell mass, 10 sec-
tions (spanning the width of the pancreas) were analyzed as
described (16). For detection of -cell apoptosis, insulin and
TUNEL staining were performed (In Situ Cell Death Detection
Kit, TMRRed; RocheApplied Science) (16). For PDX1 localiza-
tion studies, after dehydration, sections were incubated in
blocking buffer containing 0.2% Tween 20, 3% IgG-free bovine
serum albumin (BSA), 2% Triton X-100 for 1 h at room tem-
perature and overnight at 4 °C with rabbit anti-PDX1 (kindly
provided by Christopher Wright, Vanderbilt University Medi-
cal Center, Nashville, TN) in antibody buffer containing 0.2%
Tween 20, 3% IgG-free BSA, and 0.5% Triton X-100. Subse-
quently, all sections were double-stained for insulin and
detected by donkey anti-guinea pig FITC-conjugated antibody
(Dako). Fluorescent slides were analyzed using a Nikon
MEA53200 microscope (Nikon GmbH Dusseldorf, Germany),
and images were acquired using NIS-Elements software
(Nikon).
RNA Extraction and RT-PCR Analysis—Total RNA of
isolated islets was extracted after overnight culture, and RT-
PCR was performed as described previously (4). Primers
used were as follows: 5-ttcttctacacaccca-3/5-ctagttgcagt-
agttct-3 (human and mouse insulin); 5-gaggacccgtactgcct-
aca-3/5-cggggtcccgctactacgtt-3 (mouse PDX1), 5-ctgga-
ttggcgttgtttgtg-3/5-tcccaaggtggagtgctgtag-3 (human PDX1),
5-gtccatgccatcactgccac-3/5-cagcaccagtggatgcaggg-3 (mouse
GAPDH); 5-gttggccaggctggtgtccag-3/5-ctgtgatgagctgctcaggg-
tgg-3 (human and mouse tubulin), 5-ccaaccgcgagaagatga-3/5-
ccagaggcgtacagggatag-3 (human actin), and 5-tacgggtcctggcatc-
ttgt-3/5-ccatttgtgttgggtccagc-3 (human cyclophilin).
Nuclear Fractionation—Nuclear and cytoplasmic extrac-
tions of human islets were performed according to the instruc-
tions for the NE-PER nuclear and cytoplasmic extraction
reagents (Pierce). The purity of fractions was analyzed by incu-
bation of the membranes with anti-tubulin and anti-GAPDH
for cytosolic and anti-PARP or anti-histone H3 for nuclear
extracts.
Western Blot Analysis—At the end of the incubation periods,
islets were washed in ice-cold PBS and lysed as described (42).
Membranes were incubated with rabbit anti-phospho-JNK
(Thr183/Tyr185), rabbit anti-histone H3, rabbit anti-PARP,
rabbit anti-tubulin, rabbit anti-GAPDH, and rabbit anti--
actin (Cell Signaling Technology) antibodies, followed by
horseradish peroxidase-linked anti-rabbit IgG. Density of
the bands was analyzed using DocITLS image acquisition
6.6a (UVP BioImaging Systems, Upland, CA).
Statistical Analysis—Samples were evaluated in a random-
ized manner by a single investigator, who was blinded to the
treatment conditions. Data are presented as means  S.E. and
were analyzed by paired, Student’s t test or by analysis of
variance with a Bonferroni correction for multiple group
comparisons.
RESULTS
High Fat Diet Induces PDX1 Translocalization to the Cytosol
and Is Prevented by IL-1Ra—Looking into detailedmechanisms
of the loss of adaption in C57Bl/6Jmice fed a diet enriched with
fat and sucrose (HFD; Surwit), we isolated RNA from islets
from mice after 12 weeks of diet and IL-1Ra treatment and
performed RT-PCR for insulin and its transcription factor
PDX1.Whereas insulin mRNA in islets fromHFD animals was
decreased to 27% of control islets (Fig. 1A), PDX1 levels were
2.8-fold increased (Fig. 1C). Also, insulin content from isolated
islets was significantly decreased in the HFD-fed mice (Fig. 1B,
p  0.05). Such changes did not occur in IL-1Ra-treated ani-
mals. Because it has been reported that PDX1 activity is primar-
ily regulated by its subcellular localization (45, 46), we stained
pancreatic tissue sections for PDX1 and insulin. Sections from
both normal diet groups showed PDX1 immunoreactivity pre-
dominantly (95 and 94%) in the nucleus of -cells (Fig. 1D, b
and d). In contrast, the majority (67%) of the -cells under the
high fat diet expressed PDX1 in the cytoplasm (Fig. 1C, f).
IL-1Ra treatment inhibited this translocalization to the cyto-
plasm (30% cytosolic PDX1), and the islets showedmore prom-
inent staining in the nucleus (54% nuclear PDX1; Fig. 1D, h).
Western blot analysis from nuclear and cytosolic fractions
from isolated islets from WT and IL-1Ra-OE mice fed for 12
weeks with normal chow or HFD confirmed the decrease in
nuclear together with the increase in cytosolic PDX1 in islets
under theHFDcondition, whichwas prevented by IL-1Ra over-
expression (Fig. 1E).
PDX1 Translocalization to the Cytosol in db/db Mice
Is Prevented by IL-1Ra Overexpression—To investigate
whether PDX1 shuttling also occurs in another mouse model,
we examined the effects of IL-1Ra in Leprdb/db mice (db/db).
By cross-breeding mice, which endogenously overexpress
IL-1Ra (OE) to C57BLKS-Leprdb, we used four groups of
mice in the experiments: IL-1Ra-OE-Leprdb/db (db/dbIL-
1Ra) and heterozygous Leprdb/-IL-1Ra-OE (db/IL-1Ra) as
well as their littermates without IL-1Ra-overexpression,
Leprdb/db (db/db) and Leprdb/ (db/).
Heterozygous db/ and db/IL-1Ra mice showed clear
nuclear PDX1 localization independent of their age (84 and 87%
PDX1 Localization in Diabetes
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nuclear PDX1; Fig. 2A,a–f). In contrast, 6-week-old db/dbmice
showed a clear switch of PDX1 from the nucleus into the cyto-
sol (Fig. 2A, g–i). Littermates, which overexpressed IL-1Ra,
were clearly protected from such localization change (Fig. 2A,
j–l). The switch in localization was predominant in the 6-week-
oldmice.With the progression of diabetes in 10-week-oldmice,
loss of PDX1 expression was observed (only 15% PDX1 
-cells; Fig. 2A, m–o). IL-1Ra-OE mice partly restored overall
PDX1 expression and its nuclear localization (51% -cells had
nuclear and 12% cytosolic PDX1; Fig. 2A, p–r). The localization
switchwas again confirmed byWestern blot analysis in 6-week-
old mice. Although heterozygous db/ and db/IL-1Ra as well
as db/dbIL-1Ramice showedmajor nuclear PDX1 localization,
we found PDX1 predominantly in the cytosol in the db/dbmice
(Fig. 2B).
The switch in the PDX1 localization to the cytosol was
accompanied by impaired glucose tolerance. Although
db/IL-1Ra and db/ mice showed normal glucose toler-
ance, db/db mice revealed increased fasting glucose levels
and impaired glucose tolerance. IL-1Ra overexpression in
the db/IL-1Ra mice could partially but significantly restore
glucose tolerance at all time points during the intraperito-
neal glucose tolerance test and decrease fasting glucose levels
(supplemental Fig. 1A). Glucose-stimulated insulin secretion
was completely abolished in the db/db mice but was signifi-
cantly restored in the db/dbIL-1Ra mice with the significant
increase in stimulated insulin secretion and a restoration of the
stimulatory index (supplemental Fig. 1, B and C). -Cell failure
seen by the impaired GSIS was also confirmed when we ana-
lyzed -cell mass and survival. -Cell apoptosis was 4.5-fold
FIGURE 1.High fat diet induces PDX1 translocalization to the cytosol. C57Bl/6J mice treated daily with vehicle or 10 mg/kg IL-1Ra were fed a diet enriched
with fat and sucrose (HFD) or a normal chow diet (ND) for 12 weeks. A–C, RT-PCR analysis of insulin (A) and PDX1 (C) expression relative to control normal diet
conditions and insulin content (B) ofmouse islets isolated from the four treatment groups. In the LightCycler System,mRNA levels were normalized to GAPDH
and tubulinwith the same result. Islets were isolated from fourmice per treatment group. D, double immunostaining for insulin (green; a, c, e, and g) and PDX1
(red;b,d, f, andh) inmousepancreatic tissue sections fromall four treatment groups; stainingwas performedon four different pancreases per treatment group
(magnification,	250; insetmagnification,	2000). Thepercentageof nuclear and cytosolic PDX1was calculatedby counting2000 insulin-positive-cells from
fourmice in each condition. E, Western blot analysis of PDX1 fromnuclear and cytosolic fractions from isolated islets fromC57Bl/6JWT- or IL-1Ra-overexpress-
ingmice fed anNDorHFD for 12weeks. HistoneH3and tubulinwereusedas loading controls, andpurity of fractions for thenuclear and cytosolic extracts from
the same protein lysates was assessed. One representative blot of three experiments is shown. Densitometry analysis of bands normalized to histone H3 or
tubulin shows the ratio of nuclear and cytosolic PDX1 expression. Data are shown as mean S.E. *, p 0.05 HFD compared to ND WT mice, **, p 0.05 IL-1Ra
treated HFD compared to nontreated HFD mice.
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increased, and -cell mass was 2.1-fold reduced in the db/db
mice. In contrast,-cell apoptosis was reduced, and-cellmass
was partially restored in the db/db IL-1Ra mice (supplemental
Fig. 1, D and E).
PDX1 Is Localized in the Cytosol in T2DM—To investigate
whether our results in the two diabetic mouse models can be
translated into human diabetes, we analyzed PDX1 localiza-
tion and expression in human T2DM (Fig. 3, A–D) and the
effect of IL-1Ra on PDX1 localization in human isolated
islets (Fig. 3F) and in the rat -cell line INS-1E (Fig. 3, G and
H). In most -cells of the control patients investigated in
pancreatic sections (Fig. 3, A (a and b) and B) or in sections
from isolated islets (Fig. 3, A (e and f) and C), PDX1 was
clearly nuclear (Fig. 3A, b and f). In contrast, PDX1 expres-
sion was much weaker in islets from patients with T2DM,
and no nuclear PDX1 was observed in (Fig. 3, A (d and h), B,
and C). Similar opposite effects in insulin and PDX1 mRNA
expression as observed in the HFD mouse model could be
observed in human diabetes. Whereas insulin mRNA in
islets from patients with T2DM was reduced to 40% of the
expression in islets isolated from non-diabetic control
patients, PDX1 was 2.8-fold increased (Fig. 3D). This is in
FIGURE 2. PDX1 translocalization to the cytosol in db/dbmice is prevented by IL-1Ra overexpression. A, insulin staining in green (a, d, g, j, m, and p) and
PDX1 in red (b, e, h, k, n, and q) of control heterozygous db/ (a–c) and db/IL-1Ra (d–f)mice anddb/db (g–i andm–o) and db/dbIL-1Ra (j–l and p–r) littermates
at the age of 6 (g–l) and 10 weeks (m–r). Staining was performed on three different pancreases per treatment group from three independent experiments,
respectively (magnification,	250; inset magnification,	2000). Percentage of nuclear and cytosolic PDX1 was calculated by counting 2000 insulin-positive
-cells from three mice in each condition. B, Western blot analysis of islet lysates from 6-week-old heterozygous db/, db/IL-1Ra, db/db, and db/dbIL-1Ra
mice.HistoneH3and tubulinwereusedas loadingcontrols, andpurity of fractions in the samemembraneafter strippingwas assessed.One representativeblot
of three experiments is shown. Densitometry analysis of bands normalized to histone H3 or tubulin shows the ratio of nuclear and cytosolic PDX1 expression.
Data are shown as mean S.E. *, p 0.05 db/db compared to db/, **, p 0.05 OE-db/db compared to db/db.
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line with previous data from Del Guerra et al. (47). Insulin
content from diabetic islets was decreased when compared
with islets from control patients (Fig. 3E, p  0.01).
Isolated human islets were treated with increasing glucose
concentrations (5.5, 11.1, and 33.3 mM glucose) or 5.5 mM glu-
cose plus 2 ng/ml IL-1 for 72 h. As reported before and in our
previous studies (4, 48), under conditions of elevated glucose
levels or IL-1 treatment, -cells failed to adequately increase
insulin secretion in response to a glucose challenge. As shown
in Fig. 3F (b), PDX1 is localized in the nucleus in insulin-posi-
tive -cells at control conditions at 5.5 mM glucose. Co-expo-
sure of islets to IL-1Ra did not change PDX1 localization (Fig.
FIGURE 3. PDX1 is localized in the cytosol in T2DM. A, representative double immunostaining for insulin (green; a, c, e, and g) and PDX1 (red; b, d, f, and h)
performed in humanpancreatic (a–d) and human isolated islet (e–h) sections from seven (c and d) or three (g and h) poorly controlled patientswith T2DMand
seven (a and b) or three (e and f) healthy controls (magnification, 	250; inset magnification, 	2000). The percentage of nuclear and cytosolic PDX1 was
calculated by counting 2000 insulin-positive -cells from seven pancreatic sections (B) and three islet sections (C) in each condition. D, quantitative RT-PCR
analysis of insulin and PDX1 expression frommRNA; E, insulin content fromHCl-ethanol extracts fromhuman islets isolated from control patients and patients
with T2DM. In the LightCycler system, mRNA levels was normalized to cyclophilin and tubulin with the same result. Data are shown as mean S.E. (error bars)
from six (mRNA) or three (content) islet isolations from six (three) control patients and six (three) patientswith T2DM. *,p 0.05 T2DMcomparedwith controls.
F, human isolated islets were treated for 72 h with 5.5 mM glucose (control), 33.3 mM glucose, or 2 ng/ml IL-1with or without 500 ng/ml recombinant human
IL-1Ra. Fixed andparaffin-embedded islets sectionswere double-stained for insulin (green; a, c, e, g, i, and k) and PDX1 (red; b, d, f, h, j, and l) and analyzed under
the confocalmicroscope. (magnification,	1000; insetmagnification,	4000). Isletswere isolated from threedifferent donors, and3 independent experiments
were performed. The percentage of nuclear and cytosolic PDX1 was calculated by counting 2000 insulin-positive -cells from three experiments in each
condition. G and H, Western blot analysis of PDX1 of glucose-treated (3 days; 11.1–33.3; G) and IL-1-treated (2–3 days; 2 ng/ml; H) nuclear and cytosolic cell
lysatesof the-cell line INS-1E.GAPDHwasusedas loadingcontrol, andpurityof fractions for the cytosolic extracts and full-lengthPARP for thenuclear extracts
in the same membrane after stripping was assessed. One representative blot of three experiments is shown. Densitometry analysis of bands normalized to
PARP or GAPDH shows the ratio of nuclear and cytosolic PDX1 expression. Because there were no changes, the 2-day results were not analyzed in H.
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3F (h)). Increasing glucose concentrations to 11.1 (not shown)
and 33.3 mM (Fig. 3F (d)) or the addition of IL-1 (Fig. 3F (f))
shifted the PDX1 signal to the cytoplasm, resulting in co-local-
ization of PDX1 with insulin (yellow merged color), whereas
co-incubation with IL-1Ra protected from such PDX1 shift;
PDX1 remained in the nucleus in the IL-1Ra-treated islets (Fig.
3F, j and l). In order to show a -cell-specific mechanism, such
changes were confirmed by Western blot analysis of glucose-
and IL-1-treated cell lysates of the -cell line INS-1E. Glucose
induced a dose-dependent decline in nuclear PDX1 together
with an increase in cytosolic PDX1 expression after 72 h (Fig.
3G). 2 ng/ml IL-1 reduced nuclear and induced cytosolic
PDX1 expression after 3 days of exposure but not after 2 days,
showing a time-dependent IL-1 effect (Fig. 3H).
IL-1Ra Prevents Prolonged Glucose- and IL-1-induced JNK
Activation—PDX1nuclear export is induced by oxidative stress
through a signaling pathway that involves JNK activity (31, 49,
50). Therefore, we investigated whether JNK alsomediates glu-
cose- and IL-1-induced effects on PDX1 localization by first
evaluating whether IL-1Ra regulates JNK activation.
In isolated mouse islets, JNK remained in its activated state
over a 3-day period in the presence of elevated glucose concen-
trations (Fig. 4A, left). In islets from mice that endogenously
overexpress IL-1Ra (IL-1Ra-OE), glucose induced transient
JNK phosphorylation after 1 day of culture, whereas after 3
days, JNK activation decreased (Fig. 4A, right). We confirmed
these findings in isolated human islets. Phosphorylated JNK
levels were increased by a 3-day culture in 33.3mMglucose or in
the presence of 2 ng/ml IL-1 (Fig. 4B) compared with control
cultures at 5.5 mM glucose. In both cases, this increase was
ameliorated when IL-1Ra was added to the culture medium.
Because we postulated that glucose-induced JNK activation
leads to PDX1 export, JNK inhibition should prevent shuttling
despite the presence of elevated glucose or IL-1. To test this
hypothesis, we treated human islets with 22.2 mM glucose or 2
ng/ml IL-1, with or without the addition of 10 M JNKi, a
small peptide that inhibits JNK activity, as described before (51,
52). We again observed glucose- and cytokine-mediated PDX1
translocalization (Fig. 4C, top, a–c). We not only found cells
that co-express insulin and PDX1 in the cytoplasm but found
that some cells displayed PDX1 in the nuclear periphery, which
has been observed previously in cell lines kept at low glucose
concentrations (34). JNK inhibition prevented glucose- and
IL-1-induced PDX1 translocalization and kept the transcrip-
tion factor in the nucleus in most cells, indicating that the JNK
pathway is involved in regulating PDX1 localization (Fig. 4C,
bottom, d–f).
-Cell apoptosis and function were analyzed in the same
experiments. The switch of nuclear to cytosolic PDX1 was
accompanied by increased-cell apoptosis. 3-day incubation of
human islets with elevated glucose (22.2 mM) or 2 ng/ml IL-1
resulted in a 1.8- and 2.1-fold increase in -cell apoptosis, and
glucose-stimulated insulin secretion was impaired by 75 and
52%, respectively. In contrast, 1 h of pre-exposure and pro-
longed culture of the islets with 10 M JNKi or 250 ng/ml
IL-1Ra restored -cell survival (Fig. 4D) and function (Fig. 4, E
and F).
Mutation of the PDX1 Nuclear Export Signal Restores -Cell
Survival and Function—Because we have observed PDX1
nuclear exclusion in a prodiabetic milieu, we tested whether
maintaining PDX1 localization in the nucleus may restore
-cell function and survival.
PDX1 WT plasmid and a mutant PDX1, in which the NES-
like sequence was disrupted by substituting alanine for leucine
at positions 91 and 93 and linked to GFP as described before
(33, 49), were expressed in human islets by transient plasmid
Lipofectamine-mediated transfection. Plasmids were kindly
provided by Dr. Ingo Leibiger. Transfection efficiency was ana-
lyzed imunocytochemically by GFP plasmid overexpression,
which showed a 60% transfection efficiency (supplemental
Fig. S2). We also evaluated transfection efficiency by Western
blot analysis. Linking PDX1 to GFP resulted in an additional
band at 70 kDa, which gave an intensive band in the transfected
but not in the GFP-transfected islets (Fig. 5D). Under these
conditions, we analyzed -cell apoptosis and function. Overex-
pression of WT or NES mutant PDX1 did not result in signifi-
cant changes of -cell apoptosis or function at 5.5 mM glucose.
3-day exposure to 22.2mM glucose or 2 ng/ml IL-1 resulted in
a 1.9- and 2.3-fold increase in -cell apoptosis and to a 56 and
68% decrease in glucose-stimulated insulin secretion, respec-
tively (Fig. 5, A–C, p 
 0.05), compared with GFP-transfected
control. AlthoughWTPDX1 andNESmutant PDX1 improved
-cell survival significantly, glucose-stimulated insulin secre-
tion was only improved by the NES mutant PDX1 and not by
WT PDX1 overexpression, indicating 1) that PDX1 overex-
pression improved -cell survival and 2) the necessity of
nuclear PDX1 for restoration of -cell function. When
PDX1-WT was overexpressed in human islets, IL-1 and
glucose induced shuttling of transfected PDX1 to the cytosol
(Fig. 5D), which resulted in a clear decrease in the nuclear/
cytosolic PDX1 expression ratio (Fig. 5E). In contrast, PDX1-
NES overexpression inhibited such PDX1 shuttling in IL-1-
and glucose-treated islets, and the ratio of nuclear/cytosolic
PDX1 expression was significantly increased, compared with
PDX1-WT (Fig. 5, D and E).
Immunostaining of PDX1-NES and PDX1-WT confirmed
Western blot results (Fig. 5F). PDX1 was localized in the
nucleus in insulin-positive -cells in both WT- and PDX1-
NES-transfected islets (Fig. 5F, a, b, g, and h). Although
PDX1-WT expression was shifted to the cytosol in response to
IL-1 and glucose treatment (Fig. 5F, c–f), shuttling-deficient
PDX1-NES remained in the nucleus (Fig. 5F, i–l).
DISCUSSION
Human mutations of PDX1 as well as changes in its transac-
tivation are strongly associated with diabetes (53, 54). In the
present study, we show that localization of PDX1 correlates
with T2DM, -cell function, and survival. PDX1 shuttling is
one of themechanisms thatmay explain the dual role of glucose
on -cell function and survival. Although acute elevated glu-
cose induces -cell proliferation and insulin secretion, chroni-
cally elevated glucose concentrations impair -cell function,
induce apoptosis (40), and thus may accelerate diabetes. Upon
acute exposure of -cells to glucose, PDX1 translocates to the
nucleus, leading to insulin gene transcription (34). In contrast,
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oxidative stress induces PDX1 shuttling to the cytosol (49) and
impairs insulin secretion (55). We show here that in diabetic
islets or under conditions of chronic hyperglycemia or IL-1
exposure for 3 days in vitro, conditions of impaired -cell sur-
vival and function shifted PDX1 expression to the cytoplasm.
These data show the impact of PDX1 localization in regulating
-cell turnover and function.
Whenever it was shifted to the cytosol, PDX1 showed a
weaker staining and signal intensity, which suggests the possi-
bility of PDX1 degradation after translocalization. This is also
supported by the observation that overexpression of PDX1-
NES, which remains in the nucleus, prevents PDX1 shuttling
together with degradation at conditions of chronically elevated
glucose. Although transfection could not be achieved in all islet
cells, nuclear PDX1 overexpression prevented the deleterious
effects of glucose and IL-1 on -cell survival and function.
Previously, we have observed such quantitative decrease in
PDX1 induced by elevated glucose concentrations in human
and rat islets. At this time, whole islet lysates were used for the
analysis, and we did not investigate PDX1 localization. PDX1
decrease was dose-dependent on glucose concentrations (5.5–
33.3 mM) (56). In the same previous study, we also show an
age-dependent PDX1 decrease in human and rat islets,
which was confirmed in pancreatic biopsy samples (57).
Such PDX1 decrease correlated with the increased suscepti-
bility to glucose-induced apoptosis and with a decline in
FIGURE 4. IL-1Ra prevents prolonged glucose- and IL-1-induced JNK-activation. A, isolated islets from mice overexpressing IL-1Ra (IL-1Ra-OE) and wild
type littermates were treated for 24–72 h with 11.1 mM glucose (control) or 33.3 mM glucose. Shown is immunoblotting for phosphorylated JNK and -actin
(loading control). The antibodies were blotted on the same membrane. One representative experiment of three is shown. Shown is densitometry analysis of
phospho-JNK bands normalized to -actin. B–D, isolated human islets were cultured in suspension for 24–72 h in 5.5 mM glucose (control), 22.2 or 33.3 mM
glucose, or 2 ng/ml IL-1with orwithout the addition of 500 ng/ml recombinant human IL-1Ra (B) or 10M JNKi (C). B, immunoblotting of phosphorylated JNK
and-actin (loading control). The antibodies were blotted on the same membrane. One representative blot of three experiments from three donors is shown.
Shown is densitometry analysis of phospho-JNK bands normalized to -actin. C, after 72 h of treatment, fixed and paraffin-embedded islet sections were
double-stained for insulin in green and PDX1 in red and analyzed under themicroscope (magnification,	250; inset magnification,	2000). Islets were isolated
from three different donors, and 3 independent experiments were performed. D and E, for the analysis of -cell survival and glucose-stimulated insulin
secretion, islets were cultured on extracellular matrix-coated dishes and treated for 72 h. D, -cell apoptosis expressed as a percentage of TUNEL-positive
-cells S.E. Themean number of-cells scoredwas 2945 218 for each treatment condition in three independent experiments from three different donors.
E and F, glucose-stimulated insulin secretion of islets. Stimulatory index (E) denotes the ratio between stimulated (16.7mM glucose) and basal (2.8mM glucose)
values normalized to insulin content (F) of insulin secretion during successive 1-h incubations. Results are means S.E. (error bars) from three independent
experiments from three donors. *, p 0.05 comparedwith control at 5.5mM glucose. **, p 0.05, IL-1Ra- or JNKi-treated islets comparedwith untreated islets
under the same conditions.
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-cell proliferation at an older age. Neither Reers et al. (57)
nor we were able to show nuclear PDX1 localization. It was
suggested that the human pancreas embedding method pre-
vented detection of nuclear PDX1. Here we improved tissue
permeabilization and clearly detected nuclear PDX1 even in
sections from human autopsy and biopsy, with strong PDX1
signals in the nucleus in non-diabetic control pancreases and
a shift of PDX1 to the cytosol in diabetic conditions, a signal
that appeared much weaker in sections from patients with
T2DM. Together, the data support PDX1 shuttling in
response to chronic glucose to the cytosol and its subsequent
degradation as one deleterious factor contributing to -cell
failure.
Strategies to block these deleterious effects on the -cell are
needed for a successful diabetes therapy. Blocking IL-1 signals
has been suggested as a novel treatment for diabetes. The anti-
inflammatory cytokine IL-1Ra prevents glucose-induced apo-
ptosis by blocking proapoptotic IL-1 signaling in vitro (4) and
FIGURE 5. Mutation of the PDX1 nuclear export signal restores -cell survival and function. Human isolated islets were cultured on extracellular matrix-
coated dishes and transfected with a GFP control plasmid, with WT PDX1, or with an NES mutant PDX1 (PDX1-NES), in which the NES-like sequence was
disrupted. 24 h after transfection, islets were exposed to elevated glucose or IL-1 for 72 h. A, -cell apoptosis expressed as a percentage of TUNEL-positive
-cells S.E. Themean number of-cells scoredwas 1545 112 for each treatment condition in three independent experiments from three different donors.
B and C, glucose-stimulated insulin secretion of islets. Stimulatory index (B) denotes the ratio between stimulated (16.7mM glucose) and basal (2.8mM glucose)
values normalized to insulin content (C) of insulin secretion during successive 1-h incubations. Results are means S.E. from three independent experiments
from three donors. **, p 0.05 compared with control at 5.5 mM glucose. *, p 0.05, PDX1-WT- or PDX1-NES-treated islets compared with untreated islets
under the same conditions.D, Western blot analysis for transfected PDX1 fused toGFPwas performedwith nuclear and cytosolic fractions of islet lysates. PARP
andGAPDHwere used as loading control for nuclear (left) and cytosolic (right) extracts. One representative blot of three experiments is shown. E, densitometry
analysis of bands normalized to PARP or GAPDH shows the ratio of nuclear and cytosolic transfected PDX1 expression. *, p 0.05 comparedwith control at 5.5
mM glucose. Islets were isolated from three different donors, and 3 independent experiments were performed. F, fixed and paraffin-embedded islet sections
were double-stained for PDX1 (green; a, c, and e and g, i, and k) and insulin (red; b, d, and f and h, j, and l) and analyzed under the fluorescent microscope
(magnification,	800).
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improves glycemia and -cell function and survival in vivo (16,
17, 20).
In this study, we provide further mechanisms of the protec-
tive effect of IL-1Ra directly on the -cell transcriptional regu-
lation inC57BL/6Jmice fed a high fat/high sucrose diet (Surwit)
and in db/db mice, serving as two animal models of T2DM and
inhuman islets exposed to a diabeticmilieu. 12weeks of high fat
feeding induced impaired glucose tolerance, which was inhib-
ited in the IL-1Ra-OE mice. Unexpectedly, insulin and PDX1
mRNA levels were oppositely regulated in the HFD-treated
mice; insulin was reduced, and PDX1 was significantly
increased in islets after 12 weeks of high fat/high sucrose diet.
IL-1Ra prevented such changes. Many previous studies have
observed no changes or increases in insulin mRNA in response
to a high fat diet without increase in sucrose (“Western diet”) in
rat or mouse models (e.g. see Refs. 58 and 59). The addition of
sucrose to the diet (Surwit) causes -cell failure together with
reduced insulin mRNA in the -cell (60).
Although our results are in contrast to previous data showing
PDX1 down-regulation in response to hyperglycemia in -cells
in culture aswell as in type 2 diabetic animalmodels (e.g. in ZDF
rats (61), in P. obesus (29), and in partially pancreatectomized
rats (62)), studies in isolated human islets from patients with
T2DMshow a similar opposite regulation, with reduced insulin
mRNA and increased PDX1mRNA levels compared with islets
isolated from non-diabetic controls (47).
PDX1 expression seems to be important for the -cell
response to a higher insulin demand (e.g. in insulin resistance
and -cell compensation may occur through increased PDX1
mRNA). But suppression of PDX1 expression inMIN6 cells did
not lead to a decrease of insulin or glucokinase mRNA (63). To
activate insulin transcription, PDX1 translocates into the
nucleus, where it binds to the insulin gene (46, 64). Therefore,
post-translational changes, which define PDX1 localization,
rather than mRNA expression levels may play a more impor-
tant role under diabetic conditions. For instance, oxidative
stress induces PDX1 shuttling from the nucleus to the cytosol
and thus causes a severe reduction of PDX1 activity (49). Also,
24-h exposure of rat islets to palmitic acid at elevated glucose
concentrations causes PDX1 localization to the cytosol
together with a decrease in MafA expression and inhibition of
insulin expression (36). In line with these previous observa-
tions, we detected PDX1 predominantly expressed in the cyto-
sol in HFD-treated and in hyperglycemic db/db mice. In con-
trast, in IL-1Ra-treated as well as the normal diet groups, PDX1
was localized in the nucleus. Because IL-1Ra protected from the
prodiabetic effect of the diet, we propose that this is a result of
maintaining PDX1 functionally in the nucleus.
Homozygous Leprdb/db mice (db/db) on the C57BLKS/J
background with this depletion in the leptin receptor become
obese, hyperglycemic, and hyperinsulinemic within the first
month of age. In these mice, IL-1-mediated innate immunity
is augmented, which results from a diabetes-associated loss of
IL-1 counterregulation (65). To test the hypothesis that
IL-1Ra would prevent diabetes progression in this model of
T2DM, we injected db/db mice daily with IL-1Ra or with vehi-
cle from 4 weeks of age on. db/db mice that received IL-1Ra
showed improved glucose tolerance during intraperitoneal glu-
cose tolerance test experiments after 2 weeks of treatment as
compared with their vehicle-treated littermates (p  0.05 at
time points 30 and 60 min; data not shown). From 3 weeks of
treatment on, we did not observe any differences in glucose
levels between the two groups anymore. Considering the short
half-life of IL-1Ra (6–8 h) and the 10–100-fold excess that is
needed to block IL-1-mediated effects (66), we tested whether
constitutive endogenous overexpression of IL-1Ra would
improve the outcome of elevated IL-1Ra levels in db/db mice.
We could confirm in the db/dbmouse model that IL-1Ra over-
expression was protective against the development of diabetes
and -cell failure, although the effects of IL-1Ra in db/db mice
were quitemodest. However, considering the db/dbmouse as a
model of severe diabetes with rapid development of hypergly-
cemia, any significant rescue in the model and a combined
effect on glucose tolerance, insulin secretion, -cell mass, and
apoptosis confirms a protective effect on the -cell. This was
paralleled by IL-1Ra-induced PDX1 stabilization in the nucleus
in the db/db mice. Already at 6 weeks of age, PDX1 was pre-
dominantly expressed in the cytosol in the db/dbmice, whereas
at the age of 10 weeks, PDX1 was strongly decreased. IL-1Ra
restored nuclear PDX1 in 6-week-old mice, and also in
10-week-oldmice, nuclear PDX1 expression could be detected.
Previous cytochemistry analyses of db/db mouse pancreases
show a nuclear loss of MafA rather than of PDX1 (67). To
exclude differences in the background, we also analyzed PDX1
in male BKSdb/db mice and could confirm the switch of PDX1
localization to the nucleus already after 6 weeks of age.
Activation of JNK is a hallmark in glucose and IL-1 effect on
the -cell and is involved in PDX1 regulation (68, 69). We used
such well known results to confirm our study design and could
identify JNK as cellular component also involved in glucose-
and IL-1-regulated PDX1 localization. In wild type islets, JNK
was phosphorylated after short term (30 min (data not shown)
and 1 day) as well as long term (3 days) incubations with ele-
vated glucose. Therefore, it seems that acute JNK activation
does not necessarily cause impairment in -cell function and
survival, whereas chronic activation correlates with glucotox-
icity. IL-1Ra protected islets from prolonged JNK activation.
JNK activity has previously been linked to PDX1 shuttling
under conditions of oxidative stress (49) and in prostaglandin
E2-induced -cell dysfunction (32), together with Foxo1 as a
key player (31). Foxo1 cellular localization determines PDX1
localization, and both are reversely expressed. Foxo1 itself is
regulated by JNK and AKT activity; JNK induces Foxo1 nuclear
import, which leads to PDX1 export, whereas AKT-mediated
Foxo1 phosphorylation results in Foxo1 cytoplasmic and PDX1
nuclear localization. Our findings suggest the JNK-PDX1 path-
way as a critical signaling network that transduces short term as
well as long term glucose stimulation and therefore might
partly mediate the dual effect of glucose on -cell function and
survival.
The fact that IL-1Ra potentially prevented hyperglycemia
and improved -cell function favors the critical role of IL-1
signaling in the -cell not only in a type 1 but also in a type 2
diabetic environment. Our data provide new insights into
mechanisms of the protective effect of IL-1Ra on -cell func-
tion and turnover, establish the important role of nuclear PDX1
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localization, and support IL-1Ra as a potential therapy for
diabetes.
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Fig.S1: PDX1 translocalization in db/db mice is paralleled by impaired glycemia and insulin secretion 
(A,B) Blood glucose (A) and insulin (B) levels following i.p. injection of 1 (A) or 2 (B) g/kg body weight glucose in 7-
week-old control heterozygous db/+, db/+IL-1Ra, db/db and db/dbIL-1Ra littermate mice. (C) Stimulatory index 
calculated from stimulated divided by basal insulin secretion (B) shows significant decrease in the db/db mice, which 
was prevented in the db/dbIL-1Ra mice. (D) β-cell apoptosis expressed as percentage of TUNEL-positive β-cells ± SE. 
The mean number of β-cells scored was 2620 ± 256 for each treatment condition in four independent experiments. (E) 
The β-cell mass per pancreas was estimated as the product of the relative cross-sectional area of β-cells (determined 
by quantification of the cross-sectional area occupied by β-cells divided by the cross-sectional area of total tissue) and 
the weight of the pancreas. Pancreases were analyzed from 8-week-old mice. **p<0.05 db/db compared to db/+, 
*p<0.05 db/dbIL-1Ra compared to db/db mice. 
Data were collected from 4 animals per group in each of three independent experiments. 
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a b 
Suppl. Figure 2 
Fig.S2: Transfection efficiency in human islets plated on extracellular matrix coated dishes 
Human islets were plated on ECM dishes and transfected with GFP control plasmid (see material and methods). 48 h 
later, transfection efficiency was determined by fluorescence microscopy (a). (b) shows brightfield picture of all plated 
cells. 
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